A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN <12 YEARS OF AGE

Study Sponsor: BioNTech
Study Conducted By: Pfizer
Study Intervention Number: PF-07302048
Study Intervention Name: RNA-Based COVID-19 Vaccine
US IND Number: 19736
EudraCT Number: 2020-005442-42
Protocol Number: C4591007
Phase: 1/2/3

Short Title: A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age

This document and accompanying materials contain confidential information belonging to Pfizer. Except as otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer must be promptly notified.
## Protocol Amendment Summary of Changes Table

<table>
<thead>
<tr>
<th>Document</th>
<th>Version Date</th>
<th>Summary and Rationale for Changes</th>
</tr>
</thead>
</table>
| Amendment 1 | 05 Mar 2021 | - Added 2 age groups to the study: participants ≥2 to <5 years and ≥6 months to <2 years of age, to also study safety and immunogenicity in these age groups.  
- Updated efficacy objectives to apply across ages in which immunobridging has been successful, if 22 cases are accrued.  
- Made updates to match Pfizer’s response to 04 February 2021 CBER comments regarding this study, ie:  
- Exclusion criterion 3 applied to all study participants rather than just to Phase 1 participants.  
- References to “noninferiority” updated to “immunobridging.”  
- Made additions to the exclusion criteria for previous or current diagnosis of MIS-C.  
- Added to the exclusion criteria receipt of any passive antibody therapy specific to COVID-19 within 90 days prior to enrollment.  
- Specified that placebo recipients who decline BNT162b2 will be followed for 24 months (Visits X and Y).  
- Temporary delay of study intervention criteria regarding nonstudy vaccination updated to be most permissive, ie, to allow easier scheduling around childhood routine vaccinations.  
- Added the following symptoms as prompts to complete the COVID-19/MIS-C illness e-diary:  
  - Inability to eat/poor feeding in participants <5 years of age;  
  - Abdominal pain;  
  - Hospitalization due to confirmed COVID-19 infection.  
- Following updates made to the first confirmed COVID-19 case definition to accommodate inclusion of participants <5 years of age:  
  - Definition of diarrhea added.  
  - Inability to eat/poor feeding in participants <5 years of age added as an additional symptom.  
  - Definition of SARS-CoV-2–related hospitalization added.  
  - RR and HR required to meet the SARS-CoV-2–related severe case definition specified by participant age. Table 4 inserted.  
  - Added that cell-mediated immune responses will be described following isolation of PBMCs in a subset of
Phase 2/3 participants ≥10 years of age. Corresponding visit (Visit 3) added approximately 7 days after Dose 2.

This amendment incorporates all revisions to date, including amendments made at the request of country health authorities and IRBs/ECs.
TABLE OF CONTENTS

LIST OF TABLES...................................................................................................................10

1. PROTOCOL SUMMARY ...................................................................................................11
   1.1. Synopsis ..................................................................................................................11
   1.2. Schema ....................................................................................................................20
   1.3. Schedule of Activities .............................................................................................21
       1.3.1. Phase 1 ........................................................................................................21
       1.3.2. Phase 2/3 .....................................................................................................25
           1.3.2.1. Phase 2/3 Participants Who Originally Received BNT162b2 or Placebo Recipients Who Decline BNT162b2........................................................................28
           1.3.2.2. Phase 2/3 Participants Who Originally Received Placebo.........................................................................................................................29

2. INTRODUCTION ...............................................................................................................32
   2.1. Study Rationale .......................................................................................................32
   2.2. Background .............................................................................................................32
       2.2.1. Clinical Overview .......................................................................................34
   2.3. Benefit/Risk Assessment .........................................................................................34
       2.3.1. Risk Assessment .........................................................................................36
       2.3.2. Benefit Assessment .....................................................................................38
       2.3.3. Overall Benefit/Risk Conclusion ..................................................................38

3. OBJECTIVES, ESTIMANDS, AND ENDPOINTS ...........................................................38
   3.1. Phase 1 .....................................................................................................................38
   3.2. Phase 2/3 .................................................................................................................39

4. STUDY DESIGN.................................................................................................................43
   4.1. Overall Design .........................................................................................................43
       4.1.1. Phase 1 ........................................................................................................43
       4.1.2. Phase 2/3 .....................................................................................................43
       4.1.3. Number of Participants ...............................................................................44
           4.1.3.1. Phase 1: Open-Label Dose Finding ..........................................................44
           4.1.3.2. Phase 2/3: Safety, Tolerability, Immunogenicity, and Efficacy..............44
       4.1.4. Intervention Groups and Duration ..................................................................45
   4.2. Scientific Rationale for Study Design ......................................................................46
4.3. Justification for Dose ..................................................................................................46
4.4. End of Study Definition ..........................................................................................46

5. STUDY POPULATION .................................................................................................46

5.1. Inclusion Criteria ....................................................................................................47
5.2. Exclusion Criteria ...................................................................................................48
5.3. Lifestyle Considerations .........................................................................................49
  5.3.1. Contraception ....................................................................................................49
5.4. Screen Failures ........................................................................................................50
5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Study Intervention Administration ...........................................................................................................50

6. STUDY INTERVENTION .............................................................................................51

6.1. Study Intervention(s) Administered .....................................................................51
  6.1.1. Administration ..................................................................................................52
6.2. Preparation/Handling/Storage/Accountability ......................................................52
  6.2.1. Preparation and Dispensing .............................................................................53
6.3. Measures to Minimize Bias: Randomization and Blinding ..................................54
  6.3.1. Allocation to Study Intervention ......................................................................54
  6.3.2. Blinding of Site Personnel (Phase 2/3 Only).....................................................54
  6.3.3. Blinding of the Sponsor ...................................................................................54
  6.3.4. Breaking the Blind ..........................................................................................55
6.4. Study Intervention Compliance ............................................................................55
6.5. Concomitant Therapy ............................................................................................56
  6.5.1. Prohibited During the Study ..........................................................................56
  6.5.2. Permitted During the Study ............................................................................57
  6.5.3. Recording Nonstudy Vaccination and Concomitant Medications .................57
6.6. Dose Modification ..................................................................................................57
6.7. Intervention After the End of the Study ..................................................................58

7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL .........................................................................................58

7.1. Discontinuation of Study Intervention ...................................................................58
7.2. Participant Discontinuation/Withdrawal From the Study .......................................59
  7.2.1. Withdrawal of Consent ....................................................................................60
7.3. Lost to Follow-up .................................................................60

8. STUDY ASSESSMENTS AND PROCEDURES .........................................................61

8.1. Efficacy and/or Immunogenicity Assessments ........................................62

8.1.1. Immunogenicity ..............................................................................65

8.1.2. Biological Samples ........................................................................66

8.2. Safety Assessments ............................................................................66

8.2.1. Physical Examinations ....................................................................66

8.2.2. Vital Signs .......................................................................................67

8.2.3. Clinical Safety Laboratory Assessments ........................................67

8.2.4. Electronic Diary .............................................................................67

8.2.4.1. Grading Scales ........................................................................67

8.2.4.2. Local Reactions ........................................................................68

8.2.4.3. Systemic Events .........................................................................69

8.2.4.4. Fever .......................................................................................71

8.2.4.5. Antipyretic Medication ............................................................72

8.2.5. Phase 1 Stopping Rules .................................................................72

8.2.6. Randomization and Vaccination After a Stopping Rule Is Met in Phase 1 .....73

8.2.7. Pregnancy Testing ..........................................................................73

8.3. Adverse Events and Serious Adverse Events .............................................73

8.3.1. Time Period and Frequency for Collecting AE and SAE Information ....74

8.3.1.1. Reporting SAEs to Pfizer Safety ...............................................75

8.3.1.2. Recording Nonserious AEs and SAEs on the CRF ....................75

8.3.2. Method of Detecting AEs and SAEs .............................................75

8.3.3. Follow-up of AEs and SAEs ............................................................75

8.3.4. Regulatory Reporting Requirements for SAEs ................................76

8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure ..................................................................................76

8.3.5.1. Exposure During Pregnancy .................................................76

8.3.5.2. Exposure During Breastfeeding .............................................78

8.3.5.3. Occupational Exposure .........................................................78

8.3.6. Cardiovascular and Death Events ....................................................78
8.3.7. Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs or SAEs

8.3.8. Adverse Events of Special Interest

8.3.8.1. Lack of Efficacy

8.3.9. Medical Device Deficiencies

8.3.10. Medication Errors

8.4. Treatment of Overdose

8.5. Pharmacokinetics

8.6. Pharmacodynamics

8.7. Genetics

8.8. Biomarkers

8.9. Immunogenicity Assessments

8.10. Health Economics

8.11. Study Procedures

8.11.1. Phase 1

8.11.1.1. Visit 1 – Dose 1 (Day 1)

8.11.1.2. Visit 2 – Dose 2 (19 to 23 Days After Visit 1)

8.11.1.3. Visit 3 – 7-Day Follow-up Visit (1 Week After Dose 2, 6 to 8 Days After Visit 2)

8.11.1.4. Visit 4 – 1-Month Follow-up Visit (28 to 35 Days After Visit 2)

8.11.1.5. Visit 5 – 6-Month Follow-up Visit (175 to 189 Days After Visit 2)

8.11.1.6. Visit 6 – 12-Month Follow-up Visit (350 to 378 Days After Visit 2)

8.11.1.7. Visit 7 – 24-Month Follow-up Visit (714 to 742 Days After Visit 2)

8.11.2. Phase 2/3

8.11.2.1. Visit 1 – Dose 1 (Day 1)

8.11.2.2. Visit 2 – Dose 2 (19 to 23 Days After Visit 1)

8.11.2.3. Visit 3 – 1-Week Follow-up Visit (After Visit 2) (6 to 8 Days After Visit 2): Only for Those Participants Having Blood Drawn for PBMC Isolation
8.11.2.4. Visit 4 – 1-Month Follow-up Visit (After Visit 2) (28 to 35 Days After Visit 2) .................................................................95
8.11.2.5. Visit 5 – 6-Month Follow-up Visit (175 to 189 Days After Visit 2) ..................................................................................96

8.11.3. Phase 2/3 Participants Who Originally Received BNT162b2 or Placebo Recipients Who Decline BNT162b2 ..................................................97
8.11.3.1. Visit X – 12-Month Follow-up Visit (350 to 378 Days After Visit 2) ......................................................................................97
8.11.3.2. Visit Y – 24-Month Follow-up Visit (714 to 742 Days After Visit 2) ......................................................................................98

8.11.4. Phase 2/3 Participants Who Originally Received Placebo .......................98
8.11.4.1. Visit A – Dose 3 (175 to 189 Days After Dose 2 and Same Date as Visit 5) .................................................................98
8.11.4.2. Visit B – Dose 4 (19 to 23 Days After Visit A) .......................100
8.11.4.3. Visit C – 1-Month Follow-up Telephone Contact (After Dose 4) (28 to 35 Days After Visit B) ..................................................102
8.11.4.4. Visit D – 6-Month Follow-up Telephone Contact (After Dose 4) (175 to 189 Days After Visit B) ...................................................102
8.11.4.5. Visit E – 12-Month Follow-up Telephone Contact (After Dose 4) (350 to 378 Days After Visit B) ...............................................103
8.11.4.6. Visit F – 18-Month Follow-up Telephone Contact (After Dose 4) (532 to 560 Days After Visit B) ........................................103

8.12. Unscheduled Visit for Fever or a Grade 3 or Suspected Grade 4 Reaction .........104
8.13. COVID-19 and MIS-C Surveillance (All Participants) .........................................105
8.15. SARS-CoV-2 NAAT Nasal (Anterior Nares) Swab Results ..............................109

9. STATISTICAL CONSIDERATIONS .................................................................110
9.1. Estimands and Statistical Hypotheses ..............................................................110
9.1.1. Estimands ..................................................................................................110
9.1.2. Statistical Hypothesis ................................................................................111
9.1.2.1. Statistical Hypothesis Evaluation for Immunogenicity .................111
9.1.2.2. Statistical Hypothesis Evaluation for Efficacy ................................................... 111
9.1.3. Multiplicity Considerations .................................................................................. 112
9.2. Sample Size Determination .................................................................................... 112
9.3. Statistical Analysis Sets ......................................................................................... 115
9.4. Statistical Analyses .................................................................................................. 116
  9.4.1. General Considerations ..................................................................................... 116
    9.4.1.1. Analyses for Binary Data ........................................................................... 116
    9.4.1.2. Analyses for Continuous Data ................................................................. 117
  9.4.2. Primary Endpoint(s) .......................................................................................... 117
  9.4.3. Secondary Endpoint(s) ..................................................................................... 119
  9.4.4. Exploratory Endpoint(s) ................................................................................... 120
9.5. Interim Analyses ..................................................................................................... 121
  9.5.1. Analysis Timing .................................................................................................. 121
9.6. Data Monitoring Committee or Other Independent Oversight Committee ........... 122

10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS .......................................................................................................................................................... 123
  10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ............. 123
    10.1.1. Regulatory and Ethical Considerations .......................................................... 123
      10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP ................................................................................................................................. 123
    10.1.2. Financial Disclosure ....................................................................................... 124
    10.1.3. Informed Consent Process ............................................................................. 124
    10.1.4. Data Protection .............................................................................................. 125
    10.1.5. Dissemination of Clinical Study Data ............................................................ 126
    10.1.6. Data Quality Assurance ................................................................................ 127
    10.1.7. Source Documents ....................................................................................... 128
    10.1.8. Study and Site Start and Closure .................................................................. 128
    10.1.9. Publication Policy .......................................................................................... 129
    10.1.10. Sponsor’s Qualified Medical Personnel ....................................................... 130
  10.2. Appendix 2: Clinical Laboratory Tests .................................................................. 130
  10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting .................................................................................................................. 131
10.3.1. Definition of AE ..........................................................131
10.3.2. Definition of SAE .......................................................132
10.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.........134
10.3.4. Reporting of SAEs .......................................................137
10.4. Appendix 4: Contraceptive Guidance ..................................................138
10.4.1. Male Participant Reproductive Inclusion Criteria ......................138
10.4.2. Female Participant Reproductive Inclusion Criteria ....................138
10.4.3. Woman of Childbearing Potential ..........................................139
10.4.4. Contraception Methods ..................................................140
10.5. Appendix 5: Liver Safety: Suggested Actions and Follow-up Assessments ......141
10.6. Appendix 6: Abbreviations .....................................................143
10.7. Appendix 7: Criteria for Allowing Inclusion of Participants With Chronic Stable HIV, HCV, or HBV Infection ..................................................146
11. REFERENCES ................................................................................................................147

LIST OF TABLES

| Table 1. | Phase 1 Participants ..........................................................44 |
| Table 2. | Phase 2/3 Participants – Blood Draws for Immunogenicity/Efficacy Assessments ...........................................45 |
| Table 3. | Phase 2/3 Participants – Safety and Tolerability/Efficacy Assessments ...................................................45 |
| Table 4. | RR and HR, by Age, Indicative of Severe Systemic Illness ...........63 |
| Table 5. | Local Reaction Grading Scale .................................................68 |
| Table 6. | Systemic Event Grading Scale for Participants ≥2 to <12 Years of Age .................................................................69 |
| Table 7. | Systemic Event Grading Scale for Participants ≥6 Months to <2 Years of Age ...........................................................70 |
| Table 8. | Scale for Fever ......................................................................71 |
| Table 9. | Power Analysis for Immunobridging Assessment ......................113 |
| Table 10. | Precision of SARS-CoV-2 Neutralizing Titer GMT ..................113 |
| Table 11. | Power for Vaccine Efficacy Assessment ..................................114 |
| Table 12. | Probability of Observing at Least 1 AE by Assumed True Event Rates With Different Sample Sizes .........................114 |
1. PROTOCOL SUMMARY

1.1. Synopsis

Short Title: A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age.

Rationale

A pneumonia of unknown cause detected in Wuhan, China, was first reported in December 2019. In January 2020, the pathogen causing this outbreak was identified as a novel coronavirus 2019. On 11 March 2020, the WHO upgraded the status of the COVID-19 outbreak from epidemic to pandemic, which is now rapidly spreading worldwide. Children have been affected by both the primary COVID-19 disease and the less common secondary inflammatory complications, including MIS-C.

There are currently no licensed vaccines to prevent infection with SARS-CoV-2 or COVID-19. Given the rapid transmission of COVID-19 and incidence of disease in the United States and elsewhere, the rapid development of an effective vaccine is of utmost importance.

A Phase 1/2/3 study (C4591001) is currently being conducted in healthy individuals 12 years of age and older to investigate the safety, tolerability, immunogenicity, and efficacy of the prophylactic BNT162 vaccine candidates against COVID-19. The vaccine candidate selected for evaluation in the C4591001 Phase 2/3 study is BNT162b2 at a 30-µg dose level. The vaccine is administered as 2 doses approximately 21 days apart. On 18 November 2020, the primary efficacy analysis results were announced, which demonstrated BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group. Safety data from approximately 38,000 participants randomized 1:1 with a median of 2 months of follow-up after the second dose of vaccine showed a favorable safety profile at a dose of 30 µg in participants 16 years of age and older. On 11 December 2020, the US FDA issued an EUA for use in individuals 16 years of age and older. Other countries have also granted EUA (eg, Canada, Mexico, Bahrain), and Pfizer and BioNTech are anticipating further regulatory decisions in other countries.

This Phase 1/2/3 study (C4591007) will evaluate up to 3 dose levels of BNT162b2 in up to 3 age groups (participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age) for safety, tolerability, immunogenicity, and efficacy (depending on successful immunobridging and accrual of a sufficient number of cases). Phase 1 includes the dose-finding portion. Initiation of dose finding in participants ≥5 to <12 years of age is based on acceptable blinded safety data demonstrated in 2259 12- through 15-year-olds at the 30-µg dose level in the C4591001 study. The Phase 2/3 BNT162b2 dose level to be used in each age group in this study will be selected based on the Phase 1 safety, tolerability, and immunogenicity data from the same age group. Phase 2/3 includes an immunobridging analysis of immune responses in participants within each age group (participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age) to those in participants 16 to...
25 years of age in the Phase 3 C4591001 efficacy study. Safety, tolerability, and efficacy (depending on successful immunobridging and accrual of a sufficient number of cases) will also be evaluated in Phase 2/3 of this study.

Objectives, Estimands, and Endpoints

The age groups referred to in the objectives and estimands below are participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age.

<table>
<thead>
<tr>
<th>Phase 1</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary:</strong></td>
<td><strong>Primary:</strong></td>
<td><strong>Primary:</strong></td>
</tr>
<tr>
<td><strong>Objectives</strong></td>
<td><strong>Estimands</strong></td>
<td><strong>Endpoints</strong></td>
</tr>
</tbody>
</table>
| To describe the safety and tolerability profiles of prophylactic BNT162b2 at each dose level in each age group | In participants receiving at least 1 dose of study intervention, the percentage of participants in each age group reporting:  
- Local reactions for up to 7 days following each dose  
- Systemic events for up to 7 days following each dose  
- AEs from Dose 1 to 1 month after Dose 2  
- SAEs from Dose 1 to 6 months after Dose 2 | Participants ≥5 to <12 years and ≥2 to <5 years of age:  
- Local reactions (pain at the injection site, redness, and swelling)  
- Systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain)  
- AEs  
- SAEs |
| **Secondary:**  | **Secondary:**  | **Secondary:**  |
| To describe the immune responses elicited by prophylactic BNT162b2 at each dose level in each age group | In participants complying with the key protocol criteria (evaluable participants) in each age group:  
At baseline, before Dose 2, and 7 days after Dose 2,  
- GMTs at each time point  
- GMFR from before Dose 1 (baseline) to each subsequent time point after vaccination | SARS-CoV-2 neutralizing titers |
| **Exploratory:**  | **Exploratory:**  | **Exploratory:**  |
| To describe COVID-19 and severe COVID-19 cases with and without serological or virological evidence of past SARS-CoV-2 infection | | Confirmed COVID-19 cases  
Confirmed severe COVID-19 cases |
### Phase 1

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Estimands</th>
<th>Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>To describe MIS-C cases with and without evidence of past SARS-CoV-2 infection</td>
<td>• Confirmed cases as per CDC criteria</td>
<td></td>
</tr>
</tbody>
</table>

### Phase 2/3

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Estimands</th>
<th>Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Safety:</strong> To define the safety profile of prophylactic BNT162b2 at the selected dose level in the participants included in the Phase 2/3 immunobridging analysis in each age group</td>
<td>In participants receiving at least 1 dose of study intervention, from each vaccine group, the percentage of participants in each age group reporting: • Local reactions for up to 7 days following each dose • Systemic events for up to 7 days following each dose • AEs from Dose 1 to 1 month after Dose 2 • SAEs from Dose 1 to 1 month after Dose 2</td>
<td>Participants ≥5 to &lt;12 years and ≥2 to &lt;5 years of age: • Local reactions (pain at the injection site, redness, and swelling) • Systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain) • AEs • SAEs Participants ≥6 months to &lt;2 years of age: • Local reactions (tenderness at the injection site, redness, and swelling) • Systemic events (fever, decreased appetite, drowsiness, and irritability) • AEs • SAEs</td>
</tr>
<tr>
<td><strong>Primary Safety:</strong> To define the safety profile of prophylactic BNT162b2 at the selected dose level in all participants randomized in Phase 2/3 in each age group</td>
<td>In participants receiving at least 1 dose of study intervention from each vaccine group, the percentage of participants in each age group reporting: • Local reactions for up to 7 days following each dose • Systemic events for up to 7 days following each dose • AEs from Dose 1 to 1 month after Dose 2 • SAEs from Dose 1 to 6 months after Dose 2</td>
<td>Participants ≥5 to &lt;12 years and ≥2 to &lt;5 years of age: • Local reactions (pain at the injection site, redness, and swelling) • Systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain) • AEs • SAEs Participants ≥6 months to &lt;2 years of age: • Local reactions (tenderness at the injection site, redness, and swelling) • Systemic events (fever, decreased appetite, drowsiness, and irritability) • AEs • SAEs</td>
</tr>
</tbody>
</table>
## Phase 2/3

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Estimands</th>
<th>Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Immunogenicity:</strong> To demonstrate immunobridging of the immune response elicited by prophylactic BNT162b2 at the dose level selected per age group in Phase 2/3 participants without serological or virological evidence (up to 1 month after receipt of Dose 2) of past SARS-CoV-2 infection:</td>
<td>In participants complying with the key protocol criteria (evaluable participants) and no serological or virological evidence (up to 1 month after receipt of Dose 2) of past SARS-CoV-2 infection:</td>
<td>• SARS-CoV-2 neutralizing titers</td>
</tr>
<tr>
<td>• In participants ≥5 to &lt;12 years of age compared to participants 16 to 25 years of age from Phase 2/3 of the C4591001 study</td>
<td>• GMR, estimated by the ratio of the geometric mean of SARS-CoV-2 neutralizing titers in participants ≥5 to &lt;12 years of age to those in participants 16 to 25 years of age 1 month after Dose 2</td>
<td></td>
</tr>
<tr>
<td>• In participants ≥2 to &lt;5 years of age compared to participants 16 to 25 years of age from Phase 2/3 of the C4591001 study</td>
<td>• GMR, estimated by the ratio of the geometric mean of SARS-CoV-2 neutralizing titers in participants ≥2 to &lt;5 years of age to those in participants 16 to 25 years of age 1 month after Dose 2</td>
<td></td>
</tr>
<tr>
<td>• In participants ≥6 months to &lt;2 years of age compared to participants 16 to 25 years of age from Phase 2/3 of the C4591001 study</td>
<td>• GMR, estimated by the ratio of the geometric mean of SARS-CoV-2 neutralizing titers in participants ≥6 months to &lt;2 years of age to those in participants 16 to 25 years of age 1 month after Dose 2</td>
<td></td>
</tr>
</tbody>
</table>

| Secondary Immunogenicity/Efficacy: To describe the immune responses elicited by prophylactic BNT162b2 at the dose level selected per age group and persistence of immune response in Phase 2/3 participants without serological or virological evidence of past SARS-CoV-2 infection | In evaluable participants with no serological or virological evidence of past SARS-CoV-2 infection from each vaccine and age group: | • SARS-CoV-2 neutralizing titers |
| • In all age groups where immunobridging is successful, if at least 22 cases are accrued across those age groups: | At baseline (before Dose 1) and 1, 6, 12 (for the original BNT162b2 group only), and 24 (for the original BNT162b2 group only) months after Dose 2, | |
| To evaluate the efficacy of prophylactic BNT162b2 against confirmed COVID-19 occurring from 7 days after Dose 2 in participants without evidence of past SARS-CoV-2 infection | • GMTs at each time point | |
| | • GMFRs from before Dose 1 to each subsequent time point after Dose 2 | |
| | In participants complying with the key protocol criteria (evaluable participants) and with no serological or virological evidence (prior to 7 days after receipt of Dose 2) of past SARS-CoV-2 infection: | • Confirmed COVID-19 incidence from 7 days after Dose 2 per 1000 person-years of follow-up |
## Phase 2/3

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Estimands</th>
<th>Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In all age groups where immunobridging is successful, if at least 22 cases are accrued across those age groups:</strong> To evaluate the efficacy of prophylactic BNT162b2 against confirmed COVID-19 occurring from 7 days after Dose 2 in participants with or without evidence of past SARS-CoV-2 infection</td>
<td>In participants complying with the key protocol criteria (evaluable participants) and with or without serological or virological evidence (prior to 7 days after receipt of Dose 2) of past SARS-CoV-2 infection: $100 \times (1 - \text{IRR})$ [ratio of active vaccine to placebo]</td>
<td>• Confirmed COVID-19 incidence from 7 days after Dose 2 per 1000 person-years of follow-up</td>
</tr>
<tr>
<td>To describe the efficacy of prophylactic BNT162b2 against asymptomatic infection in participants without evidence of past SARS-CoV-2 infection</td>
<td>In evaluable participants without serological or virological evidence of past SARS-CoV-2 infection from each vaccine group: $100 \times (1 - \text{IRR})$ [ratio of active vaccine to placebo]</td>
<td>• Incidence of asymptomatic infection of SARS-CoV-2 based on N-binding antibody seroconversion</td>
</tr>
<tr>
<td><strong>Exploratory:</strong> To evaluate the immune response over time to prophylactic BNT162b2 at the dose level selected per age group and persistence of immune response in Phase 2/3 participants with and without serological or virological evidence of past SARS-CoV-2 infection</td>
<td>In evaluable participants with or without serological or virological evidence of past SARS-CoV-2 infection from each vaccine group: At baseline and at 1, 6, 12 (for the original BNT162b2 group only), and 24 (for the original BNT162b2 group only) months after Dose 2, • GMTs at each time point • GMFRs from before Dose 1 to each subsequent time point after Dose 2</td>
<td>• SARS-CoV-2 neutralizing titers</td>
</tr>
<tr>
<td><strong>Exploratory:</strong> To evaluate the immune response (non-S) to SARS-CoV-2 in Phase 2/3 participants with and without confirmed COVID-19 during the study</td>
<td></td>
<td>• N-binding antibody</td>
</tr>
<tr>
<td>To describe COVID-19 and severe COVID-19 cases in all participants with and without serological or virological evidence of past SARS-CoV-2 infection</td>
<td></td>
<td>• Confirmed COVID-19 cases • Confirmed COVID-19 cases resulting in hospitalization • Confirmed severe COVID-19 cases</td>
</tr>
<tr>
<td>To describe MIS-C cases with and without evidence of past SARS-CoV-2 infection</td>
<td></td>
<td>• Confirmed cases as per CDC criteria</td>
</tr>
<tr>
<td>To describe the serological responses in Phase 2/3 participants to BNT162b2 at the dose level selected per age group in cases of: • Confirmed COVID-19 • Confirmed severe COVID-19 • SARS-CoV-2 infection without confirmed COVID-19</td>
<td></td>
<td>• SARS-CoV-2 neutralizing titers</td>
</tr>
</tbody>
</table>
## Phase 2/3

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Estimands</th>
<th>Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>To describe the safety and immunogenicity of prophylactic BNT162b2 at the dose level selected per age group in children with stable HIV disease</td>
<td></td>
<td>• All safety and immunogenicity endpoints described above will be analyzed descriptively</td>
</tr>
<tr>
<td>To describe the cell-mediated immune response, and additional humoral immune response parameters, to the reference strain in a subset of participants:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 7 days and 1 and 6 months after Dose 2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Overall Design

This is a Phase 1/2/3 study in healthy children <12 years of age.

Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants <6 months of age may subsequently be evaluated.

**Phase 1** is the open-label dose-finding portion of the study to evaluate safety, tolerability, and immunogenicity of BNT162b2 on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age). Dose finding is being initiated in this study in participants ≥5 to <12 years of age based on the acceptable blinded safety assessment of the 30-µg dose in 12- to 15-year-olds in the C4591001 study.

The purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3 different dose levels in each age group.

Dependent upon safety and/or immunogenicity data generated during the course of this study, it is possible that dose levels may not be started, may be terminated early, and/or may be added with dose levels below the lowest stated dose.

Participants will have blood drawn prior to both Dose 1 and Dose 2 and 7 days after Dose 2 to assess immunogenicity to determine the final BNT162b2 dose level for Phase 2/3.

**Phase 2/3** will evaluate the safety, tolerability, and immunogenicity in each age group at the selected dose level from Phase 1. Efficacy will be evaluated across all age groups in which immunobridging is successful, depending on accrual of a sufficient number of cases across those age groups.

All participants will have blood drawn at baseline prior to Dose 1 and 6 months after Dose 2. Immunobridging to participants 16 to 25 years of age in the C4591001 study will be based on...
immunogenicity data collected at baseline and 1 month after Dose 2. The persistence of the immune response will be based on immunogenicity data collected in participants at baseline and at 1, 6, 12 (original BNT162b2 group only), and 24 months after Dose 2 (original BNT162b2 group only). In addition, efficacy against confirmed COVID-19 and against asymptomatic infection will also be assessed.

At designated sites, an additional optional whole blood sample of approximately 10 mL will be obtained prior to Dose 1 and at 7 days and 6 months after Dose 2 from up to approximately 60 participants ≥10 years of age. These samples will be used on an exploratory basis to investigate the postvaccination cell-mediated immune response at these time points.

At the 6-month follow-up visit, all participants will be unblinded. Participants who originally received placebo will be offered the opportunity to receive BNT162b2 as part of the study.

**Number of Participants**

**Phase 1** is an open-label dose-finding study that will consist of up to 3 different dose levels in each age group, with 16 participants per dose level (total of 144 participants).

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Phase 1 Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>Up to 3 Dose Levels of BNT162b2</td>
</tr>
<tr>
<td>≥5 to &lt;12 Years</td>
<td>48</td>
</tr>
<tr>
<td>≥2 to &lt;5 Years</td>
<td>48</td>
</tr>
<tr>
<td>≥6 Months to &lt;2 years</td>
<td>48</td>
</tr>
</tbody>
</table>

**Phase 2/3** will evaluate the safety, tolerability, and immunogenicity of the selected dose level in each age group from Phase 1, with a total of approximately 4500 participants. Participants will be randomized in a 2:1 ratio to receive active vaccine or placebo.

Approximately 450 participants (300 in the active vaccine group and 150 in the placebo group) randomized in each age group in this phase will contribute to the immunobridging analysis at 1 month after Dose 2 and will contribute to the overall analysis of the persistence of immune response at 6 months after Dose 2. These participants will be enrolled from both US and EU sites to ensure this subset is representative of the whole study.

For the persistence time points of 12 and 24 months after Dose 2, approximately 70 participants from each age group in the original BNT162b2 vaccine group will have an immunogenicity blood draw in order to contribute to the analysis. All approximately 4500 participants will contribute to the VE analysis for conditional VE and asymptomatic infection. Efficacy will be evaluated across all age groups in which immunobridging is successful, depending on accrual of a sufficient number of cases across those age groups.
Phase 2/3 Participants – Blood Draws for Immunogenicity/Efficacy Assessments

<table>
<thead>
<tr>
<th>All Age Groups</th>
<th>≥5 to &lt;12 Years of Age</th>
<th>≥2 to &lt;5 Years and ≥6 Months to &lt;2 Years of Agea</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>Active</td>
<td>Placebo</td>
</tr>
<tr>
<td>Baseline blood draw</td>
<td>4500</td>
<td>3000</td>
</tr>
<tr>
<td>1 Month after Dose 2</td>
<td>1350</td>
<td>900</td>
</tr>
<tr>
<td>6 Months after Dose 2</td>
<td>4500</td>
<td>3000</td>
</tr>
<tr>
<td>12 Months after Dose 2</td>
<td>210</td>
<td>210</td>
</tr>
<tr>
<td>24 Months after Dose 2</td>
<td>210</td>
<td>210</td>
</tr>
</tbody>
</table>

a. Number of participants shown is for each of these 2 younger age groups.

All participants will contribute to the safety, tolerability, and efficacy assessments.

<table>
<thead>
<tr>
<th>Phase 2/3 Participants – Safety and Tolerability/Efficacy Assessments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
</tr>
<tr>
<td>-------</td>
</tr>
<tr>
<td>4500</td>
</tr>
</tbody>
</table>

Intervention Groups and Duration

**Phase 1:** Dose finding will begin at the low-dose level in participants ≥5 to <12 years of age. The IRC will review safety data (e-diary and AE) acquired up to 7 days after Dose 1 for the low-dose-level group; upon confirmation of an acceptable safety assessment by the IRC:

- Dosing may commence at the mid-dose level in the same age group, and
- Dosing may commence at the low-dose level in participants ≥2 to <5 years of age.

The same process will be followed when moving up dose levels in each age group, and when progressing between age groups at the low-dose level as shown in Section 1.2. Dosing may commence at the low-dose level in participants ≥6 months to <2 years of age after IRC review of safety data (e-diary and AE) acquired up to 7 days after Dose 1 at the low-dose level from participants ≥2 to <5 years of age.

In each age group, if the low-dose level is considered not acceptable based on safety assessment after Dose 1, the mid-dose level or high-dose level will not commence. In this case, an optional lower dose level may commence. Dependent on the results obtained, dose level(s) may be omitted. In each age group, if the mid-dose level is considered not acceptable based on safety assessment after Dose 1, the high-dose level will not commence.

Based on safety assessments, the second dose may be given at a lower dose level.

**Phase 2/3:** Progression of each age group into Phase 2/3 will occur independently; it is therefore possible that each age group may not start Phase 2/3 concurrently and the dose level selected for Phase 2/3 may differ by age group. For each age group to proceed to Phase 2/3, safety, tolerability, and immunogenicity data from 7 days after Dose 2 for the
selected vaccine dose level in that age group from Phase 1 will be confirmed to be acceptable.

**Duration:** Participants are expected to participate for up to a maximum of approximately 26 months.

**Data Monitoring Committee or Other Independent Oversight Committee**

The study will utilize an IRC, an internal Pfizer committee that will review data to allow dose finding in Phase 1.

An external DMC will review cumulative unblinded data and monitor vaccine safety throughout the study.

**Statistical Methods**

Immunobridging of the immune response to prophylactic BNT162b2 in participants within each age group to the response in participants 16 to 25 years of age from Phase 2/3 of the C4591001 study will be assessed separately for each age group and based on the GMR of SARS-CoV-2 neutralizing titers using a 1.5-fold margin. Immunobridging success will be declared if the lower limit of the 95% CI for the GMR (each age group to the 16- to 25-year age group from C4591001) is >0.67. A sample size of 225 evaluable participants in each age group will provide a power of 90.4% to declare immunobridging success. The immunogenicity data from the active vaccine recipients in approximately 450 participants randomized in each age group in Phase 2/3 will be used for the immunobridging assessment.

The other immunogenicity objectives will be evaluated descriptively by GMT, GMFR, and the associated 95% CIs for SARS-CoV-2 neutralizing titers at the various time points.

The secondary efficacy objectives are to evaluate VE, defined as 100 × (1 – IRR), against the confirmed COVID-19 illness, in all age groups where immunobridging success is declared. IRR is calculated as the ratio of the first confirmed COVID-19 illness rate in the vaccine group to the corresponding illness rate in the placebo group. Hypothesis testing will be conducted only if at least 22 cases are accrued in those age groups. With the assumption of a true VE of 75%, 22 cases will provide 70% power to conclude true VE >20%.

VE against asymptomatic infection will be evaluated descriptively. VE estimate and 2-sided 95% CI for VE will be provided using the Clopper-Pearson method.

The primary safety objective will be evaluated by descriptive summary statistics for local reactions, systemic events, and AEs/SAEs for each vaccine and age group. A 3-tier approach will be used to summarize AEs in Phase 2/3.
1.2. Schema

<table>
<thead>
<tr>
<th>≥5 to &lt;12 Years</th>
<th>≥2 to &lt;5 Years</th>
<th>≥6 Months to &lt;2 Years</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phase 1</strong></td>
<td><strong>Phase 1</strong></td>
<td><strong>Phase 1</strong></td>
</tr>
<tr>
<td>All participants receive BNT162b2</td>
<td>All participants receive BNT162b2</td>
<td>All participants receive BNT162b2</td>
</tr>
<tr>
<td>Low-dose level (n=16)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Low-dose level (n=16)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Low-dose level (n=16)&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>IRC&lt;sup&gt;b&lt;/sup&gt;</td>
<td>IRC&lt;sup&gt;b&lt;/sup&gt;</td>
<td>IRC&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Mid-dose level (n=16)</td>
<td>Mid-dose level (n=16)</td>
<td>Mid-dose level (n=16)</td>
</tr>
<tr>
<td>IRC</td>
<td>IRC</td>
<td>IRC</td>
</tr>
<tr>
<td>High-dose level (n=16)</td>
<td>High-dose level (n=16)</td>
<td>High-dose level (n=16)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Phase 2/3</strong></th>
<th><strong>Phase 2/3</strong></th>
<th><strong>Phase 2/3</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants randomized to receive 2:1 BNT162b2 : placebo</td>
<td>Participants randomized to receive 2:1 BNT162b2 : placebo</td>
<td>Participants randomized to receive 2:1 BNT162b2 : placebo</td>
</tr>
</tbody>
</table>

- **a.** In each age group, if the low-dose level is considered not acceptable based on safety assessment after Dose 1, the mid-dose level or high-dose level will not commence. In this case, an optional lower dose level may commence.
- **b.** The IRC will review safety data (e-diary and AE) acquired up to 7 days after Dose 1 in the low-dose-level group, and dosing may commence at the low-dose level in the next age group based upon confirmation of an acceptable safety assessment at this review.
- **c.** IRC choice of dose level for each age group. Dependent on safety, tolerability, and immunogenicity data from 7 days after Dose 2 in each age group.
1.3. Schedule of Activities

The SoA table provides an overview of the protocol visits and procedures. Refer to the Study Assessments and Procedures section of the protocol for detailed information on each procedure and assessment required for compliance with the protocol.

The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evaluations or assessments required to protect the well-being of the participant.

1.3.1. Phase 1

An unplanned potential COVID-19/MIS-C illness visit and unplanned potential COVID-19/MIS-C convalescent visit are required at any time for the duration of the study that COVID-19/MIS-C symptoms are reported. During the 7 days following each dose, potential COVID-19/MIS-C symptoms that overlap with specific systemic events (ie, fever, chills, new or increased muscle pain, diarrhea, vomiting) should not trigger a potential COVID-19/MIS-C illness visit unless, in the investigator’s opinion, the clinical picture is more indicative of a possible COVID-19/MIS-C illness rather than vaccine reactogenicity. For details, see Section 8.13.

<table>
<thead>
<tr>
<th>Visit Number</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>Unplanned</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit Description</td>
<td>Dose 1(^a) Dose 2</td>
<td>7 Day Follow-up Visit (1 Week After Dose 2) 1-Month Follow-up Visit 6-Month Follow-up Visit 12-Month Follow-up Visit 24-Month Follow-up Visit Potential COVID-19/MIS-C Illness Visit(^b) Potential COVID-19/MIS-C Convalescent Visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit Window (Days)</td>
<td>Day 1 19 to 23 Days After Visit 1 6 to 8 Days After Visit 2 28 to 35 Days After Visit 2 175 to 189 Days After Visit 2 350 to 378 Days After Visit 2 714 to 742 Days After Visit 2 Optimally Within 3 Days After Potential COVID-19/MIS-C Illness Onset 28 to 35 Days After Potential COVID-19/MIS-C Illness Visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of Visit</td>
<td>Clinic Clinic Clinic Clinic or Telephone Telephone Telephone Clinic or Telephone Clinic or Telehealth Clinic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obtain informed consent and assent (if appropriate)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assign participant number</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obtain demography and significant medical history data</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measure vital signs (including body temperature)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perform targeted physical examination including height and weight(^c)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Dose 1 and Dose 2 may be administered at the same visit

\(^b\) Potential COVID-19/MIS-C Illness Visit should only be scheduled if COVID-19/MIS-C symptoms are reported

\(^c\) Performance may be conducted via telehealth
<table>
<thead>
<tr>
<th>Visit Number</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>Unplanned</th>
<th>Unplanned</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit Description</td>
<td>Dose 1#</td>
<td>Dose 2</td>
<td>7 Day Follow-up Visit (1 Week After Dose 2)</td>
<td>1-Month Follow-up Visit</td>
<td>6-Month Follow-up Visit</td>
<td>12-Month Follow-up Visit</td>
<td>24-Month Follow-up Visit</td>
<td>Potential COVID-19/MIS-C Illness Visit</td>
<td>Potential COVID-19/MIS-C Convalescent Visit</td>
</tr>
<tr>
<td>Visit Window (Days)</td>
<td>Day 1</td>
<td>19 to 23 Days After Visit 1</td>
<td>6 to 8 Days After Visit 2</td>
<td>28 to 35 Days After Visit 2</td>
<td>175 to 189 Days After Visit 2</td>
<td>350 to 378 Days After Visit 2</td>
<td>714 to 742 Days After Visit 2</td>
<td>Optimally Within 3 Days After Potential COVID-19/MIS-C Illness Onset</td>
<td>28 to 35 Days After Potential COVID-19/MIS-C Illness Visit</td>
</tr>
<tr>
<td>Type of Visit</td>
<td>Clinic</td>
<td>Clinic</td>
<td>Clinic</td>
<td>Clinic or Telephone</td>
<td>Telephone</td>
<td>Telephone</td>
<td>Clinic or Telephone</td>
<td>Clinic or Telehealth</td>
<td>Clinic</td>
</tr>
<tr>
<td>Perform urine pregnancy test (only for female participants biologically capable of having children)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirm use of contraceptives (if appropriate)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect nonstudy vaccine information</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect prohibited medication use</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Review temporary delay criteria</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirm eligibility</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obtain randomization number and study intervention allocation</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obtain anterior nasal swab</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Collect blood sample for immunogenicity</td>
<td>~5 mL</td>
<td>~5 mL</td>
<td>~5 mL</td>
<td>~5 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administer study intervention</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assess acute reactions for at least 30 minutes after study intervention administration</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Explain communication methods (including for e-diary completion), assist with downloading the app, or issue provisioned device, if required</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit Number</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>Unplanned</td>
<td>Unplanned</td>
</tr>
<tr>
<td>--------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>Visit Description</strong></td>
<td>Dose 1(^a)</td>
<td>Dose 2</td>
<td>7 Day Follow-up Visit (1 Week After Dose 2)</td>
<td>1-Month Follow-up Visit</td>
<td>6-Month Follow-up Visit</td>
<td>12-Month Follow-up Visit</td>
<td>24-Month Follow-up Visit</td>
<td>Potential COVID-19/MIS-C Illness Visit(^b)</td>
<td>Potential COVID-19/MIS-C Convalescent Visit</td>
</tr>
<tr>
<td><strong>Visit Window (Days)</strong></td>
<td>Day 1</td>
<td>19 to 23 Days After Visit 1</td>
<td>6 to 8 Days After Visit 2</td>
<td>28 to 35 Days After Visit 2</td>
<td>175 to 189 Days After Visit 2</td>
<td>350 to 378 Days After Visit 2</td>
<td>714 to 742 Days After Visit 2</td>
<td>Optimally Within 3 Days After Potential COVID-19/MIS-C Illness Onset</td>
<td>28 to 35 Days After Potential COVID-19/MIS-C Illness Visit</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type of Visit</th>
<th>Clinic</th>
<th>Clinic</th>
<th>Clinic</th>
<th>Clinic or Telephone</th>
<th>Telephone</th>
<th>Telephone</th>
<th>Clinic or Telephone</th>
<th>Clinic or Telehealth</th>
<th>Clinic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provide a thermometer and caliper (measuring) device</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ensure the participant’s parent(s)/legal guardian has a caliper device and thermometer</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ask the participant’s parent(s)/legal guardian to complete e-diary and ensure the participant’s parent(s)/legal guardian remains comfortable with chosen e-diary platform</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review reactogenicity e-diary data (daily review is optimal during the active diary period)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review ongoing reactogenicity e-diary symptoms and obtain stop dates</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect AEs(^d)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Collect SAEs(^e)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Collect e-diary or assist the participant’s parent(s)/legal guardian to delete application</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collection of COVID-19/MIS-C–related clinical and laboratory information (including local diagnosis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Visit Number</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>Unplanned</td>
<td>Unplanned</td>
</tr>
<tr>
<td>--------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>Visit Description</td>
<td>Dose 1(^a)</td>
<td>Dose 2</td>
<td>7 Day Follow-up Visit (1 Week After Dose 2)</td>
<td>1-Month Follow-up Visit</td>
<td>6-Month Follow-up Visit</td>
<td>12-Month Follow-up Visit</td>
<td>24-Month Follow-up Visit</td>
<td>Potential COVID-19/MIS-C Illness Visit(^b)</td>
<td>Potential COVID-19/MIS-C Convalescent Visit</td>
</tr>
<tr>
<td>Visit Window (Days)</td>
<td>Day 1</td>
<td>19 to 23 Days After Visit 1</td>
<td>6 to 8 Days After Visit 2</td>
<td>28 to 35 Days After Visit 2</td>
<td>175 to 189 Days After Visit 2</td>
<td>350 to 378 Days After Visit 2</td>
<td>714 to 742 Days After Visit 2</td>
<td>Optimally Within 3 Days After Potential COVID-19/MIS-C Illness Onset</td>
<td>28 to 35 Days After Potential COVID-19/MIS-C Illness Visit</td>
</tr>
<tr>
<td>Type of Visit</td>
<td>Clinic</td>
<td>Clinic</td>
<td>Clinic</td>
<td>Clinic or Telephone</td>
<td>Telephone</td>
<td>Telephone</td>
<td>Clinic or Telephone</td>
<td>Clinic or Telehealth</td>
<td>Clinic</td>
</tr>
</tbody>
</table>

Abbreviations: CRF = case report form; MIS-C = multisystem inflammatory syndrome in children.

a. The visit may be conducted across 2 consecutive days; if so, all steps from assessing the inclusion and exclusion criteria onwards must be conducted on the day of vaccination.
b. Potential MIS-C visit: hospitalization for a severe illness with no other alternative etiology.
c. Height and weight will be collected only at Visit 1.
d. Any AEs occurring up to 48 hours after blood draw and anterior nasal swab collection must be recorded (see Section 8.3.1). Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.
e. Refer to Section 8.3.1 for the time period for collecting SAEs.
1.3.2. Phase 2/3

An unplanned potential COVID-19/MIS-C illness visit and unplanned potential COVID-19/MIS-C convalescent visit are required at any time for the duration of the study that potential COVID-19/MIS-C symptoms are reported. During the 7 days following each dose, potential COVID-19/MIS-C symptoms that overlap with specific systemic events (ie, fever, chills, new or increased muscle pain, diarrhea, vomiting) should not trigger a potential COVID-19/MIS-C illness visit unless, in the investigator’s opinion, the clinical picture is more indicative of a possible COVID-19/MIS-C illness rather than vaccine reactogenicity. For details, see Section 8.13.

At the 6-month (Visit 5) follow-up visit, all participants will be unblinded. Participants who originally received placebo will be offered the opportunity to receive BNT162b2 as part of the study.

<table>
<thead>
<tr>
<th>Visit Number</th>
<th>Visit Description</th>
<th>1 Dose 1a</th>
<th>2 Dose 2</th>
<th>3 1-Week Follow-up Visitb</th>
<th>4 1-Month Follow-up Visitc</th>
<th>5 6-Month Follow-up Visitc</th>
<th>Unplanned Potential COVID-19 Illness/MIS-C Visitd</th>
<th>Unplanned Potential COVID-19/MIS-C Convalescent Visit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Visit Window (Days)</td>
<td>Day 1</td>
<td>19 to 23 Days After Visit 1</td>
<td>6 to 8 Days After Visit 2</td>
<td>28 to 35 Days After Visit 2</td>
<td>175 to 189 Days After Visit 2</td>
<td>Optimally Within 3 Days After Potential COVID-19/MIS-C Illness Onset</td>
<td>28 to 35 Days After Potential COVID-19/MIS-C Illness Visit</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type of Visit</th>
<th>Clinic</th>
<th>Clinic</th>
<th>Clinic</th>
<th>Clinic or Telephone</th>
<th>Clinic</th>
<th>Clinic or Telehealth</th>
<th>Clinic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obtain informed consent and assent (if appropriate)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assign participant number</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obtain demography and significant medical history data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measure vital signs (including body temperature)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perform targeted physical examination including height and weightd</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For participants who are HIV positive, record latest CD4 count and HIV viral load</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perform urine pregnancy test (only for female participants biologically capable of having children)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirm use of contraceptives (if appropriate)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect nonstudy vaccine information</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect prohibited medication use</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit Number</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>Unplanned</td>
<td>Unplanned</td>
</tr>
<tr>
<td>--------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>Visit Description</td>
<td>Dose 1*</td>
<td>Dose 2</td>
<td>1-Week Follow-up Visit†</td>
<td>1-Month Follow-up Visit</td>
<td>6-Month Follow-up Visit</td>
<td>Potential COVID-19 Illness/MIS-C Visit‡</td>
<td>Potential COVID-19/MIS-C Convalescent Visit</td>
</tr>
<tr>
<td>Visit Window (Days)</td>
<td>Day 1</td>
<td>19 to 23 Days After Visit 1</td>
<td>6 to 8 Days After Visit 2</td>
<td>28 to 35 Days After Visit 2</td>
<td>175 to 189 Days After Visit 2</td>
<td>Optimally Within 3 Days After Potential COVID-19/MIS-C Illness Onset</td>
<td>28 to 35 Days After Potential COVID-19/MIS-C Illness Visit</td>
</tr>
<tr>
<td>Type of Visit</td>
<td>Clinic</td>
<td>Clinic</td>
<td>Clinic or Telephone</td>
<td>Clinic</td>
<td>Clinic or Telephone</td>
<td>Clinic or Telehealth</td>
<td>Clinic</td>
</tr>
<tr>
<td>Review temporary delay criteria</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirm eligibility</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obtain randomization number and study intervention allocation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obtain anterior nasal swab</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect blood sample for immunogenicity</td>
<td>~5 mL</td>
<td>~5 mL†</td>
<td>~5 mL</td>
<td>~5 mL</td>
<td></td>
<td>~5 mL</td>
<td></td>
</tr>
<tr>
<td>Collect blood sample for PBMC isolation§</td>
<td>~10 mL</td>
<td>~10 mL</td>
<td>~10 mL</td>
<td>~10 mL</td>
<td></td>
<td>~10 mL</td>
<td></td>
</tr>
<tr>
<td>Administer study intervention</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assess acute reactions for at least 30 minutes after study intervention administration</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Explain communication methods (including for e-diary completion), assist with downloading the app, or issue provisioned device, if required</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provide thermometer and caliper (measuring) device</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ensure the participant’s parent(s)/legal guardian has a caliper device and thermometer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Ask the participant’s parent(s)/legal guardian to complete e-diary and ensure the participant’s parent(s)/legal guardian remains comfortable with chosen e-diary platform</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review reactogenicity e-diary data (daily review is optimal during the active diary period)</td>
<td>⬤ ⬤</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review ongoing reactogenicity e-diary symptoms and obtain stop dates</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect AEs as appropriate§</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Visit Number</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>Unplanned Visit</td>
<td>Unplanned Visit</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>------------</td>
<td>-------------------------</td>
<td>------------</td>
<td>------------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Visit Description</td>
<td>Dose 1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Dose 2</td>
<td>1-Week Follow-up Visit&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1-Month Follow-up Visit</td>
<td>6-Month Follow-up Visit&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Potential COVID-19 Illness/MIS-C Visit&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Potential COVID-19/MIS-C Convalescent Visit</td>
</tr>
<tr>
<td>Visit Window (Days)</td>
<td>Day 1</td>
<td>19 to 23 Days After Visit 1</td>
<td>6 to 8 Days After Visit 2</td>
<td>28 to 35 Days After Visit 2</td>
<td>175 to 189 Days After Visit 2</td>
<td>Optimally Within 3 Days After Potential COVID-19/MIS-C Illness Onset</td>
<td>28 to 35 Days After Potential COVID-19/MIS-C Illness Visit</td>
</tr>
<tr>
<td>Type of Visit</td>
<td>Clinic</td>
<td>Clinic</td>
<td>Clinic</td>
<td>Clinic or Telephone</td>
<td>Clinic</td>
<td>Clinic or Telehealth</td>
<td>Clinic</td>
</tr>
<tr>
<td>Collect SAEs as appropriate&lt;sup&gt;b&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Unblind the participant and move to either Section 1.3.2.1 or Section 1.3.2.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collection of COVID-19/MIS-C–related clinical and laboratory information (including local diagnosis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CRF = case report form; HIV = human immunodeficiency virus; MIS-C = multisystem inflammatory syndrome in children; PBMC = peripheral blood mononuclear cell.

a. This visit may be conducted across 2 consecutive dates; if so, all steps from assessing the inclusion and exclusion criteria onwards must be conducted on the day of vaccination.
b. Applicable at designated sites only for participants ≥10 years of age whose parent(s)/legal guardian have given consent for this additional blood draw.
c. For Phase 2/3 participants who originally received placebo, it is preferable that Visit 5 and Visit A (Section 1.3.2.2) occur on the same day.
d. Potential MIS-C visit: hospitalization for a severe illness with no other alternative etiology.
e. Height and weight will be collected only at Visit 1.
f. Only approximately 450 randomized participants in each age group will have blood drawn at 1 month after Dose 2.
g. Any AEs occurring up to 48 hours after blood draw and anterior nasal swab collection must be recorded (see Section 8.3.1). Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.
h. Refer to Section 8.3.1 for the time period for collecting SAEs.
1.3.2.1. Phase 2/3 Participants Who Originally Received BNT162b2 or Placebo Recipients Who Decline BNT162b2

After unblinding at Visit 5, participants who originally received BNT162b2 or placebo recipients who decline BNT162b2 will follow this SoA for their remaining visits.

An unplanned potential COVID-19/MIS-C illness visit and unplanned potential COVID-19/MIS-C convalescent visit are required at any time for the duration of the study that potential COVID-19/MIS-C symptoms are reported.

<table>
<thead>
<tr>
<th>Visit Number</th>
<th>Visit X</th>
<th>Visit Y</th>
<th>Unplanned</th>
<th>Unplanned</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit Description</td>
<td>12-Month Follow-up Visit</td>
<td>24-Month Follow-up Visit</td>
<td>Potential COVID-19 Illness/MIS-C Visit&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Potential COVID-19/MIS-C Convalescent Visit</td>
</tr>
<tr>
<td>Visit Window (Days)</td>
<td>350 to 378 Days After Visit 2</td>
<td>714 to 742 Days After Visit 2</td>
<td>Optimally Within 3 Days After Potential COVID-19/MIS-C Illness Onset</td>
<td>28 to 35 Days After Potential COVID-19/MIS-C Illness Visit</td>
</tr>
<tr>
<td>Type of Visit</td>
<td>Clinic or Telephone</td>
<td>Clinic or Telephone</td>
<td>Clinic or Telehealth</td>
<td>Clinic</td>
</tr>
</tbody>
</table>

- For participants who are HIV positive, record latest CD4 count and HIV viral load: X X
- Collect prohibited medication use: X X X X
- Obtain anterior nasal swab: X
- Collect blood sample for immunogenicity<sup>b</sup>: ~5 mL<sup>c</sup> ~5 mL<sup>c</sup> ~5 mL
- Collect AEs as appropriate<sup>d</sup>: X X X X
- Collect e-diary or assist the participant’s parent(s)/legal guardian to delete application: X
- Collection of COVID-19/MIS-C–related clinical and laboratory information (including local diagnosis): X X

Abbreviations: CRF = case report form; HIV = human immunodeficiency virus; MIS-C = multisystem inflammatory syndrome in children.

<sup>a</sup> Potential MIS-C visit: hospitalization for a severe illness with no other alternative etiology.

<sup>b</sup> The participants who are part of the evaluation of persistence of immune response will have blood drawn either at Visit X or Visit Y.

<sup>c</sup> If the participants had an unplanned potential COVID-19/MIS-C convalescent visit within ≤42 days before the scheduled visit (Visit X or Visit Y) and if a blood sample was collected as part of the convalescent visit, or if the participant originally received placebo and declines the offer of BNT162b2, blood sample collection at the scheduled visit is not required.

<sup>d</sup> Any AEs occurring up to 48 hours after blood draw and anterior nasal swab collection must be recorded (see Section 8.3.1). Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.
1.3.2.2. Phase 2/3 Participants Who Originally Received Placebo

Participants who originally received placebo and accept the offer for receiving BNT162b2 will follow this SoA after unblinding at Visit 5 (in Section 1.3.2).

An unplanned potential COVID-19/MIS-C illness visit and unplanned potential COVID-19/MIS-C convalescent visit are required at any time for the duration of the study that potential COVID-19/MIS-C symptoms are reported. During the 7 days following each dose, potential COVID-19/MIS-C symptoms that overlap with specific systemic events (ie, fever, chills, new or increased muscle pain, diarrhea, vomiting) should not trigger a potential COVID-19/MIS-C illness visit unless, in the investigator’s opinion, the clinical picture is more indicative of a possible COVID-19 illness rather than vaccine reactogenicity. For details, see Section 8.13.

<table>
<thead>
<tr>
<th>Visit Number</th>
<th>Visit Description</th>
<th>A Dose 3</th>
<th>B Dose 4</th>
<th>C 1-Month Follow-up Visit</th>
<th>D 6-Month Follow-up Visit</th>
<th>E 12-Month Follow-up Visit</th>
<th>F 18-Month Follow-up Visit</th>
<th>Unplanned Potential COVID-19/MIS-C Visit</th>
<th>Unplanned Potential COVID-19/MIS-C Convalescent Visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit Window (Days)</td>
<td>175 to 189 Days After Dose 2</td>
<td>19 to 23 Days After Visit A</td>
<td>28 to 35 Days After Visit B</td>
<td>175 to 189 Days After Visit B</td>
<td>350 to 378 Days After Visit B</td>
<td>532 to 560 Days After Visit B</td>
<td>Optimally Within 3 Days After Potential COVID-19/MIS-C Illness Onset</td>
<td>28 to 35 Days After Potential COVID-19 Illness Visit</td>
<td></td>
</tr>
<tr>
<td>Type of Visit</td>
<td>Clinic</td>
<td>Clinic</td>
<td>Telephone</td>
<td>Telephone</td>
<td>Telephone</td>
<td>Clinic or Telephone</td>
<td>Clinic or Telehealth</td>
<td>Clinic</td>
<td></td>
</tr>
<tr>
<td>Confirm participant originally received placebo</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measure vital signs (including body temperature)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perform targeted physical examination</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For participants who are HIV positive, record latest CD4 count and HIV viral load</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perform urine pregnancy test (only for female participants biologically capable of having children)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirm use of contraceptives (if appropriate)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect prohibited medication use</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Visit Number</td>
<td>A</td>
<td>B</td>
<td>C</td>
<td>D</td>
<td>E</td>
<td>F</td>
<td>Unplanned</td>
<td>Unplanned</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>-----------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>Visit Description</td>
<td>Dose 3</td>
<td>Dose 4</td>
<td>1-Month Follow-up Visit</td>
<td>6-Month Follow-up Visit</td>
<td>12-Month Follow-up Visit</td>
<td>18-Month Follow-up Visit</td>
<td>Potential COVID-19 Illness/MIS-C Visit</td>
<td>Potential COVID-19/MIS-C Convalescent Visit</td>
<td></td>
</tr>
<tr>
<td>Visit Window (Days)</td>
<td>175 to 189 Days After Dose 2</td>
<td>19 to 23 Days After Visit A</td>
<td>28 to 35 Days After Visit B</td>
<td>175 to 189 Days After Visit B</td>
<td>350 to 378 Days After Visit B</td>
<td>532 to 560 Days After Visit B</td>
<td>Optimally Within 3 Days After Potential COVID-19 Illness Onset</td>
<td>28 to 35 Days After Potential COVID-19 Illness Visit</td>
<td></td>
</tr>
<tr>
<td>Type of Visit</td>
<td>Clinic</td>
<td>Clinic</td>
<td>Telephone</td>
<td>Telephone</td>
<td>Telephone</td>
<td>Clinic or Telephone</td>
<td>Clinic or Telehealth</td>
<td>Clinic</td>
<td></td>
</tr>
<tr>
<td>Obtain anterior nasal swab</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Collect blood sample for immunogenicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>~5 mL</td>
<td></td>
</tr>
<tr>
<td>Review temporary delay criteria</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review and consider eligibility</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obtain vaccine vial allocation via IRT</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administer BNT162b2</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assess acute reactions for at least 30 minutes after study intervention administration</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect AEs as appropriate§</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect SAEs as appropriate¶§</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect e-diary or assist the participant’s parent(s)/legal guardian to delete application</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit Number</td>
<td>A</td>
<td>B</td>
<td>C</td>
<td>D</td>
<td>E</td>
<td>F</td>
<td>Unplanned</td>
<td>Unplanned</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>-----------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>Visit Description</td>
<td>Dose 3</td>
<td>Dose 4</td>
<td>1-Month Follow-up Visit</td>
<td>6-Month Follow-up Visit</td>
<td>12-Month Follow-up Visit</td>
<td>18-Month Follow-up Visit</td>
<td>Potential COVID-19 Illness/MIS-C Visit*</td>
<td>Potential COVID-19/MIS-C Convalescent Visit</td>
<td></td>
</tr>
<tr>
<td>Visit Window (Days)</td>
<td>175 to 189 Days After Dose 2</td>
<td>19 to 23 Days After Visit A</td>
<td>28 to 35 Days After Visit B</td>
<td>175 to 189 Days After Visit B</td>
<td>350 to 378 Days After Visit B</td>
<td>532 to 560 Days After Visit B</td>
<td>Optimally Within 3 Days After Potential COVID-19 Illness Onset</td>
<td>28 to 35 Days After Potential COVID-19 Illness Visit</td>
<td></td>
</tr>
<tr>
<td>Type of Visit</td>
<td>Clinic</td>
<td>Clinic</td>
<td>Telephone</td>
<td>Telephone</td>
<td>Telephone</td>
<td>Clinic or Telephone</td>
<td>Clinic or Telehealth</td>
<td>Clinic</td>
<td></td>
</tr>
<tr>
<td>Collection of COVID-19/MIS-C–related clinical and laboratory information (including local diagnosis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CRF = case report form; HIV = human immunodeficiency virus; IRT = interactive response technology; MIS-C = multisystem inflammatory syndrome in children.

a. Potential MIS-C visit: hospitalization for a severe illness with no other alternative etiology.
b. Any AEs occurring up to 48 hours after blood draw and anterior nasal swab collection must be recorded (see Section 8.3.1). Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.
c. Refer to Section 8.3.1 for the time period for collecting SAEs.
2. INTRODUCTION

The BNT162b2 RNA-based COVID-19 vaccine is being investigated for prevention of COVID-19 in healthy children.

2.1. Study Rationale

The purpose of the study is to rapidly describe the safety, tolerability, immunogenicity, and efficacy (depending on accrual of sufficient cases) of the BNT162b2 RNA-based COVID-19 vaccine candidate against COVID-19 in healthy children. There are currently no licensed vaccines to prevent infection with SARS-CoV-2 or development of COVID-19. Given the global crisis of COVID-19 and fast expansion of the disease in the United States and elsewhere, the rapid development of an effective vaccine is of utmost importance.

2.2. Background

In December 2019, a pneumonia outbreak of unknown cause occurred in Wuhan, China. In January 2020, it became clear that a novel coronavirus (2019-nCoV) was the underlying cause. Later in January, the genetic sequence of the 2019-nCoV became available to the WHO and public (MN908947.3), and the virus was categorized in the Betacoronavirus subfamily. By sequence analysis, the phylogenetic tree revealed a closer relationship to SARS virus isolates than to another coronavirus infecting humans, the MERS virus.\textsuperscript{1,2}

SARS-CoV-2 infections and the resulting disease, COVID-19, have spread globally, affecting a growing number of infections in countries worldwide. Children have been affected by both the primary COVID-19 disease and the less common secondary inflammatory complications, including MIS-C.\textsuperscript{3,4}

On 11 March 2020, the WHO characterized the COVID-19 outbreak as a pandemic.\textsuperscript{5} The WHO Weekly Epidemiology Update Report dated 27 September 2020 noted more than 32.7 million COVID-19 cases and 991,000 deaths globally, including 16,233,110 confirmed cases with 546,864 deaths in the Americas.\textsuperscript{6} COVID-19 is generally milder in children than adults, possibly because common risk factors for severe COVID-19 in adults are generally less prevalent in pediatric age groups. Children present with fever and dry cough over half the time and symptoms can include GI symptoms, including diarrhea and vomiting, and in some cases can be the only presenting features. Pulmonary involvement in symptomatic children is generally mild.\textsuperscript{7,8,9} Nevertheless, severe cases, including those requiring intensive care support, have been reported.\textsuperscript{3} Of US children diagnosed with COVID-19, 5.7% to 20% were hospitalized, including 0.58% to 2.0% admitted to an ICU.\textsuperscript{10}

MIS-C, an emerging condition that appears to be temporally related to recent exposure to SARS-CoV-2, has been described and frequently requires ICU admission, and may have a fatal outcome.\textsuperscript{4,11} MIS-C is a febrile hyperinflammatory condition with frequent evidence of cardiac damage and dermatologic, mucocutaneous, and GI features.\textsuperscript{11} The syndrome appears to have some overlap with Kawasaki disease shock syndrome.\textsuperscript{12,13} Compared with Kawasaki disease, patients with MIS-C are older, have more cardiac injury, and are more likely to be black, Hispanic, or of South Asian descent.\textsuperscript{14} As of 29 June 2020, approximately 1000 cases...
have been reported.\textsuperscript{14} As of 29 July 2020, a total of 570 cases were reported in the US to the CDC. Of these, 86.0\% involved 4 or more organ systems, 63.9\% of patients required ICU admission, and severe complications included cardiac dysfunction (40.6\%), shock (35.4\%), myocarditis (22.8\%), coronary artery dilation or aneurysm (18.6\%), and acute kidney injury (18.4\%).\textsuperscript{15} Death rates of 2\% to 4\% have been reported.\textsuperscript{14} MIS-C has been reported in many countries throughout North America, Europe, Asia, and Latin America,\textsuperscript{16} including the US,\textsuperscript{4,11} Italy,\textsuperscript{17} and France.\textsuperscript{18} The United States currently has the most reported cases globally, with the number of confirmed cases continuing to rise globally. There are currently no licensed vaccines or effective antiviral drugs to prevent SARS-CoV-2 infections or the disease it causes, COVID-19.\textsuperscript{19}

A prophylactic, RNA-based SARS-CoV-2 vaccine provides one of the most flexible and fastest approaches available to immunize against the emerging virus.\textsuperscript{20,21}

The development of an RNA-based vaccine encoding a viral antigen, which is then expressed by the vaccine recipient as a protein capable of eliciting protective immune responses, provides significant advantages over more traditional vaccine approaches. Unlike live attenuated vaccines, RNA vaccines do not carry the risks associated with infection and may be given to people who cannot be administered live virus (eg, pregnant women and immunocompromised persons). RNA-based vaccines are manufactured via a cell-free in vitro transcription process, which allows an easy and rapid production and the prospect of producing high numbers of vaccination doses within a shorter time period than achieved with traditional vaccine approaches. This capability is pivotal to enable the most effective response in outbreak scenarios.\textsuperscript{20,21}

A Phase 1/2/3 study (C4591001) is being conducted in healthy individuals 12 years of age and older to investigate the safety, tolerability, immunogenicity, and efficacy of the prophylactic BNT162 vaccine candidates against COVID-19. The vaccine candidate selected for evaluation in the C4591001 Phase 2/3 study is BNT162b2 at a dose level of 30 \(\mu\)g and as 2 doses given approximately 21 days apart. On 18 November 2020, the primary efficacy analysis results were announced, which demonstrated BNT162b2 to be 95\% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group. Safety data from approximately 38,000 participants randomized 1:1 with a median of 2 months of follow-up after the second dose of vaccine showed a favorable safety profile at a dose of 30 \(\mu\)g in participants 16 years of age and older.\textsuperscript{22} On 11 December 2020, the US FDA issued an EUA for use in individuals 16 years of age and older. Other countries have also granted EUA (eg, Canada, Mexico, Bahrain), and Pfizer and BioNTech are anticipating further regulatory decisions in other countries.

This Phase 1/2/3 study (C4591007) will evaluate up to 3 different dose levels of BNT162b2 in children in up to 3 age groups (participants \(\geq 5\) to \(<12\) years, \(\geq 2\) to \(<5\) years, and \(\geq 6\) months to \(<2\) years of age). Safety, tolerability, immunogenicity, and efficacy (depending on successful immunobridging and accrual of a sufficient number of cases) will be evaluated. Phase 1 includes the dose-finding portion. Initiation of dose finding in participants \(\geq 5\) to
<12 years of age will be based on the acceptable blinded safety data demonstrated in 2259 12- through 15-year-olds at the 30-µg dose level in the C4591001 study. The Phase 2/3 BNT162b2 dose level to be used in each age group in this study will be selected based on the Phase 1 safety, tolerability, and immunogenicity data from the same age group. Phase 2/3 includes an immunobridging analysis of immune responses in participants ≥6 months to <12 years of age to those in participants 16 to 25 years of age in the Phase 3 C4591001 efficacy study. Safety, tolerability, and efficacy (depending on successful immunobridging and accrual of a sufficient number of cases) will also be evaluated in Phase 2/3 of this study.

### 2.2.1. Clinical Overview

The BNT162 vaccine candidates use an RNA to deliver genetic information to cells, where it is used to express proteins for the therapeutic effect. This vaccine is for the prevention of COVID-19. Prior to this study, clinical data from the BNT162b2 vaccine established a favorable safety profile, with mild, localized, and transient effects. The C4591001 study is currently in Phase 3, which includes >40,000 individuals in the US and other countries, of whom >21,000 participants have now been administered BNT162b2 at the 30-µg dose level on a 2-dose schedule. Vaccine-related enhanced disease for vaccines against related coronaviruses (SARS-CoV-1 and MERS) has been reported only in animal models. To date, no enhanced disease has been observed in SARS-CoV-2 animal models with any SARS-CoV-2 vaccine platform, including RNA-based vaccines. Such effects have not been documented so far for SARS-CoV-2. The currently available safety and immunogenicity data are presented in the BNT162 IB.

### 2.3. Benefit/Risk Assessment

There is an ongoing global pandemic of COVID-19 with no approved or licensed preventive options available. However, based on the data available from the C4591001 study, multiple temporary or emergency use authorizations have been granted. The available safety and immunogenicity data from the ongoing Pfizer/BioNTech clinical trial combined with available nonclinical data with BNT162 vaccines, and data from nonclinical studies and clinical trials with the same or related RNA components, or antigens, support a favorable benefit/risk profile and support continued clinical development of BNT162b2.

In the C4591001 study, BNT162b2 has been shown to elicit increased local and systemic adverse reactions as compared to those in the placebo arm, usually lasting a few days. The most common solicited adverse reactions were injection site reactions (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), and fever (14.2%). Adverse reactions characterized as reactogenicity were generally mild to moderate. The number of participants reporting hypersensitivity-related AEs was numerically higher in the active vaccine group compared with the placebo group (137 [0.63%] vs 111 [0.51%]). Severe adverse reactions occurred in 0.0% to 4.6% of participants, were more frequent after Dose 2 than after Dose 1, and were generally less frequent in older adults (>55 years of age) (<2.8%) as compared to younger participants (≤4.6%). Among reported unsolicited AEs, lymphadenopathy occurred much more frequently in the active vaccine group than the placebo group and is plausibly related to
vaccination. SAEs, while uncommon (<1.0%), represented medical events that occur in the general population at similar frequency as observed in the study.²²

No specific safety concerns were identified in subgroup analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection. Although participants 16 through 17 years of age were enrolled in the Phase 3 trial, safety data for this age group are limited. However, available data are consistent with the safety profile in the adult population, and it is biologically reasonable to extrapolate the greater safety experience in adults, in particular younger adults, to the oldest pediatric age group of 16 through 17 years. The potential risks are based on the observed safety profile to date, which shows mostly mild reactogenicity, low incidence of severe or serious events, and no clinically concerning safety observations. The preponderance of severe cases of COVID-19 in the placebo group relative to the BNT162b2 group (9 of 10) suggests no evidence of VAED.²²

In order for the study population to be as representative and diverse as possible, the inclusion of participants with known chronic stable HIV, HCV, or HBV is permitted in Phase 2/3. Individuals with chronic viral diseases are at increased risk for COVID-19 complications and severe disease. In addition, with the currently available therapies for their treatment, many individuals with chronic stable HIV, HCV, or HBV infections are less likely to be at increased safety risk as a participant in this vaccine study than individuals with other chronic stable medical conditions.

More detailed information about the known and expected benefits and risks and reasonably expected AEs of BNT162b2 RNA-based COVID-19 vaccine may be found in the IB, which is the SRSD for this study.
### 2.3.1. Risk Assessment

<table>
<thead>
<tr>
<th>Potential Risk of Clinical Significance</th>
<th>Summary of Data/Rationale for Risk</th>
<th>Mitigation Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Intervention(s) [BNT162b2 RNA-Based COVID-19 Vaccine]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potential for greater local reactions (injection site redness, injection site swelling, and injection site pain) and systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, muscle pain, and joint pain) following vaccination as compared to adults/adolescents in the C4591001 study.</td>
<td>These are common adverse reactions seen with other vaccines, as noted in the FDA CBER guidelines on toxicity grading scales for healthy adult and adolescent volunteers in preventive vaccine clinical trials. The most common events reported in C4591001 were mild to moderate pain at the injection site, fatigue, and headache. To address reactogenicity concerns, dose finding has been included as outlined. In addition, the study employs the use of a reactogenicity e-diary to monitor local reactions and systemic events in real time. All study participants will be observed for at least 30 minutes after vaccination.</td>
<td></td>
</tr>
<tr>
<td>Unknown AEs with a novel vaccine in children ≥6 months to &lt;12 years of age.</td>
<td>Data available from the C4591001 study showed low incidence of severe or serious events, and no clinically concerning safety observations. The vaccine appears to be safe and well-tolerated across the safety population and within demographic subgroups based on age, sex, race/ethnicity, country, and baseline SARS-CoV-2 status.</td>
<td>The current Phase 3 C4591001 study includes participants 12 years of age and older.</td>
</tr>
<tr>
<td>Potential for COVID-19 enhancement.</td>
<td>Disease enhancement has been seen following vaccination with RSV, feline coronavirus, and Dengue virus vaccines.</td>
<td>No evidence of disease enhancement has been reported in the C4591001 study to date. Temporary delay criteria defer vaccination of participants with symptoms of potential COVID-19. All participants are followed for any potential COVID-19 illness, including markers of severity, and have blood samples taken for potential measurement of SARS-CoV-2 neutralizing titers.</td>
</tr>
<tr>
<td>MIS-C.</td>
<td>Febrile hyperinflammatory condition with multisystem (≥2) organ involvement as defined in Section 8.1.</td>
<td>MIS-C will be prospectively collected as a potential for COVID-19/MIS-C illness visits for the duration of study participation.</td>
</tr>
<tr>
<td>Potential Risk of Clinical Significance</td>
<td>Summary of Data/Rationale for Risk</td>
<td>Mitigation Strategy</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Participants will be required to attend healthcare facilities during the global SARS-CoV-2 pandemic.</td>
<td>Without appropriate social distancing and PPE, there is a potential for increased exposure to SARS-CoV-2.</td>
<td>Pfizer will work with sites to ensure an appropriate COVID-19 prevention strategy. Potential COVID-19/MIS-C illness visits can be conducted via telehealth, without the need for an in-person visit, if required, with the participant’s parent(s)/legal guardian performing an anterior nasal swab for the participant.</td>
</tr>
<tr>
<td>Venipuncture will be performed during the study.</td>
<td>There is the risk of bleeding, bruising, hematoma formation, and infection at the venipuncture site.</td>
<td>Only appropriately qualified personnel will obtain the blood draw. To minimize the total amount of blood drawn, all participants in Phase 1 and participants contributing to the immunogenicity analysis in Phase 2/3 will have at most 3 planned blood draws, with all remaining participants having 2 planned blood draws.</td>
</tr>
</tbody>
</table>
2.3.2. Benefit Assessment

Benefits to individual participants may include:

- Receipt of an efficacious COVID-19 vaccine during a global pandemic
- Access to COVID-19 diagnostic testing
- Contributing to research to help others in a time of global pandemic

2.3.3. Overall Benefit/Risk Conclusion

Taking into account the measures taken to minimize risk to participants participating in this study, the potential risks identified in association with BNT162b2 RNA-based COVID-19 vaccine are justified by the anticipated benefits that may be afforded to healthy participants.

3. OBJECTIVES, ESTIMANDS, AND ENDPOINTS

The age groups referred to in the objectives and estimands below are participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age.

3.1. Phase 1

<table>
<thead>
<tr>
<th>Phase 1</th>
<th>Objectives</th>
<th>Estimands</th>
<th>Endpoints</th>
</tr>
</thead>
</table>
| Primary: | To describe the safety and tolerability profiles of prophylactic BNT162b2 at each dose level in each age group. | In participants receiving at least 1 dose of study intervention, the percentage of participants in each age group reporting:  
  - Local reactions for up to 7 days following each dose  
  - Systemic events for up to 7 days following each dose  
  - AEs from Dose 1 to 1 month after Dose 2  
  - SAEs from Dose 1 to 6 months after Dose 2 | Participants ≥5 to <12 years and ≥2 to <5 years of age:  
  - Local reactions (pain at the injection site, redness, and swelling)  
  - Systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain)  
  - AEs  
  - SAEs  
  Participants ≥6 months to <2 years of age:  
  - Local reactions (tenderness at the injection site, redness, and swelling)  
  - Systemic events (fever, decreased appetite, drowsiness, and irritability)  
  - AEs  
  - SAEs |
<table>
<thead>
<tr>
<th>Phase 1</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Objectives</strong></td>
<td><strong>Estimands</strong></td>
<td><strong>Endpoints</strong></td>
</tr>
<tr>
<td><strong>Secondary:</strong></td>
<td><strong>Secondary:</strong></td>
<td><strong>Secondary:</strong></td>
</tr>
<tr>
<td>To describe the immune responses elicited by prophylactic BNT162b2 at each dose level in each age group</td>
<td>In participants complying with the key protocol criteria (evaluable participants) in each age group: At baseline, before Dose 2, and 7 days after Dose 2, • GMTs at each time point • GMFR from before Dose 1 (baseline) to each subsequent time point after vaccination</td>
<td>• SARS-CoV-2 neutralizing titers</td>
</tr>
<tr>
<td><strong>Exploratory:</strong></td>
<td><strong>Exploratory:</strong></td>
<td><strong>Exploratory:</strong></td>
</tr>
<tr>
<td>To describe COVID-19 and severe COVID-19 cases with and without serological or virological evidence of past SARS-CoV-2 infection</td>
<td></td>
<td>• Confirmed COVID-19 cases • Confirmed severe COVID-19 cases</td>
</tr>
<tr>
<td>To describe MIS-C cases with and without evidence of past SARS-CoV-2 infection</td>
<td></td>
<td>• Confirmed cases as per CDC criteria</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phase 2/3</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Objectives</strong></td>
<td><strong>Estimands</strong></td>
<td><strong>Endpoints</strong></td>
</tr>
<tr>
<td><strong>Primary Safety:</strong></td>
<td><strong>Primary Safety:</strong></td>
<td><strong>Primary Safety:</strong></td>
</tr>
<tr>
<td>To define the safety profile of prophylactic BNT162b2 at the selected dose level in participants included in the Phase 2/3 immunobridging analysis in each age group</td>
<td>In participants receiving at least 1 dose of study intervention, from each vaccine group, the percentage of participants in each age group reporting: • Local reactions for up to 7 days following each dose • Systemic events for up to 7 days following each dose • AEs from Dose 1 to 1 month after Dose 2 • SAEs from Dose 1 to 1 month after Dose 2</td>
<td>Participants ≥5 to &lt;12 years and ≥2 to &lt;5 years of age: • Local reactions (pain at the injection site, redness, and swelling) • Systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain) • AEs • SAEs Participants ≥6 months to &lt;2 years of age: • Local reactions (tenderness at the injection site, redness, and swelling) • Systemic events (fever, decreased appetite, drowsiness, and irritability) • AEs • SAEs</td>
</tr>
</tbody>
</table>
### Phase 2/3

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Estimands</th>
<th>Endpoints</th>
</tr>
</thead>
</table>
| To define the safety profile of prophylactic BNT162b2 at the selected dose level in all participants randomized in Phase 2/3 in each age group | In participants receiving at least 1 dose of study intervention from each vaccine group, the percentage of participants in each age group reporting:  
- Local reactions for up to 7 days following each dose  
- Systemic events for up to 7 days following each dose  
- AEs from Dose 1 to 1 month after Dose 2  
- SAEs from Dose 1 to 6 months after Dose 2 | Participants ≥5 to <12 years and ≥2 to <5 years of age:  
- Local reactions (pain at the injection site, redness, and swelling)  
- Systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain)  
- AEs  
- SAEs  
Participants ≥6 months to <2 years of age:  
- Local reactions (tenderness at the injection site, redness, and swelling)  
- Systemic events (fever, decreased appetite, drowsiness, and irritability)  
- AEs  
- SAEs |

**Primary Immunogenicity:**

To demonstrate immunobridging of the immune response elicited by prophylactic BNT162b2 at the dose level selected per age group in Phase 2/3 participants without serological or virological evidence (up to 1 month after receipt of Dose 2) of past SARS-CoV-2 infection:

- In participants ≥5 to <12 years of age compared to participants 16 to 25 years of age from Phase 2/3 of the C4591001 study
- In participants ≥2 to <5 years of age compared to participants 16 to 25 years of age from Phase 2/3 of the C4591001 study
- In participants ≥6 months to <2 years of age compared to participants 16 to 25 years of age from Phase 2/3 of the C4591001 study

- GMR, estimated by the ratio of the geometric mean of SARS-CoV-2 neutralizing titers in participants ≥5 to <12 years of age to those in participants 16-25 years of age 1 month after Dose 2
- GMR, estimated by the ratio of the geometric mean of SARS-CoV-2 neutralizing titers in participants ≥2 to <5 years of age to those in participants 16 to 25 years of age 1 month after Dose 2
- GMR, estimated by the ratio of the geometric mean of SARS-CoV-2 neutralizing titers in participants ≥6 months to <2 years of age to those in participants 16 to 25 years of age 1 month after Dose 2

- SARS-CoV-2 neutralizing titers
### Phase 2/3

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Estimands</th>
<th>Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Secondary Immunogenicity/Efficacy:</strong> To describe the immune responses elicited by prophylactic BNT162b2 at the dose level selected per age group and persistence of immune response in Phase 2/3 participants without serological or virological evidence of past SARS-CoV-2 infection</td>
<td>In evaluable participants with no serological or virological evidence of past SARS-CoV-2 infection from each vaccine and age group:</td>
<td>• SARS-CoV-2 neutralizing titers</td>
</tr>
<tr>
<td><strong>Secondary Immunogenicity/Efficacy:</strong> At baseline (before Dose 1) and 1, 6, 12 (for the original BNT162b2 group only), and 24 (for the original BNT162b2 group only) months after Dose 2,</td>
<td>• GMTs at each time point  • GMFRs from before Dose 1 to each subsequent time point after Dose 2</td>
<td></td>
</tr>
<tr>
<td><strong>In all age groups where immunobridging is successful, if at least 22 cases are accrued across those age groups:</strong> To evaluate the efficacy of prophylactic BNT162b2 against confirmed COVID-19 occurring from 7 days after Dose 2 in participants without evidence of past SARS-CoV-2 infection</td>
<td>In participants complying with the key protocol criteria (evaluable participants) and with no serological or virological evidence (prior to 7 days after receipt of Dose 2) of past SARS-CoV-2 infection: 100 × (1 – IRR) [ratio of active vaccine to placebo]</td>
<td>• Confirmed COVID-19 incidence from 7 days after Dose 2 per 1000 person-years of follow-up</td>
</tr>
<tr>
<td><strong>In all age groups where immunobridging is successful, if at least 22 cases are accrued across those age groups:</strong> To evaluate the efficacy of prophylactic BNT162b2 against confirmed COVID-19 occurring from 7 days after Dose 2 in participants with or without serological or virological evidence of past SARS-CoV-2 infection</td>
<td>In participants complying with the key protocol criteria (evaluable participants) and with or without serological or virological evidence (prior to 7 days after receipt of Dose 2) of past SARS-CoV-2 infection: 100 × (1 – IRR) [ratio of active vaccine to placebo]</td>
<td>• Confirmed COVID-19 incidence from 7 days after Dose 2 per 1000 person-years of follow-up</td>
</tr>
<tr>
<td><strong>To describe the efficacy of prophylactic BNT162b2 against asymptomatic infection in participants without evidence of past SARS-CoV-2 infection</strong></td>
<td>In evaluable participants without serological or virological evidence of past SARS-CoV-2 infection from each vaccine group: 100 × (1 – IRR) [ratio of active vaccine to placebo]</td>
<td>• Incidence of asymptomatic infection of SARS-CoV-2 based on N-binding antibody seroconversion</td>
</tr>
<tr>
<td>Phase 2/3</td>
<td>Objectives</td>
<td>Estimands</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>Exploratory:</strong></td>
<td>To evaluate the immune response over time to prophylactic BNT162b2 at the dose level selected per age group and persistence of immune response in Phase 2/3 participants with and without serological or virological evidence of past SARS-CoV-2 infection</td>
<td>In evaluable participants with or without serological or virological evidence of past SARS-CoV-2 infection from each vaccine group: At baseline and at 1, 6, 12 (for the original BNT162b2 group only), and 24 (for the original BNT162b2 group only) months after Dose 2, • GMTs at each time point • GMFRs from before Dose 1 to each subsequent time point after Dose 2</td>
</tr>
<tr>
<td><strong>N-bounding antibody</strong></td>
<td>To describe COVID-19 and severe COVID-19 cases in all participants with and without serological or virological evidence of past SARS-CoV-2 infection</td>
<td></td>
</tr>
<tr>
<td><strong>Confirmed cases as per CDC criteria</strong></td>
<td>To describe MIS-C cases with and without evidence of past SARS-CoV-2 infection</td>
<td></td>
</tr>
<tr>
<td><strong>All safety and immunogenicity endpoints described above will be analyzed descriptively</strong></td>
<td>To describe the serological responses in Phase 2/3 participants to BNT162b2 at the dose level selected per age group in cases of: •Confirmed COVID-19 •Confirmed severe COVID-19 •SARS-CoV-2 infection without confirmed COVID-19</td>
<td></td>
</tr>
<tr>
<td><strong>To describe the safety and immunogenicity of prophylactic BNT162b2 at the dose level selected per age group in children with stable HIV disease</strong></td>
<td>To describe the cell-mediated immune response, and additional humoral immune response parameters, to the reference strain in a subset of participants: •7 days and 1 and 6 months after Dose 2</td>
<td></td>
</tr>
</tbody>
</table>
4. STUDY DESIGN

4.1. Overall Design

This is a Phase 1/2/3 study in healthy children <12 years of age.

Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants <6 months of age may subsequently be evaluated.

4.1.1. Phase 1

Phase 1 is the open-label dose-finding portion of the study to evaluate safety, tolerability, and immunogenicity of BNT162b2 administered on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age). Dose finding is being initiated in this study in participants ≥5 to <12 years of age based on the acceptable blinded safety assessment of the 30-µg dose in 12- to 15-year-olds in the C4591001 study.

The purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3 different dose levels in each age group.

Dependent upon safety and/or immunogenicity data generated during the course of this study, it is possible that dose levels may not be started, may be terminated early, and/or may be added with dose levels below the lowest stated dose.

Participants will have blood drawn prior to both Dose 1 and Dose 2 and 7 days after Dose 2 to assess for immunogenicity to determine the final BNT162b2 dose level for the Phase 2/3.

4.1.2. Phase 2/3

Phase 2/3 will evaluate safety, tolerability, and immunogenicity in each age group at the selected dose level from Phase 1. Efficacy will be evaluated across all age groups in which immunobridging is successful, depending on accrual of a sufficient number of cases across those age groups.

All participants will have blood drawn at baseline prior to Dose 1 and 6 months after Dose 2. Immunobridging to participants 16 to 25 years of age in the C4591001 study will be based on immunogenicity data collected at baseline and 1 month after Dose 2. The persistence of the immune response will be based on immunogenicity data collected in participants at baseline and at 1, 6, 12 (original BNT162b2 group only), and 24 months after Dose 2 (original BNT162b2 group only). In addition, efficacy against confirmed COVID-19 and against asymptomatic infection will also be assessed.

At a 6-month follow-up visit, all participants will be unblinded. Participants who originally received placebo will be offered the opportunity to receive BNT162b2 as part of the study.
4.1.3. Number of Participants

4.1.3.1. Phase 1: Open-Label Dose Finding

This open-label dose-finding phase will consist of up to 3 different dose levels in each age group, with 16 participants per dose level, and a total of 144 participants; see Table 1.

Table 1. Phase 1 Participants

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Total</th>
<th>Up to 3 Dose Levels of BNT162b2</th>
<th>Active</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥5 to &lt;12 Years</td>
<td>48</td>
<td>16/16/16</td>
<td>16</td>
<td>N/A</td>
</tr>
<tr>
<td>≥2 to &lt;5 Years</td>
<td>48</td>
<td>16/16/16</td>
<td>16</td>
<td>N/A</td>
</tr>
<tr>
<td>≥6 Months to &lt;2 years</td>
<td>48</td>
<td>16/16/16</td>
<td>16</td>
<td>N/A</td>
</tr>
</tbody>
</table>

4.1.3.2. Phase 2/3: Safety, Tolerability, Immunogenicity, and Efficacy

Phase 2/3 will evaluate the safety, tolerability, and immunogenicity of the selected dose level in each age group at the selected dose level from Phase 1, with a total of approximately 4500 participants. Participants will be randomized in a 2:1 ratio to receive active vaccine or placebo (Table 2).

Approximately 450 participants (300 in the active vaccine group and 150 in the placebo group) randomized in each age group in this phase will contribute to the immunobridging analysis at 1 month after Dose 2 and will contribute to the overall analysis of the persistence of immune response at 6 months after Dose 2. These participants will be enrolled from both US and EU sites to ensure this subset is representative of the whole study.

For the persistence time points of 12 and 24 months after Dose 2, approximately 70 participants from each age group in the original BNT162b2 group will have an immunogenicity blood draw in order to contribute to the analysis. All approximately 4500 participants will contribute to the VE analysis for conditional VE and asymptomatic infection. Efficacy will be evaluated across all age groups in which immunobridging is successful, depending on accrual of a sufficient number of cases across those age groups.

At designated sites, an additional optional whole blood sample of approximately 10 mL will be obtained prior to Dose 1 and at 7 days and 6 months after Dose 2 from up to approximately 60 participants ≥10 years of age. These samples will be used on an exploratory basis to investigate the postvaccination cell-mediated immune response at these time points.
Table 2. **Phase 2/3 Participants – Blood Draws for Immunogenicity/Efficacy Assessments**

<table>
<thead>
<tr>
<th></th>
<th>All Age Groups</th>
<th>≥5 to &lt;12 Years of Age</th>
<th>≥2 to &lt;5 Years and ≥6 Months to &lt;2 Years of Age</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Active</td>
<td>Placebo</td>
</tr>
<tr>
<td>Baseline blood draw</td>
<td>4500</td>
<td>3000</td>
<td>1500</td>
</tr>
<tr>
<td>1 Month after Dose 2</td>
<td>1350</td>
<td>900</td>
<td>450</td>
</tr>
<tr>
<td>6 Months after Dose 2</td>
<td>4500</td>
<td>3000</td>
<td>1500</td>
</tr>
<tr>
<td>12 Months after Dose 2</td>
<td>210</td>
<td>210</td>
<td>N/A</td>
</tr>
<tr>
<td>24 Months after Dose 2</td>
<td>210</td>
<td>210</td>
<td>N/A</td>
</tr>
</tbody>
</table>

a. Number of participants shown is for each of these 2 younger age groups.

All participants will contribute to the safety, tolerability, and efficacy assessments (Table 3).

Table 3. **Phase 2/3 Participants – Safety and Tolerability/Efficacy Assessments**

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Active</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4500</td>
<td>3000</td>
<td>1500</td>
</tr>
</tbody>
</table>

4.1.4. Intervention Groups and Duration

**Phase 1**: Dose finding will begin at the low-dose level in participants ≥5 to <12 years of age. The IRC will review safety data (e-diary and AE) acquired up to 7 days after Dose 1 for the low-dose group; upon confirmation of an acceptable safety assessment by the IRC:

- Dosing may commence at the mid-dose level in the same age group, and
- Dosing may commence at the low-dose level in participants ≥2 to <5 years of age.

The same process will be followed when moving up dose levels in each age group, and when progressing between age groups at the low-dose level as shown in Section 1.2. Dosing may commence at the low-dose level in participants ≥6 months to <2 years of age after IRC review of safety data (e-diary and AE) acquired up to 7 days after Dose 1 at the low-dose level from participants ≥2 to <5 years of age.

In each age group, if the low-dose level is considered not acceptable based on safety assessment after Dose 1, the mid-dose level or high-dose level will not commence. In this case, an optional lower dose level may commence. Dependent on the results obtained, dose level(s) may be omitted. In each age group, if the mid-dose level is considered not acceptable based on safety assessment after Dose 1, the high-dose level will not commence.

Based on safety assessment, the second dose may be given at a lower dose level.
Phase 2/3: Progression of each age group into Phase 2/3 will occur independently; it is therefore possible that each age group may not start Phase 2/3 concurrently and the dose level selected for Phase 2/3 may differ in each age group. For each age group to proceed to Phase 2/3, safety, tolerability, and immunogenicity data from 7 days after Dose 2 for the selected vaccine dose level in the age group from Phase 1 will be confirmed to be acceptable.

Duration: Participants are expected to participate for up to a maximum of approximately 26 months.

4.2. Scientific Rationale for Study Design

Additional surveillance for COVID-19 will be conducted as part of the study, given the potential risk of disease enhancement. If a participant experiences symptoms, as detailed in Section 8.13, a COVID-19/MIS-C illness visit and subsequent convalescent visit will occur. As part of these visits, samples (anterior nasal swab and blood [convalescent visit]) will be taken for antigen and antibody assessment as well as recording of COVID-19/MIS-C–related clinical and laboratory information (including local diagnosis).

Human reproductive safety data are not available for BNT162b2 RNA-based COVID-19 vaccine, but there is no suspicion of human teratogenicity based on the intended mechanism of action of the compound. Therefore, the use of a highly effective method of contraception is required (see Appendix 4) for WOCBP.

4.3. Justification for Dose

Based on acceptable blinded safety data in 2259 12- through 15-year-olds at the 30-µg dose level in the C4591001 study, dose finding is considered in this study using the same vaccine candidate. Therefore, this study will start with a 10-µg dose level for Phase 1 participants ≥5 to <12 years of age, which was well tolerated in adults 18 to 55 years of age in C4591001, before moving to another dose level in this age group or initiating the younger age groups.

4.4. End of Study Definition

A participant is considered to have completed the study if he/she has completed all phases of the study, including the last visit.

The end of the study is defined as the date of the last visit of the last participant in the study.

5. STUDY POPULATION

This study can fulfill its objectives only if appropriate participants are enrolled. The following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a particular participant is suitable for this protocol.

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:

Age and Sex:
1. Male or female participants ≥6 months to <12 years of age, at the time of randomization, at Visit 1.
   - Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.

Type of Participant and Disease Characteristics:
2. Participants’ parent(s)/legal guardian(s) and participants, as age appropriate, who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
3. Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.

   Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in the therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.

   Phase 2/3: Specific criteria for such participants with known stable infection with HIV, HCV, or HBV can be found in Section 10.7.
4. Participants are expected to be available for the duration of the study and whose parent(s)/legal guardian can be contacted by telephone during study participation.
5. Negative urine pregnancy test for female participants who are biologically capable of having children.
6. Female participant of childbearing potential or male participant able to father children who is willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the last dose of study intervention if at risk of pregnancy with her/his partner; or female participant not of childbearing potential or male participant not able to father children.

Informed Consent:
7. The participant’s parent(s)/legal guardian is capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. Depending on the age of the participant and according to local requirements, participants will also be asked to provide assent as appropriate (verbal or written).
The investigator, or a person designated by the investigator, will obtain written or electronically signed informed consent (and assent) from each study participant’s legal guardian (as defined in Appendix 1) and the participant’s assent, when applicable, before any study-specific activity is performed. All legal guardians should be fully informed, and participants should be informed to the fullest extent possible, about the study in language and terms they are able to understand. The investigator will retain the original copy of each participant's signed consent/assent document.

5.2. Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

**Medical Conditions:**

1. **Phase 1 only:** Past clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.

2. **Phase 1 only:** Known infection with HIV, HCV, or HBV.


4. Previous or current diagnosis of MIS-C.

5. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study.

6. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).

7. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.

8. Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic lupus erythematosus.

9. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.

10. Female who is pregnant or breastfeeding.

**Prior/Concomitant Therapy:**

11. Previous vaccination with any coronavirus vaccine.
12. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

13. Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19 from 90 days before study intervention administration, or planned receipt throughout the study.

Prior/Concurrent Clinical Study Experience:

14. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.

15. Previous participation in other studies involving study intervention containing LNPs.

Diagnostic Assessments:

Not applicable.

Other Exclusions:

16. Participants who are direct descendants (child or grandchild) of investigational site staff members or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

5.3. Lifestyle Considerations

5.3.1. Contraception

All male and female participants who, in the opinion of the investigator, are biologically capable of having children must agree to use a highly effective method of contraception consistently and correctly for at least 28 days after the last study vaccination.

The investigator or his or her designee, in consultation with the participant, will confirm that the participant has selected an appropriate method of contraception for the individual participant and his or her partner(s) from the permitted list of contraception methods (see Appendix 4, Section 10.4.4) and will confirm that the participant has been instructed in its consistent and correct use. At time points indicated in the SoA, the investigator or designee will inform the participant of the need to use highly effective contraception consistently and correctly and document the conversation and the participant’s affirmation in the participant’s chart (participants need to affirm their consistent and correct use of at least 1 of the selected methods of contraception). In addition, the investigator or designee will
instruct the participant’s parent(s)/legal guardian to call immediately if the selected contraception method is discontinued or if pregnancy is known or suspected in the participant or partner.

5.4. Screen Failures

Screen failures are defined as participants who consent to participate in the clinical study but are not subsequently randomly assigned to study intervention/enrolled in the study. A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants to meet the CONSORT publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any SAEs.

Individuals who do not meet the criteria for participation in this study (screen failure) may be rescreened under a different participant number.

5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Study Intervention Administration

The following conditions are temporary or self-limiting and a participant may be vaccinated once the condition(s) has/have resolved and no other exclusion criteria are met.

1. Current febrile illness (body temperature ≥100.4°F [≥38°C]) or other acute illness within 48 hours before study intervention administration. This includes current symptoms that could represent a potential COVID-19 illness (for Phase 1, confirmed COVID-19 infection is an exclusion criterion):
   - New or increased cough;
   - New or increased shortness of breath;
   - Diarrhea;
   - Vomiting;
   - Chills;
   - New or increased muscle pain;
   - New loss of taste/smell;
   - Sore throat;
   - Nausea;
   - Abdominal pain;
• Inability to eat/poor feeding in participants <5 years of age.

2. Receipt of any nonlive vaccine within 14 days, or any live vaccine within 28 days, before study intervention administration.

3. Anticipated receipt of any vaccine between Doses 1 and 2, or between Doses 3 and 4, of study intervention, or within 7 days after Dose 2 or 4.

4. Receipt of short-term (<14 days) systemic corticosteroids. Study intervention administration should be delayed until systemic corticosteroid use has been discontinued for at least 28 days. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

6. STUDY INTERVENTION

Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, medical device(s), or study procedure(s) intended to be administered to a study participant according to the study protocol.

Phase 1 will evaluate a 2-dose (separated by approximately 21 days) schedule of up to 3 different dose levels of RNA vaccine candidate BNT162b2 for active immunization against COVID-19, to determine the final dose level of BNT162b2 in Phase 2/3 for each age group. The investigational RNA vaccine candidate and saline placebo, in Phase 2/3, are the 2 potential study interventions that may be administered to a study participant:

• BNT162b2 (BNT162 RNA-LNP vaccine utilizing modRNA and encoding the P2 S): 10 µg, 20 µg, and 30 µg, with an option for 3 µg.

• Normal saline (0.9% sodium chloride solution for injection).

6.1. Study Intervention(s) Administered

<table>
<thead>
<tr>
<th>Intervention Name</th>
<th>BNT162b2 (BNT162 RNA-LNP Vaccine Utilizing modRNA)</th>
<th>Saline Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type</td>
<td>Vaccine</td>
<td>Placebo</td>
</tr>
<tr>
<td>Dose Formulation</td>
<td>modRNA</td>
<td>Normal saline (0.9% sodium chloride solution for injection)</td>
</tr>
<tr>
<td>Unit Dose Strength(s)</td>
<td>250 µg/0.5 mL</td>
<td>N/A</td>
</tr>
<tr>
<td>Dosage Level(s)*</td>
<td>10 µg, 20 µg, or 30 µg, with an option for 3 µg</td>
<td>N/A</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>Intramuscular injection</td>
<td>Intramuscular injection</td>
</tr>
<tr>
<td>Use</td>
<td>Experimental</td>
<td>Placebo</td>
</tr>
<tr>
<td>IMP or NIMP</td>
<td>IMP</td>
<td>IMP</td>
</tr>
<tr>
<td>Sourcing</td>
<td>Provided centrally by the sponsor</td>
<td>Provided centrally by the sponsor</td>
</tr>
</tbody>
</table>
**Intervention Name** | **BNT162b2** *(BNT162 RNA-LNP Vaccine Utilizing modRNA)* | **Saline Placebo**  
--- | --- | ---  
**Packaging and Labeling** | Study intervention will be provided in a glass vial as open-label supply. Each vial will be labeled as required per country requirement. | Study intervention will be provided in a glass or plastic vial as open-label supply. Each vial will be labeled as required per country requirement.  

a. Dependent upon safety and/or immunogenicity data generated during the course of this study, it is possible that dose levels may not be started, may be terminated early, and/or may be added with dose levels below the lowest stated dose.

### 6.1.1. Administration

Participants will receive 1 dose of study intervention as randomized at each vaccination visit (Visits 1 and 2, and Visit A and Visit B for Phase 2/3 participants who go on to receive BNT162b2) in accordance with the study’s SoA. The volume to be administered may vary by dose level; full details are described in the IP manual.

For participants ≥2 to <12 years of age, study intervention should be administered intramuscularly into the deltoid muscle, preferably of the nondominant arm. Study intervention will be administered by an **unblinded** administrator.

For participants 6 months to <2 years of age, study intervention should be administered intramuscularly into the anterior thigh muscle, preferably of the left leg. Study intervention will be administered by an **unblinded** administrator.

Standard vaccination practices must be observed and vaccine must not be injected into blood vessels. Appropriate medication and other supportive measures for management of an acute hypersensitivity reaction should be available in accordance with local guidelines for standard immunization practices.

Administration of study interventions should be performed by an appropriately qualified, GCP-trained, and vaccine-experienced member of the study staff (e.g., physician, nurse, physician’s assistant, nurse practitioner, pharmacist, or medical assistant) as allowed by local, state, and institutional guidance.

Study intervention administration details will be recorded on the CRF.

### 6.2. Preparation/Handling/Storage/Accountability

1. The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study interventions received and any discrepancies are reported and resolved before use of the study intervention.

2. Only participants enrolled in the study may receive study intervention and only authorized site staff may supply or administer study intervention. All study interventions must be stored in a secure, environmentally controlled, and monitored (manual or automated recording) area in accordance with the labeled storage conditions with access...
limited to the investigator and authorized site staff. At a minimum, daily minimum and maximum temperatures for all site storage locations must be documented and available upon request. Data for nonworking days must indicate the minimum and maximum temperatures since previously documented for all site storage locations upon return to business.

3. Any excursions from the study intervention label storage conditions should be reported to Pfizer upon discovery along with any actions taken. The site should actively pursue options for returning the study intervention to the storage conditions described in the labeling, as soon as possible. Once an excursion is identified, the study intervention must be quarantined and not used until Pfizer provides permission to use the study intervention. Specific details regarding the definition of an excursion and information the site should report for each excursion will be provided to the site in the IP manual.

4. Any storage conditions stated in the SRSD will be superseded by the storage conditions stated on the label.

5. Study interventions should be stored in their original containers.

6. See the IP manual for storage conditions of the study intervention.

7. The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records), such as the IPAL or sponsor-approved equivalent. All study interventions will be accounted for using a study intervention accountability form/record.

8. Further guidance and information for the final disposition of unused study interventions are provided in the IP manual. All destruction must be adequately documented. If destruction is authorized to take place at the investigator site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by Pfizer.

Upon identification of a product complaint, notify the sponsor within 1 business day of discovery as described in the IP manual.

6.2.1. Preparation and Dispensing

See the IP manual for instructions on how to prepare the study intervention for administration. Study intervention should be prepared and dispensed by an appropriately qualified and experienced member of the study staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as allowed by local, state, and institutional guidance. A second staff member will verify the dispensing.

Study intervention and placebo (for Doses 1 and 2 in Phase 2/3) will be prepared by qualified unblinded site personnel according to the IP manual. The study intervention will be administered in such a way as to ensure the participants remain blinded.
6.3. Measures to Minimize Bias: Randomization and Blinding

6.3.1. Allocation to Study Intervention

Allocation (randomization) of participants to vaccine groups will proceed through the use of an IRT system (IWR). The site personnel (study coordinator or specified designee) will be required to enter or select information including but not limited to the user’s ID and password, the protocol number, and the participant number. The site personnel will then be provided with a vaccine assignment and randomization number. The IRT system will provide a confirmation report containing the participant number, randomization number, and study intervention allocation assigned. The confirmation report must be stored in the site’s files.

The study-specific IRT reference manual and IP manual will provide the contact information and further details on the use of the IRT system.

6.3.2. Blinding of Site Personnel (Phase 2/3 Only)

The study staff receiving, storing, dispensing, preparing, and administering the study interventions will be unblinded. All other study and site personnel, including the investigator, investigator staff, and participants, will be blinded to study intervention assignments. In particular, the individuals who evaluate participant safety will be blinded. Because BNT162b2 and placebo are different in physical appearance, the study intervention syringes will be administered in a manner that prevents the study participants from identifying the study intervention type based on its appearance.

The responsibility of the unblinded dispenser and administrator must be assigned to an individual or individuals who will not participate in the evaluation of any study participants. Contact between the unblinded dispenser and study participants and unblinded administrator and study participants should be kept to a minimum. The remaining site personnel must not know study intervention assignments.

At Visit 5 (6 months after Dose 2), to allow administration of BNT162b2 to participants who originally received placebo, site staff will be unblinded to an individual participant’s original vaccine allocation.

6.3.3. Blinding of the Sponsor

For the Phase 1 in which only active vaccine is being administered, blinding is not applicable to the participants in Phase 1. The majority of sponsor staff will be blinded to study intervention allocation for Doses 1 and 2 in Phase 2/3. All laboratory personnel performing serology assays will remain blinded to study intervention assigned/received throughout the study in Phase 2/3. The following sponsor staff, who will have no part in the blinded conduct of the study, will be unblinded in Phase 2/3 (further details will be provided in a data blinding plan):

- Those study team members who are involved in ensuring that protocol requirements for study intervention preparation, handling, allocation, and administration are fulfilled at the
site will be unblinded for the duration of the study (eg, unblinded study manager, unblinded clinical research associate).

- Unblinded clinician(s) who are not direct members of the study team and will not participate in any other study-related activities will review unblinded protocol deviations.

- An unblinded team supporting interactions with, and analyses for, the DMC (see Section 9.6). This will comprise a statistician and programmer(s).

- An unblinded submissions team will be responsible for preparing unblinded analyses and documents to support regulatory activities that may be required while the study is ongoing. This team will only be unblinded at the group level and not have access to individual participant assignments. The programs that produce the summary tables will be developed and validated by the blinded study team, and these programs will be run by the unblinded DMC team.

- At Visit 5, when a participant who originally received placebo receives BNT162b2 per the SoA in Section 1.3.2.2, the study team will become unblinded to the participant’s original study intervention allocation.

- After the study data used for submission become public, the blinded study team will also have access to those data and become unblinded at a group level.

6.3.4. Breaking the Blind

For Phase 2/3 up to Visit 5, the IRT will be programmed with blind-breaking instructions. In case of an emergency, the investigator has the sole responsibility for determining if unblinding of a participant’s study intervention assignment is warranted. Participant safety must always be the first consideration in making such a determination. If the investigator decides that unblinding is warranted, the investigator should make every effort to contact the sponsor prior to unblinding a participant’s vaccine assignment unless this could delay further management of the participant. If a participant’s vaccine assignment is unblinded, the sponsor must be notified within 24 hours after breaking the blind. The date and reason that the blind was broken must be recorded in the source documentation and CRF.

The study-specific IRT reference manual and IP manual will provide the contact information and further details on the use of the IRT system.

Instructions on how to unblind participants at Visit 5 will be provided separately.

6.4. Study Intervention Compliance

When participants are dosed at the site, they will receive study intervention directly from the investigator or designee, under medical supervision. The date and time, as well as the anatomical location, of each dose administered in the clinic will be recorded in the source documents and recorded in the CRF. The dose of study intervention and study participant
identification will be confirmed at the time of dosing by a member of the study site staff other than the person administering the study intervention.

6.5. Concomitant Therapy

6.5.1. Prohibited During the Study

Receipt of the following vaccines and medications during the time periods listed below may exclude a participant from the per-protocol analysis from that point onwards, and may require vaccinations to be discontinued in that participant; however, it is anticipated that the participant would not be withdrawn from the study (see Section 7).

Medications or vaccinations should not be withheld if required for a participant’s medical care.

- Receipt of any nonlive vaccine within 14 days, or any live vaccine within 28 days, before study intervention administration.
- Receipt of any vaccine between Doses 1 and 2, or between Doses 3 and 4, of study intervention, or within 7 days after Dose 2 or 4.
- Receipt of chronic systemic treatment with known immunosuppressant medications, or radiotherapy, is prohibited within 60 days before enrollment through conclusion of the study.
- Receipt of systemic corticosteroids (>2 mg/kg/dose of prednisone or equivalent) for ≥14 days is prohibited from 28 days prior to enrollment through Visit 4.
- Receipt of blood/plasma products, immunoglobulins, or monoclonal antibodies is prohibited within 60 days before enrollment through conclusion of the study.
- Receipt of any passive antibody therapy specific to COVID-19 is prohibited within 90 days before enrollment through conclusion of the study.
- Receipt of any other (nonstudy) coronavirus vaccine at any time prior to or during study participation is prohibited.
- Prophylactic antipyretics and other pain medication to prevent symptoms associated with study intervention administration are not permitted. However, if a participant is taking a medication for another condition, even if it may have antipyretic or pain-relieving properties, it should not be withheld prior to study vaccination.
6.5.2. Permitted During the Study

The use of antipyretics and other pain medication to treat symptoms associated with study intervention administration or ongoing conditions is permitted.

Medication other than that described as prohibited in Section 6.5.1 required for treatment of preexisting stable conditions is permitted.

Inhaled, topical, or localized injections of corticosteroids (eg, intra-articular or intrabursal administration) are permitted.

6.5.3. Recording Nonstudy Vaccination and Concomitant Medications

The following nonstudy vaccinations (to include start date) and concomitant medications (to include start and stop dates and name of the medication) will be recorded in the CRF if administration occurred during study participation, unless otherwise noted:

- Details of any nonstudy vaccinations received from 28 days prior to study enrollment until the 6-month follow-up visit (Visit 5 for Phase 1 participants and Visit 5 for Phase 2/3 participants).

- Details of any blood/plasma products, immunoglobulins (eg, IVIG), or immunomodulators (eg, anakinra, tocilizumab) during study participation.

- Antiplatelets (eg, aspirin, clopidogrel) or anticoagulants (eg, heparin, exoparin, warfarin).

- Any prescribed medication to treat potential COVID-19 or MIS-C illness cases.

6.6. Dose Modification

This protocol allows some alteration of vaccine dose for individual participants and/or dose level from the currently outlined dosing schedule. For reasons of reactogenicity, tolerability, or safety, the IRC may recommend to reduce the second dose of study intervention and/or increase the interval between doses.

If, because of a medication error, a participant receives 1 dose of BNT162b2 at Visit 1 and 1 dose of placebo at Visit 2 (or vice versa), the participant should be offered the possibility to receive a second dose of BNT162b2 at an unscheduled visit. In this situation:

- Obtain informed consent for administration of the additional dose.

- Measure the participant’s body temperature.

- Perform urine pregnancy test on WOCBP as described in Section 8.2.7.

- Discuss contraceptive use as described in Section 5.3.1.
6.7. Intervention After the End of the Study

No intervention will be provided to study participants at the end of the study.

7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL

7.1. Discontinuation of Study Intervention

In rare instances, it may be necessary for a participant to permanently discontinue study intervention (definitive discontinuation). Reasons for definitive discontinuation of study intervention may include the following: AEs, participant or participant’s parent(s)/legal guardian’s request; investigator request; pregnancy; protocol deviation (including no longer meeting all the inclusion criteria or meeting 1 or more exclusion criteria). In general, unless the investigator considers it unsafe to administer the second dose, or the participant does not wish to receive it, it is preferred that the second dose be administered.

Note: Phase 1 participants with a positive SARS-CoV-2 NAAT result without symptoms do not meet exclusion criterion 1 and this should not result in discontinuation of study intervention. However, a confirmed COVID-19 diagnosis with the presence of at least 1 of the symptoms meets exclusion criterion 1 and the participant should be discontinued from study intervention (see Section 8.15).

Note that discontinuation of study intervention does not represent withdrawal from the study. Per the study estimands, if study intervention is definitively discontinued, the participant will remain in the study to be evaluated for safety, tolerability, immunogenicity, and efficacy. See the SoA for data to be collected at the time of discontinuation of study intervention and follow-up for any further evaluations that need to be completed.
In the event of discontinuation of study intervention, it must be documented on the appropriate CRF/in the medical records whether the participant is discontinuing further receipt of study intervention or also from study procedures, postvaccination study follow-up, and/or future collection of additional information.

### 7.2. Participant Discontinuation/Withdrawal From the Study

A participant may withdraw from the study at any time at the request of the participant or his or her parent(s) and/or legal guardian. Reasons for discontinuation from the study include the following:

- Refused further follow-up;
- Lost to follow-up;
- Death;
- Study terminated by sponsor;
- AEs;
- Participant/participant’s parent(s)/legal guardian request;
- Investigator request;
- Protocol deviation.

If a participant does not return for a scheduled visit, every effort should be made to contact the participant’s parent(s)/legal guardian. All attempts to contact the participant’s parent(s)/legal guardian and information received during contact attempts must be documented in the participant’s source document. In any circumstance, every effort should be made to document participant outcome, if possible.

The participant’s parent(s)/legal guardian should be questioned regarding the reason for the participant’s withdrawal. The investigator or his or her designee should capture the reason for withdrawal in the CRF for all participants.

If a participant withdraws from the study, the participant’s parent(s)/legal guardian may request destruction of any remaining samples taken and not tested, and the investigator must document any such requests in the site study records and notify the sponsor accordingly.

If the participant’s parent(s)/legal guardian or a child who has provided assent during any phase of the study withdraws from the study and also withdraws consent/assent (Section 7.2.1) for disclosure of further information, no further evaluations should be performed and no additional data should be collected. The sponsor may retain and continue to use any data collected before such withdrawal of consent.
Lack of completion of all or any of the withdrawal/early termination procedures will not be viewed as protocol deviations so long as the participant’s safety was preserved.

7.2.1. Withdrawal of Consent

A participant who has provided assent during any phase of the study, or a participant’s parent(s)/legal guardian who requests to discontinue receipt of study intervention, will remain in the study, and the participant must continue to be followed for protocol-specified follow-up procedures. The only exception to this is when a participant’s parent(s)/legal guardian specifically withdraws consent for any further contact with persons previously authorized to provide this information. The participant’s parent(s)/legal guardian should notify the investigator in writing of the decision to withdraw consent from future follow-up, whenever possible. The withdrawal of consent should be explained in detail in the medical records by the investigator, as to whether the withdrawal is only from further receipt of study intervention or also from study procedures and/or postvaccination study follow-up, and entered on the appropriate CRF page. In the event that vital status (whether the participant is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with local law.

7.3. Lost to Follow-up

A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and the participant’s parent(s)/legal guardian is unable to be contacted by the study site.

The following actions must be taken if a participant or participant’s parent(s)/legal guardian fails to attend a required study visit:

- The site must attempt to contact the participant’s parent(s)/legal guardian and reschedule the missed visit as soon as possible and counsel the participant’s parent(s)/legal guardian on the importance of maintaining the assigned visit schedule and ascertain whether or not the participant’s parent(s)/legal guardian wishes for the participant to and/or should continue in the study;

- Before a participant is deemed lost to follow-up, the investigator or designee must make every effort to regain contact with the participant’s parent(s)/legal guardian (where possible, 3 telephone calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). These contact attempts should be documented in the participant’s medical record;

- Should the participant’s parent(s)/legal guardian continue to be unreachable, the participant will be considered to have withdrawn from the study.
8. STUDY ASSESSMENTS AND PROCEDURES

The investigator (or an appropriate delegate at the investigator site) must obtain a signed and dated ICD before performing any study-specific procedures.

The full date of birth will be collected to critically evaluate the immune response and safety profile by age.

Study procedures and their timing are summarized in the SoA. Protocol waivers or exemptions are not allowed.

Safety issues should be discussed with the sponsor immediately upon occurrence or awareness to determine whether the participant should continue or discontinue study intervention.

Adherence to the study design requirements, including those specified in the SoA, is essential and required for study conduct.

All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.

Every effort should be made to ensure that protocol-required tests and procedures are completed as described. However, it is anticipated that from time to time there may be circumstances outside the control of the investigator that may make it unfeasible to perform the test. In these cases, the investigator must take all steps necessary to ensure the safety and well-being of the participant. When a protocol-required test cannot be performed, the investigator will document the reason for the missed test and any corrective and preventive actions that he or she has taken to ensure that required processes are adhered to as soon as possible. The study team must be informed of these incidents in a timely manner.

For samples being collected and shipped, detailed collection, processing, storage, and shipment instructions and contact information will be provided to the investigator site prior to initiation of the study.

The total blood sampling volume for individual participants in this study is approximately 15 mL for Phase 1 and Phase 2/3 participants who will contribute to immunogenicity assessments. The remaining Phase 2/3 participants will have a 10-mL blood draw. Those participants in the subset who consent to additional blood collection for isolation of PBMCs may have a total blood sampling volume up to approximately 45 mL. Additionally, 5 mL of blood will be taken at an unplanned convalescent visit at any time a participant develops symptoms indicating a potential COVID-19/MIS-C infection. Note: If the participants had an unplanned potential COVID-19/MIS-C convalescent visit within ≤42 days before the scheduled visit (Visit X or Y) and if a blood sample was collected as part of the convalescent visit, blood sample collection at the scheduled visit is not required.
8.1. Efficacy and/or Immunogenicity Assessments

Surveillance for potential cases of COVID-19 and MIS-C will occur throughout a participant’s involvement in the study to describe both COVID-19 and MIS-C.

If, at any time, a participant develops an acute illness (described in Section 8.13), for the purposes of the study he or she will be considered to potentially have COVID-19 illness. In this circumstance, the participant’s parent(s)/legal guardian should contact the site. An in-person or telehealth visit should occur, and assessments should be conducted as specified in the SoA. The assessments will include a nasal (anterior nares) swab sample collection either by site staff personnel (clinical visit) or by a participant’s parent/legal guardian, which will be tested at a central laboratory using an RT-PCR test (Cepheid; FDA approved under EUA) or other equivalent nucleic acid amplification–based test (ie, NAAT), to detect SARS-CoV-2. In addition, clinical information and results from local standard-of-care tests (as detailed in Section 8.13) will be assessed. The central laboratory NAAT result will be used for the case definition, unless no result is available from the central laboratory, in which case a local NAAT result may be used if it was obtained using 1 of the following assays:

- Cepheid Xpert Xpress SARS-CoV-2
- Roche Cobas SARS-CoV-2 Real-Time RT-PCR test (EUA200009/A001)
- Abbott Molecular/RealTime SARS-CoV-2 assay (EUA200023/A001)

Two definitions (first and second definitions) of SARS-CoV-2–related cases, SARS-CoV-2–related severe cases, and MIS-C will be considered in assessing COVID-19/MIS-C cases. In all cases, the onset date of the case will be the date that symptoms were first experienced by the participant; if new symptoms are reported within 4 days after resolution of all previous symptoms, they will be considered as part of a single illness:

**SARS-CoV-2–Related Cases**

**Confirmed COVID-19, first definition:** presence of at least 1 of the following symptoms and SARS-CoV-2 NAAT positive during, or within 4 days before or after, the symptomatic period, either at the central laboratory or at a local testing facility (using an acceptable test), which triggers a potential COVID-19 illness visit (see Section 8.13.1):

- Fever;
- New or increased cough;
- New or increased shortness of breath;
- Chills;
- New or increased muscle pain;
• New loss of taste or smell;
• Sore throat;
• Diarrhea, as defined by ≥3 loose stools/day;
• Vomiting;
• Inability to eat/poor feeding in participants <5 years of age

The second definition, which may be updated as more is learned about COVID-19, will include the following additional symptoms defined by the CDC (listed at https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html), but does not trigger a potential COVID-19 illness visit unless in the opinion of the PI deemed necessary:

• Fatigue;
• Headache;
• Nasal congestion or runny nose;
• Nausea or abdominal pain


SARS-CoV-2–related severe case definition: confirmed COVID-19 and presence of at least 1 of the following triggers a potential COVID-19 illness visit:

• Clinical signs at rest indicative of severe systemic illness:
  • RR (breaths/min) and HR (beats/min) as shown in Table 4;
  • SpO₂ ≤92% on room air or >50% FiO₂ to maintain ≥92%, or PaO₂/FiO₂ <300 mm Hg;

Table 4. RR and HR, by Age, Indicative of Severe Systemic Illness

<table>
<thead>
<tr>
<th>Participant Age</th>
<th>RR</th>
<th>HR</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 to &lt;9 Months</td>
<td>&gt;61</td>
<td>&gt;168</td>
</tr>
<tr>
<td>9 Months to &lt;12 months</td>
<td>&gt;58</td>
<td>&gt;161</td>
</tr>
<tr>
<td>12 to &lt;18 Months</td>
<td>&gt;53</td>
<td>&gt;156</td>
</tr>
<tr>
<td>18 to &lt;24 Months</td>
<td>&gt;46</td>
<td>&gt;149</td>
</tr>
<tr>
<td>2 to &lt;3 Years</td>
<td>&gt;38</td>
<td>&gt;142</td>
</tr>
<tr>
<td>3 to &lt;4 Years</td>
<td>&gt;33</td>
<td>&gt;136</td>
</tr>
<tr>
<td>4 to &lt;6 Years</td>
<td>&gt;29</td>
<td>&gt;131</td>
</tr>
</tbody>
</table>
Table 4. RR and HR, by Age, Indicative of Severe Systemic Illness

<table>
<thead>
<tr>
<th>Participant Age</th>
<th>RR</th>
<th>HR</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 to &lt;8 Years</td>
<td>&gt;27</td>
<td>&gt;123</td>
</tr>
<tr>
<td>8 to &lt;12 Years</td>
<td>&gt;25</td>
<td>&gt;115</td>
</tr>
</tbody>
</table>

Abbreviations: HR = heart rate; RR = respiratory rate.


- Respiratory failure (defined as needing high-flow oxygen, including CPaP, BiPaP, noninvasive ventilation, mechanical ventilation, or ECMO);

- Evidence of shock or cardiac failure:
  - SBP (mm Hg):
    - \(<70 + (\text{age in years} \times 2)\) for age up to 10 years, \(<90 + (\text{age in years} \times 2)\) for age \(\geq 10\) years; or requiring vasoactive drugs to maintain BP in the normal range;

- Significant acute renal failure: serum creatinine \(\geq 2\) times ULN for age or 2-fold increase in baseline creatinine;

- Significant GI/hepatic failure: total bilirubin \(\geq 4\) mg/dL or ALT 2 times ULN for age;

- Significant neurological dysfunction: Glasgow Coma Scale score \(\leq 11\) or acute change in mental status with a decrease in Glasgow Coma Scale score \(\geq 3\) points from abnormal baseline\(^{32}\);

- Admission to an ICU;

- Death.

**Confirmed MIS-C definition:****\(^{31}\) as per the CDC MIS-C case definition:

- An individual <21 years of age presenting with fever (\(\geq 38.0^\circ\text{C}\) for \(\geq 24\) hours or report of subjective fever lasting \(\geq 24\) hours); AND

- Laboratory evidence of inflammation (based on local laboratory ranges) including, but not limited to, 1 or more of the following: an elevated CRP, ESR, fibrinogen, procalcitonin, D-dimer, ferritin, LDH, or IL-6, elevated neutrophils, reduced lymphocytes, and low albumin; AND
• Evidence of clinically severe illness requiring hospitalization (definition as noted above for severe disease), with multisystem (≥2) organ involvement:
  o Cardiac (eg, shock, elevated troponin, elevated BNP, abnormal echocardiogram, arrhythmia);
  o Renal (eg, acute kidney injury);
  o Respiratory (eg, pneumonia, ARDS, pulmonary embolism);
  o Hematologic (eg, elevated D-dimers, thrombophilia, or thrombocytopenia);
  o GI/hepatic (eg, elevated bilirubin, elevated liver enzymes, or diarrhea);
  o Dermatologic (eg, rash, mucocutaneous lesions);
  o Neurological (eg, CVA, aseptic meningitis, encephalopathy); AND

• No alternative plausible diagnoses; AND

• Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; OR

• COVID-19 exposure within the 4 weeks prior to the onset of symptoms.

Serological definition will be used for participants without clinical presentation of COVID-19:

• Confirmed seroconversion to SARS-CoV-2 without confirmed COVID-19: positive N-binding antibody result in a participant with a prior negative N-binding antibody result;

• Current or recent exposure is established by SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms;

• Past serological and virological status is established by SARS-CoV-2 PCR or history of reported COVID-19.

8.1.1. Immunogenicity

Serum samples will be obtained for immunogenicity testing at the visits specified in the SoA. The following assays will be performed:

• SARS-CoV-2 neutralization assay to establish immune responses to prefusion spike glycoprotein

• N-binding antibody assay to establish prior serological exposure to SARS-CoV-2

Note that all immunogenicity analyses will be based upon samples analyzed at the central laboratory.
At designated sites, an additional optional whole blood sample of approximately 10 mL will be obtained prior to Dose 1, and at 7 days and 6 months after Dose 2, from up to approximately 60 participants ≥10 years of age for isolation of PBMCs. These samples will be used on an exploratory basis to investigate the postvaccination cell-mediated immune response at these time points.

8.1.2 Biological Samples

Blood and nasal swab samples will be used only for scientific research. Each sample will be labeled with a code so that the laboratory personnel testing the samples will not know the participant’s identity. Samples that remain after performing assays outlined in the protocol may be stored by Pfizer. Unless a time limitation is required by local regulations or ethical requirements, the samples will be stored for up to 15 years after the end of the study and then destroyed. If allowed by the ICD, stored samples may be used for additional testing to better understand the immune responses to the vaccine(s) under study in this protocol, to inform the development of other products, and/or for vaccine-related assay work supporting vaccine programs. No testing of the participant’s DNA will be performed.

The participant’s parent(s)/legal guardian may request that the participant’s samples, if still identifiable, be destroyed at any time; however, any data already collected from those samples will still be used for this research. The biological samples may be shared with other researchers as long as confidentiality is maintained, and no testing of the participant’s DNA is performed.

8.2 Safety Assessments

Planned time points for all safety assessments are provided in the SoA. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.

A clinical assessment, including medical history, will be performed on all participants at their first visit to establish a baseline. Significant medical history and observations from any physical examination, if performed, will be documented in the CRF.

AEs and SAEs are collected, recorded, and reported as defined in Section 8.3.

Acute reactions within the first 30 minutes will be assessed and documented in the AE CRF.

The safety parameters also include reactogenicity e-diary reports of local reactions and systemic events (including fever) and use of antipyretic medication that occur in the 7 days after administration of the study intervention. These prospectively self-collected occurrences of local reactions and systemic events are graded as described in Section 8.2.4

8.2.1 Physical Examinations

A brief targeted physical examination will include, at a minimum, measurement of height and weight, assessments of general appearance, lungs, cardiovascular system, and lymph node survey.
Investigators should pay special attention to clinical signs related to previous serious illnesses.

8.2.2. Vital Signs
Temperature, pulse rate, and RR will be assessed in all participants. BP will be assessed in participants ≥5 years of age.

8.2.3. Clinical Safety Laboratory Assessments
Clinical safety laboratory assessments will not be collected in this study.

8.2.4. Electronic Diary
The participant’s parent(s)/legal guardian will be required to complete a reactogenicity e-diary through an application (see Section 8.14) installed on a provisioned device or on the personal device of the participant’s parent(s)/legal guardian. At the time of randomization, all participants’ parents/legal guardians will be asked to monitor and record local reactions, systemic events, and antipyretic medication use for 7 days following administration of the study intervention (Dose 1 and Dose 2). The reactogenicity e-diary allows recording of these assessments only within a fixed time window, thus providing the accurate representation of the participant’s experience at that time. Data on local reactions and systemic events reported in the reactogenicity e-diary will be transferred electronically to a third-party vendor, where they will be available for review by investigators and the Pfizer clinicians at all times via an internet-based portal. At intervals agreed to by the vendor and Pfizer, these data will be transferred electronically into Pfizer's database for analysis and reporting. These data do not need to be reported by the investigator in the CRF as AEs.

Those participants who originally received placebo and then received BNT162b2 will not complete a reactogenicity e-diary but will have their local reactions and systemic events detected and reported as AEs in accordance with Section 8.3.1.

Investigators (or designee) will be required to review the reactogenicity e-diary data online at frequent intervals as part of the ongoing safety review.

The investigator or designee must obtain stop dates from the participant for any ongoing local reactions, systemic events, or use of antipyretic medication on the last day that the reactogenicity e-diary was completed. The stop dates should be documented in the source documents and the information entered in the CRF.

8.2.4.1. Grading Scales
The grading scales used in this study to assess local reactions and systemic events as described below are derived from the FDA CBER guidelines on toxicity grading scales for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials.28
8.2.4.2. Local Reactions

During the reactogenicity e-diary reporting period, participants’ parents/legal guardians will be asked to assess redness, swelling, and pain/tenderness at the injection site and to record the symptoms in the reactogenicity e-diary daily for 7 days (Days 1 through 7) after each vaccination. If a local reaction persists beyond the end of the reactogenicity e-diary period following vaccination, the participant’s parents/legal guardians will be requested to report that information. The investigator will enter this additional information in the CRF.

Redness and swelling will be measured and recorded in caliper units (measuring device units; range: 1 to 14 for pediatric caliper device) for the first 7 days following vaccination (Days 1 through 7), and then categorized as mild, moderate, or severe using the scale shown in Table 5. Measuring device units can be converted to centimeters according to the following formula: 1 measuring device unit = 0.5 cm. Pain at the injection site will be assessed for participants ≥2 to <12 years of age as absent, mild, moderate, or severe according to the grading scale in Table 5. Tenderness at the injection site will be assessed for participants ≥6 months to <2 years of age as absent, mild, moderate, or severe according to the grading scale in Table 5.

If redness or swelling >14 caliper units is reported in the reactogenicity e-diary, a telephone contact should occur to ascertain further details and determine whether a site visit is clinically indicated. If Grade 3 pain or tenderness at the injection site is reported in the reactogenicity e-diary, a telephone contact should occur to ascertain further details and determine whether a site visit is clinically indicated. Only an investigator or medically qualified person is able to classify a participant’s local reaction as Grade 4. If a participant experiences a confirmed Grade 4 local reaction, the investigator must immediately notify the sponsor and, if it is determined to be related to the administration of the study intervention, further vaccinations will be discontinued in that participant.

### Table 5. Local Reaction Grading Scale

<table>
<thead>
<tr>
<th></th>
<th>Participant Age</th>
<th>Mild (Grade 1)</th>
<th>Moderate (Grade 2)</th>
<th>Severe* (Grade 3)*</th>
<th>Potentially Life Threatening (Grade 4)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain at the injection site</td>
<td>≥2 to &lt;12 Years</td>
<td>Does not interfere with activity</td>
<td>Interferes with activity</td>
<td>Prevents daily activity</td>
<td>Emergency room visit or hospitalization for severe pain (tenderness) at the injection site</td>
</tr>
<tr>
<td>Tenderness at injection site</td>
<td>≥6 Months to &lt;2 years</td>
<td>Hurts if gently touched (eg, whimpers, winces, protests, or withdraws)</td>
<td>Hurts if gently touched with crying</td>
<td>Causes limitation of limb movement</td>
<td>Emergency room visit or hospitalization for severe pain (tenderness) at the injection site</td>
</tr>
<tr>
<td>Redness</td>
<td>≥6 Months to &lt;12 years</td>
<td>1 to 4 caliper units (or measuring device units) = 0.5 to 2.0 cm</td>
<td>5 to 14 caliper units (or measuring device unit) = &gt;2.0 to 7.0 cm</td>
<td>&gt;14 caliper units (or measuring device unit) = &gt;7 cm</td>
<td>Necrosis or exfoliative dermatitis</td>
</tr>
</tbody>
</table>
Table 5. Local Reaction Grading Scale

<table>
<thead>
<tr>
<th>Participant Age</th>
<th>Mild (Grade 1)</th>
<th>Moderate (Grade 2)</th>
<th>Severe* (Grade 3)*</th>
<th>Potentially Life Threatening (Grade 4)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swelling ≥6 Months to &lt;12 years</td>
<td>1 to 4 caliper units (or measuring device units) = 0.5 to 2.0 cm</td>
<td>5 to 14 caliper units (or measuring device units) = &gt;2.0 to 7.0 cm</td>
<td>&gt;14 caliper units (or measuring device units) = &gt;7 cm</td>
<td>Necrosis</td>
</tr>
</tbody>
</table>

a. Parent(s)/legal guardians of the participants experiencing local reactions >14 caliper units (>7 cm) are to be contacted by the study site. An unscheduled visit may be required.
b. Only an investigator or qualified designee is able to classify a participant’s local reaction as Grade 4, after clinical evaluation of the participant or documentation from another medically qualified source (eg, emergency room or hospital record). Grade 4 local reactions will be collected on the AE case report form and assessed by the investigator using the AE intensity grading scale as detailed in Section 10.3.3.

8.2.4.3. Systemic Events

If a Grade 3 systemic event is reported in the reactogenicity e-diary, a telephone contact should occur to ascertain further details and determine whether a site visit is clinically indicated. Only an investigator or medically qualified person is able to classify a participant’s systemic event as Grade 4. If a participant experiences a confirmed Grade 4 systemic event, the investigator must immediately notify the sponsor and, if it is determined to be related to the administration of the study intervention, further vaccinations will be discontinued in that participant.

8.2.4.3.1. Participants ≥2 to <12 Years of Age

During the reactogenicity e-diary reporting period, the participant’s parent(s)/legal guardian will be asked to assess vomiting, diarrhea, headache, fatigue, chills, new or worsened muscle pain, and new or worsened joint pain and to record the symptoms in the reactogenicity e-diary. The symptoms will be assessed by the participant’s parent(s)/legal guardian as absent, mild, moderate, or severe according to the grading scale in Table 6.

Table 6. Systemic Event Grading Scale for Participants ≥2 to <12 Years of Age

<table>
<thead>
<tr>
<th></th>
<th>Mild (Grade 1)</th>
<th>Moderate (Grade 2)</th>
<th>Severe (Grade 3)</th>
<th>Potentially Life Threatening (Grade 4)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting</td>
<td>1-2 times in 24 hours</td>
<td>&gt;2 times in 24 hours</td>
<td>Requires IV hydration</td>
<td>Emergency room visit or hospitalization for hypotensive shock</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2 to 3 loose stools in 24 hours</td>
<td>4 to 5 loose stools in 24 hours</td>
<td>6 or more loose stools in 24 hours</td>
<td>Emergency room visit or hospitalization for severe diarrhea</td>
</tr>
<tr>
<td>Headache</td>
<td>Does not interfere with activity</td>
<td>Some interference with activity</td>
<td>Prevents daily routine activity</td>
<td>Emergency room visit or hospitalization for severe headache</td>
</tr>
</tbody>
</table>
Table 6. Systemic Event Grading Scale for Participants ≥2 to <12 Years of Age

<table>
<thead>
<tr>
<th>Event</th>
<th>Mild (Grade 1)</th>
<th>Moderate (Grade 2)</th>
<th>Severe (Grade 3)</th>
<th>Potentially Life Threatening (Grade 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue/tiredness</td>
<td>Does not interfere with activity</td>
<td>Some interference with activity</td>
<td>Prevents daily routine activity</td>
<td>Emergency room visit or hospitalization for severe fatigue</td>
</tr>
<tr>
<td>Chills</td>
<td>Does not interfere with activity</td>
<td>Some interference with activity</td>
<td>Prevents daily routine activity</td>
<td>Emergency room visit or hospitalization for severe chills</td>
</tr>
<tr>
<td>New or worsened muscle pain</td>
<td>Does not interfere with activity</td>
<td>Some interference with activity</td>
<td>Prevents daily routine activity</td>
<td>Emergency room visit or hospitalization for severe new or worsened muscle pain</td>
</tr>
<tr>
<td>New or worsened joint pain</td>
<td>Does not interfere with activity</td>
<td>Some interference with activity</td>
<td>Prevents daily routine activity</td>
<td>Emergency room visit or hospitalization for severe new or worsened joint pain</td>
</tr>
</tbody>
</table>

Abbreviation: IV = intravenous.

a. Only an investigator or qualified designee is able to classify a participant’s systemic event as Grade 4, after clinical evaluation of the participant or documentation from another medically qualified source (e.g., emergency room or hospital record). Grade 4 local reactions will be collected on the AE case report form and assessed by the investigator using the AE intensity grading scale as detailed in Section 10.3.3.

8.2.4.3.2. Participants ≥6 Months to <2 Years of Age

During the reactogenicity e-diary reporting period, the participant’s parent(s)/legal guardian will be asked to assess decreased appetite, drowsiness, and irritability and to record the symptoms in the reactogenicity e-diary. The symptoms will be assessed by the participant’s parent(s)/legal guardian as absent, mild, moderate, or severe according to the grading scale in Table 7.

Table 7. Systemic Event Grading Scale for Participants ≥6 Months to <2 Years of Age

<table>
<thead>
<tr>
<th>Event</th>
<th>Mild (Grade 1)</th>
<th>Moderate (Grade 2)</th>
<th>Severe (Grade 3)</th>
<th>Potentially Life Threatening (Grade 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased appetite (loss of appetite)</td>
<td>Decreased interest in eating</td>
<td>Decreased oral intake</td>
<td>Refusal to feed</td>
<td>Emergency room visit or hospitalization for severe decreased appetite (loss of appetite)</td>
</tr>
<tr>
<td>Drowsiness (increased sleep)</td>
<td>Increased or prolonged sleeping bouts</td>
<td>Slightly subdued interfering with daily activity</td>
<td>Disabling: not interested in usual daily activity</td>
<td>Emergency room visit or hospitalization for severe drowsiness (increased sleep)</td>
</tr>
</tbody>
</table>
**Table 7. Systemic Event Grading Scale for Participants ≥6 Months to <2 Years of Age**

<table>
<thead>
<tr>
<th>Mild (Grade 1)</th>
<th>Moderate (Grade 2)</th>
<th>Severe (Grade 3)</th>
<th>Potentially Life Threatening (Grade 4)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irritability (fussiness) (synonymous with restless sleep; decreased sleep)</td>
<td>Easily consolable</td>
<td>Requiring increased attention</td>
<td>Inconsolable; crying cannot be comforted</td>
</tr>
<tr>
<td>*Only an investigator or qualified designee is able to classify a participant’s systemic event as Grade 4, after clinical evaluation of the participant or documentation from another medically qualified source (eg, emergency room or hospital record). Grade 4 local reactions will be collected on the AE case report form and assessed by the investigator using the AE intensity grading scale as detailed in Section 10.3.3.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: IV = intravenous.

**8.2.4.4. Fever**

In order to record information on fever, a thermometer will be given to participants with instructions on how to measure temperature at home. Temperatures will be taken orally for participants ≥2 to <12 years of age, and axillary for participants <2 years of age. Temperature will be collected in the reactogenicity e-diary in the evening daily during the reactogenicity e-diary reporting period. It will also be collected at any time during the reactogenicity e-diary data collection periods when fever is suspected. Fever is defined as a temperature of ≥38.0°C (100.4°F). The highest temperature for each day will be recorded in the reactogenicity e-diary. Temperature will be measured and recorded to 1 decimal place. Temperatures recorded in degrees Fahrenheit will be programmatically converted to degrees Celsius and then categorized according to the scale shown in Table 8 during analysis.

If a fever of ≥39.0°C (102.1°F) is reported in the reactogenicity e-diary, a telephone contact should occur to ascertain further details and determine whether a site visit is clinically indicated. Only an investigator or medically qualified person is able to confirm a participant’s fever as >40.0°C (>104.0°F). If a participant experiences a confirmed fever >40.0°C (>104.0°F), the investigator must immediately notify the sponsor and, if it is determined to be related to the administration of the study intervention, further vaccinations will be discontinued in that participant.

**Table 8. Scale for Fever**

<table>
<thead>
<tr>
<th>Range</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>≥38.0-38.4°C (100.4-101.1°F)</td>
<td></td>
</tr>
<tr>
<td>&gt;38.4-38.9°C (101.2-102.0°F)</td>
<td></td>
</tr>
<tr>
<td>&gt;38.9-40.0°C (102.1-104.0°F)</td>
<td></td>
</tr>
<tr>
<td>&gt;40.0°C (&gt;104.0°F)</td>
<td></td>
</tr>
</tbody>
</table>
8.2.4.5. Antipyretic Medication

The use of antipyretic medication to treat symptoms associated with study intervention administration will be recorded in the reactogenicity e-diary daily during the reporting period (Day 1 through Day 7).

8.2.5. Phase 1 Stopping Rules

The following stopping rules apply by age group and are in place for all Phase 1 participants, based on review of AE data and e-diary reactogenicity data, until the start of Phase 2/3 or 30 days after the last dose of study intervention in Phase 1 in each age group, whichever is later. These data will be monitored on an ongoing basis by the investigator (or medically qualified designee) and sponsor in order to promptly identify and flag any event that potentially contributes to a stopping rule.

The sponsor study team will be unblinded during Phase 1, so will be able to assess whether or not a stopping rule has been met on the basis of a participant’s individual study intervention allocation.

In the event that sponsor personnel confirm that a stopping rule is met, the following actions will commence:

- The IRC will review all appropriate data.
- The stopping rule will PAUSE randomization and study intervention administration for all dose levels in the impacted age group.
- The DMC will review all appropriate data.
- For all participants vaccinated, all other routine study conduct activities, including ongoing data entry, reporting of AEs, participant reactogenicity e-diary completion, blood sample collection, and participant follow-up, will continue during the pause.

A stopping rule is met if any of the following rules occur after administration of investigational BNT162b2. Reactogenicity e-diary data confirmed by the investigator as being entered by the participant in error will not contribute toward a stopping rule.

The BNT162b2 dose levels within an age group will contribute to stopping rules together.

**Stopping Rule Criteria for Each BNT162b2 Dose Level:**

1. If any participant vaccinated with the BNT162b2 candidate at any dose level develops an SAE that is assessed by the investigator as possibly related, or for which there is no alternative, plausible, attributable cause.

2. If any participant vaccinated with the BNT162b2 candidate at any dose level develops a Grade 4 local reaction or systemic event after vaccination (see **Section 8.2.4**) that is
assessed as possibly related by the investigator, or for which there is no alternative, plausible, attributable cause.

3. If any participant vaccinated with the BNT162b2 candidate at any dose level develops a fever >40.0°C (>104.0°F) for at least 1 daily measurement after vaccination (see Section 8.2.4) that is assessed as possibly related by the investigator, or for which there is no alternative, plausible, attributable cause.

4. If any 2 participants vaccinated with the BNT162b2 candidate at any dose level within the same age group report the same or similar severe (Grade 3) AE after vaccination, assessed as possibly related by the investigator, or for which there is no alternative, plausible, attributable cause.

5. If any participant dies or requires ICU admission due to SARS-CoV-2 infection; if this stopping rule is met, all available clinical and preclinical safety and immunogenicity data should be reviewed to evaluate for enhanced COVID-19.

8.2.6. Randomization and Vaccination After a Stopping Rule Is Met in Phase 1

Once the IRC and DMC have reviewed the safety data and provided guidance, a notification will be sent from the sponsor to the sites with guidance on how to proceed.

8.2.7. Pregnancy Testing

Pregnancy tests may be urine or serum tests, but must have a sensitivity of at least 25 mIU/mL. Pregnancy tests will be performed in WOCBP at the times listed in the SoA, immediately before the administration of each vaccine dose. A negative pregnancy test result will be required prior to the participant’s receiving the study intervention. Pregnancy tests may also be repeated if requested by IRBs/ECs or if required by local regulations. In the case of a positive confirmed pregnancy, the participant will be withdrawn from administration of study intervention but may remain in the study. In the case of a positive pregnancy test for a female participant, it is a responsibility of investigator to share the information with the participant’s parent(s)/legal guardian.

8.3. Adverse Events and Serious Adverse Events

The definitions of an AE and an SAE can be found in Appendix 3.

AEs will be reported by the participant's parent(s)/legal guardian.

The investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE and remain responsible to pursue and obtain adequate information both to determine the outcome and to assess whether the event meets the criteria for classification as an SAE or caused the participant to discontinue the study intervention (see Section 7.1).

Each participants’ parent/legal guardian will be questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may be requested by Pfizer Safety to obtain specific follow-up information in an expedited fashion.

8.3.1. Time Period and Frequency for Collecting AE and SAE Information

The time period for actively eliciting and collecting AEs and SAEs (“active collection period”) for each participant begins from the time the participant’s parent(s)/legal guardian provides informed consent, which is obtained before the participant’s participation in the study (ie, before undergoing any study-related procedure and/or receiving study intervention), through and including 1 month after Dose 2 (Phase 1 – Visit 4; Phase 2/3 – Visit 4). In addition, any AEs occurring up to 48 hours after each subsequent blood draw and nasal swab collection must be recorded on the CRF.

SAEs will be collected from the time the participant provides informed consent through 6 months after Dose 2 (Phase 1 – Visit 5; Phase 2/3 – Visit 5).

Phase 2/3 Participants Who Originally Received Placebo:

At Visit 5, all participants will be unblinded and if they originally received placebo will be offered BNT162b2. For participants who originally received placebo and go on to receive BNT162b2 as Dose 3 and Dose 4, the time period for actively eliciting and collecting AEs and SAEs will continue from the receipt of BNT162b2 (Dose 3 and Dose 4), through and including 1 month after Dose 4 (Visit C). SAEs will be collected from the time of receipt of BNT162b2 (Dose 3 and Dose 4) through approximately 6 months after Dose 4 of BNT162b2 (Visit D).

Follow-up by the investigator continues throughout and after the active collection period and until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the investigator and Pfizer concurs with that assessment.

For participants who are screen failures, the active collection period ends when screen failure status is determined.

If the participant who provided assent in any phase of the study or the participant’s parent(s)/legal guardian withdraws from the study and also withdraws consent/assent for the collection of future information, the active collection period ends when consent/assent is withdrawn.

If a participant definitively discontinues or temporarily discontinues study intervention because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE reported using the Vaccine SAE Reporting Form.

Investigators are not obligated to actively seek AEs or SAEs after the participant has concluded study participation. However, if the investigator learns of any SAE, including a death, at any time after a participant has completed the study, and he/she considers the event to be reasonably related to the study intervention, the investigator must promptly report the SAE to Pfizer using the Vaccine SAE Reporting Form.
Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

8.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in Section 8.3.1 are reported to Pfizer Safety on the Vaccine SAE Reporting Form immediately upon awareness and under no circumstance should this exceed 24 hours, as indicated in Appendix 3. The investigator will submit any updated SAE data to the sponsor within 24 hours of it being available.

8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, which begins after obtaining informed consent as described in Section 8.3.1, will be recorded on the AE section of the CRF.

The investigator is to record on the CRF all directly observed and all spontaneously reported AEs and SAEs reported by the participant.

8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures for completing and transmitting SAE reports are provided in Appendix 3.

Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrences.

8.3.3. Follow-up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. For each event, the investigator must pursue and obtain adequate information until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3).

In general, follow-up information will include a description of the event in sufficient detail to allow for a complete medical assessment of the case and independent determination of possible causality. Any information relevant to the event, such as concomitant medications and illnesses, must be provided. In the case of a participant death, a summary of available autopsy findings must be submitted as soon as possible to Pfizer Safety.

Further information on follow-up procedures is given in Appendix 3.
8.3.4. Regulatory Reporting Requirements for SAEs

Prompt notification by the investigator to the sponsor of an SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.

The sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The sponsor will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, IRBs/ECs, and investigators.

Investigator safety reports must be prepared for SUSARs according to local regulatory requirements and sponsor policy and forwarded to investigators as necessary.

An investigator who receives SUSARs or other specific safety information (eg, summary or listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the study and will notify the IRB/EC, if appropriate according to local requirements.

8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure

Exposure to the study intervention under study during pregnancy or breastfeeding and occupational exposure are reportable to Pfizer Safety within 24 hours of investigator awareness.

8.3.5.1. Exposure During Pregnancy

An EDP occurs if:

- A female participant is found to be pregnant while receiving or after discontinuing study intervention.

- A male participant who is receiving or has discontinued study intervention exposes a female partner prior to or around the time of conception.

- A female is found to be pregnant while being exposed or having been exposed to study intervention due to environmental exposure. Below are examples of environmental exposure during pregnancy:
  - A female family member or healthcare provider reports that she is pregnant after having been exposed to the study intervention by inhalation or skin contact.
  - A male family member or healthcare provider who has been exposed to the study intervention by inhalation or skin contact then exposes his female partner prior to or around the time of conception.

The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s awareness, irrespective of whether an SAE has occurred. The initial information submitted...
should include the anticipated date of delivery (see below for information related to termination of pregnancy).

- If EDP occurs in a participant or a participant’s partner, the investigator must report this information to Pfizer Safety on the Vaccine SAE Reporting Form and an EDP Supplemental Form, regardless of whether an SAE has occurred. Details of the pregnancy will be collected as per the time period for actively collecting AEs and SAEs (after the start of study intervention and until 6 months after the last dose of study intervention).

- If EDP occurs in the setting of environmental exposure, the investigator must report information to Pfizer Safety using the Vaccine SAE Reporting Form and EDP Supplemental Form. Since the exposure information does not pertain to the participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed Vaccine SAE Reporting Form is maintained in the investigator site file.

Follow-up is conducted to obtain general information on the pregnancy and its outcome for all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth. In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by gross visual inspection (unless preprocedure test findings are conclusive for a congenital anomaly and the findings are reported).

Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly), the investigator should follow the procedures for reporting SAEs. Additional information about pregnancy outcomes that are reported to Pfizer Safety as SAEs follows:

- Spontaneous abortion including miscarriage and missed abortion;

- Neonatal deaths that occur within 1 month of birth should be reported, without regard to causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs when the investigator assesses the infant death as related or possibly related to exposure to the study intervention.

Additional information regarding the EDP may be requested by the sponsor. Further follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the participant with the Pregnant Partner Release of Information Form to deliver to his partner. The investigator must document in the source documents that the participant was given the Pregnant Partner Release of Information Form to provide to his partner.
8.3.5.2. Exposure During Breastfeeding

An exposure during breastfeeding occurs if:

- A female participant is found to be breastfeeding while receiving or after discontinuing study intervention.

- A female is found to be breastfeeding while being exposed or having been exposed to study intervention (i.e., environmental exposure). An example of environmental exposure during breastfeeding is a female family member or healthcare provider who reports that she is breastfeeding after having been exposed to the study intervention by inhalation or skin contact.

The investigator must report exposure during breastfeeding to Pfizer Safety within 24 hours of the investigator’s awareness, irrespective of whether an SAE has occurred. The information must be reported using the Vaccine SAE Reporting Form. When exposure during breastfeeding occurs in the setting of environmental exposure, the exposure information does not pertain to the participant enrolled in the study, so the information is not recorded on a CRF. However, a copy of the completed Vaccine SAE Reporting Form is maintained in the investigator site file.

An exposure during breastfeeding report is not created when a Pfizer drug specifically approved for use in breastfeeding women (e.g., vitamins) is administered in accord with authorized use. However, if the infant experiences an SAE associated with such a drug, the SAE is reported together with the exposure during breastfeeding.

8.3.5.3. Occupational Exposure

An occupational exposure occurs when a person receives unplanned direct contact with the study intervention, which may or may not lead to the occurrence of an AE. Such persons may include healthcare providers, family members, and other roles that are involved in the trial participant’s care.

The investigator must report occupational exposure to Pfizer Safety within 24 hours of the investigator’s awareness, regardless of whether there is an associated SAE. The information must be reported using the Vaccine SAE Reporting Form. Since the information does not pertain to a participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed Vaccine SAE Reporting Form is maintained in the investigator site file.

8.3.6. Cardiovascular and Death Events

Not applicable.
8.3.7. Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs or SAEs

Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition should not be recorded as AEs. These data will be captured as efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

Potential COVID-19/MIS-C illnesses and their sequelae will not be reported according to the standard process for expedited reporting of SAEs, even though the event may meet the definition of an SAE. These events will be recorded on the COVID-19 illness pages in the participant’s CRF within 1 business day.

NOTE: However, if either of the following conditions applies, then the event must be recorded and reported as an SAE (instead of a disease-related event):

The event is, in the investigator’s opinion, of greater intensity, frequency, or duration than expected for the individual participant.

OR

The investigator considers that there is a reasonable possibility that the event was related to study intervention.

Potential COVID-19/MIS-C illness events and their sequelae will be reviewed by internal blinded case reviewers. Any SAE that is determined by the internal blinded case reviewers NOT to meet endpoint criteria is reported back to the investigator site of incidence. The investigator must report the SAE to Pfizer Safety within 24 hours of being made aware that the SAE did not meet endpoint criteria. The investigator’s SAE awareness date is the date on which the investigator site of incidence receives the SAE back from the internal case reviewers.

8.3.8. Adverse Events of Special Interest

Not applicable.

8.3.8.1. Lack of Efficacy

Lack of efficacy is reportable to Pfizer Safety only if associated with an SAE.

8.3.9. Medical Device Deficiencies

Not applicable.

8.3.10. Medication Errors

Medication errors may result from the administration or consumption of the study intervention by the wrong participant, or at the wrong time, or at the wrong dosage strength.
Exposures to the study intervention under study may occur in clinical trial settings, such as medication errors.

<table>
<thead>
<tr>
<th>Safety Event</th>
<th>Recorded on the CRF</th>
<th>Reported on the Vaccine SAE Reporting Form to Pfizer Safety Within 24 Hours of Awareness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication errors</td>
<td>All (regardless of whether associated with an AE)</td>
<td>Only if associated with an SAE</td>
</tr>
</tbody>
</table>

Medication errors include:

- Medication errors involving participant exposure to the study intervention;
- Potential medication errors or uses outside of what is foreseen in the protocol that do or do not involve the study participant.

Such medication errors occurring to a study participant are to be captured on the medication error page of the CRF, which is a specific version of the AE page.

In the event of a medication dosing error, the sponsor should be notified within 24 hours.

Whether or not the medication error is accompanied by an AE, as determined by the investigator, the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the CRF.

Medication errors should be reported to Pfizer Safety within 24 hours on a Vaccine SAE Reporting Form only when associated with an SAE.

8.4. Treatment of Overdose

For this study, any dose of study intervention greater than 1 dose of study intervention within a 24-hour time period will be considered an overdose.

Pfizer does not recommend specific treatment for an overdose.

In the event of an overdose, the investigator should:

1. Contact the medical monitor within 24 hours.
2. Closely monitor the participant for any AEs/SAEs.
3. Document the quantity of the excess dose as well as the duration of the overdose in the CRF.
4. Overdose is reportable to Safety only when associated with an SAE.

Decisions regarding dose interruptions or modifications will be made by the investigator in consultation with the medical monitor based on the clinical evaluation of the participant.

8.5. Pharmacokinetics
Pharmacokinetic parameters are not evaluated in this study.

8.6. Pharmacodynamics
Pharmacodynamic parameters are not evaluated in this study.

8.7. Genetics
Genetics (specified analyses) are not evaluated in this study.

8.8. Biomarkers
Biomarkers are not evaluated in this study.

8.9. Immunogenicity Assessments
Immunogenicity assessments are described in Section 8.1.1.

8.10. Health Economics
Health economics/medical resource utilization and health economics parameters are not evaluated in this study.

8.11. Study Procedures
Unless stated otherwise, all study visits are intended to be conducted in-person at the study site. If this is not possible, because of local circumstances related to the COVID-19 pandemic, study procedures that do not require in-person participant contact may be performed by telehealth. Telehealth includes the exchange of healthcare information and services via telecommunication technologies (eg, audio, video, videoconferencing software) remotely, allowing the participant and the investigator to communicate on aspects of clinical care, including medical advice, reminders, education, and safety monitoring. Irrespective of the nature of the contact, all visit procedures are expected to be performed on the same day.

8.11.1. Phase 1
8.11.1.1. Visit 1 – Dose 1 (Day 1)
Before enrollment and before any study-related procedures are performed, voluntary, written study-specific informed consent and assent if appropriate will be obtained from the participant or participant’s parent(s)/legal guardian. Each signature on the ICD must be personally dated by the signatory. The investigator or his or her designee will also sign the ICD. A copy of the signed and dated ICD must be given to the participant or
participant/participant’s parent(s)/legal guardian. The source data must reflect that the informed consent was obtained before participation in the study.

It is anticipated that the procedures below will be conducted in a stepwise manner; however, the visit can occur in 2 consecutive days; if so, all steps from assessing the inclusion and exclusion criteria onwards must be conducted on the day of vaccination. Ensure that procedures listed prior to administration of the vaccine are conducted prior to vaccination and on the day of the vaccination.

- Assign a single participant number using the IRT system.
- Obtain the participant’s demography (including date of birth, sex, race, and ethnicity). The full date of birth will be collected to critically evaluate the immune response and safety profile by age.
- Obtain the participant’s medical history of clinical significance.
- Measure the participant’s vital signs (including body temperature).
- On the day of and before vaccination, perform physical examination including, at a minimum, measurement of height and weight, assessments of general appearance, lungs, cardiovascular system, and lymph node survey.
- On the day of and prior to vaccination, perform a urine pregnancy test on all female participants who are biologically capable of having children as described in Section 8.2.7. A negative pregnancy test result is required before the participant may receive the study intervention.
- If appropriate, discuss contraceptive use as described in Section 5.3.1.
- Record nonstudy vaccinations as described in Section 6.5.
- Ensure and document that all of the inclusion criteria and none of the exclusion criteria are met.
- Ensure that the participant meets none of the temporary delay criteria as described in Section 5.5.
- Obtain the participant’s randomization number and study intervention allocation using the IRT system. Only an unblinded site staff member may obtain this information.
- Obtain a nasal (anterior nares) swab (collected by site staff) and provide nasal swab, media, and instructions to the participant’s parent(s)/legal guardian on the technique for collecting a nasal swab at home.
- Collect a blood sample (approximately 5 mL) for immunogenicity.
Unblinded site staff member(s) will dispense/administer 1 dose of study intervention:

- For participants ≥2 to <12 years of age, into the deltoid muscle of the (preferably) nondominant arm.
- For participants 6 months to <2 years of age, into the anterior thigh muscle of the (preferably) left leg.
- Please refer to the IP manual for further instruction on this process.

Blinded site staff must observe the participant for at least 30 minutes after study intervention administration for any acute reactions. Record any acute reactions (including time of onset) in the participant’s source documents and on the AE page of the CRF, and on an SAE form as applicable.

Record AEs and SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

Issue a caliper device to measure local reactions at the injection site and a thermometer for recording daily temperatures and provide instructions on their use.

Explain the e-diary technologies available for this study (see Section 8.14), and assist the participant’s parent(s)/legal guardian in downloading the study application onto his or her own device or issue a provisioned device if required.

Provide instructions on reactogenicity e-diary completion and ask the participant’s parent(s)/legal guardian to complete the reactogenicity e-diary from Day 1 through Day 7, with Day 1 being the day of vaccination.

Provide instructions on COVID-19/MIS-C illness e-diary completion and ask the participant’s parent(s)/legal guardian to complete the COVID-19/MIS-C illness e-diary if the participant is diagnosed with COVID-19/MIS-C or has possible new or increased symptoms, and when a reminder is received, at least weekly. See Section 8.14 for further details.

Ask the participant’s parent(s)/legal guardian, as appropriate, to contact the site staff or investigator immediately if the participant experiences any of the following from Day 1 through Day 7 after vaccination (where Day 1 is the day of vaccination) to determine if an unscheduled reactogenicity visit is required:

- Fever ≥39.0°C (≥102.1°F).
- Redness or swelling at the injection site >14 caliper units (or >7 cm).
Grade 3 pain or tenderness at the injection site.

Any severe systemic event.

Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator immediately if a medically attended event (eg doctor’s visit, emergency room visit) or hospitalization occurs.

Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any symptoms as detailed in Section 8.13.

Schedule an appointment for the participant to return for the next study visit.

Remind the participant’s parent(s)/legal guardian to bring the e-diary to the next visit.

Complete the source documents.

The investigator or an authorized designee completes the CRFs and an unblinded dispenser/administrator updates the study intervention accountability records.

The investigator or appropriately qualified designee reviews the reactogenicity e-diary data online following vaccination to evaluate participant compliance and as part of the ongoing safety review. Daily review is optimal during the active diary period.

8.11.1.2. Visit 2 – Dose 2 (19 to 23 Days After Visit 1)

It is anticipated that the procedures below will be conducted in a stepwise manner; ensure that procedures listed prior to administration of the vaccine are conducted prior to vaccination.

Record AEs and SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

Review the participant’s reactogenicity e-diary data. Collect stop dates of any reactogenicity e-diary events ongoing on the last day that the reactogenicity e-diary was completed and record stop dates in the CRF if required.

Measure the participant’s vital signs (including body temperature).

On the day of and before vaccination, perform physical examination including, at a minimum, assessments of general appearance, lungs, cardiovascular system, and lymph node survey.
• On the day of and prior to vaccination, perform a urine pregnancy test on all female participants who are biologically capable of having children as described in Section 8.2.7. A negative pregnancy test result is required before the participant may receive the study intervention.

• If appropriate, discuss contraceptive use as described in Section 5.3.1.

• Record nonstudy vaccinations as described in Section 6.5.

• Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

• Ensure and document that all of the inclusion criteria and none of the exclusion criteria are met. If not, the participant may not receive further study intervention but will remain in the study to be evaluated for safety, immunogenicity, and efficacy (see Section 7.1).

• Obtain a nasal (anterior nares) swab (collected by site staff). Review with the participant’s parent(s)/legal guardian the technique for collecting a nasal swab at home.

• Ensure that the participant meets none of the temporary delay criteria as described in Section 5.5.

• Collect a blood sample (approximately 5 mL) for immunogenicity testing.

• Unblinded site staff member(s) will dispense/administer 1 dose of study intervention:
  • For participants ≥2 to <12 years of age, into the deltoid muscle of the (preferably) nondominant arm.
  • For participants 6 months to <2 years of age, into the anterior thigh muscle of the (preferably) left leg.
  • Please refer to the IP manual for further instruction on this process.

• Blinded site staff must observe the participant for at least 30 minutes after study intervention administration for any acute reactions. Record any acute reactions (including time of onset) in the participant’s source documents and on the AE page of the CRF, and on an SAE form as applicable.

• Ensure the participant’s parent(s)/legal guardian has a caliper device to measure local reactions at the injection site and a thermometer for recording daily temperatures.

• Ensure the participant’s parent(s)/legal guardian remains comfortable with the chosen e-diary platform, confirm instructions on e-diary completion, and ask the participant’s parent/legal guardian to complete the reactogenicity e-diary from Day 1 through Day 7, with Day 1 being the day of vaccination.
• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator immediately if the participant experiences any of the following from Day 1 through Day 7 after vaccination (where Day 1 is the day of vaccination) to determine if an unscheduled reactogenicity visit is required:
  • Fever ≥39.0°C (≥102.1°F).
  • Redness or swelling at the injection site measuring greater than 14 caliper units (or >7 cm).
  • Grade 3 pain or tenderness at the injection site.
  • Any severe systemic event.
• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator if a medically attended event (eg, doctor’s visit, emergency room visit) or hospitalization occurs.
• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.
• Schedule an appointment for the participant to return for the next study visit.
• Remind the participant’s parent(s)/legal guardian to bring the e-diary to the next visit.
• Complete the source documents.
• The investigator or an authorized designee completes the CRFs and an unblinded dispenser/administrator updates the study intervention accountability records.
• The investigator or appropriately qualified designee reviews the reactogenicity e-diary data online following vaccination to evaluate participant compliance and as part of the ongoing safety review. Daily review is optimal during the active diary period.

8.11.1.3. Visit 3 – 7-Day Follow-up Visit (1 Week After Dose 2, 6 to 8 Days After Visit 2)
• Review the participant’s reactogenicity e-diary data.
• Record AEs/SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.
• Record nonstudy vaccinations as described in Section 6.5.
• Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

• If appropriate, discuss contraceptive use as described in Section 5.3.1.

• Collect a blood sample (approximately 5 mL) for immunogenicity testing.

• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator if a medically attended event (eg, doctor’s visit, emergency room visit) or hospitalization occurs.

• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

• Schedule an appointment for the participant for the next study visit.

• Complete the source documents.

• The investigator or an authorized designee completes the CRFs.

8.11.1.4. Visit 4 – 1-Month Follow-up Visit (28 to 35 Days After Visit 2)

This visit can be performed as a telephone visit if the study procedure is not required for the participant.

• Review the participant’s reactogenicity e-diary data. Collect stop dates of any reactogenicity e-diary events ongoing on the last day that the reactogenicity e-diary was completed and record stop dates in the CRF if required.

• Record AEs/SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

• Record nonstudy vaccinations as described in Section 6.5.

• Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

• If appropriate, discuss contraceptive use as described in Section 5.3.1.

• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator if a medically attended event (eg, doctor’s visit, emergency room visit) or hospitalization occurs.
Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

Schedule an appointment for the participant for the next study visit.

Complete the source documents.

The investigator or an authorized designee completes the CRFs.

**8.11.1.5. Visit 5 – 6-Month Follow-up Visit (175 to 189 Days After Visit 2)**

- Contact the participant’s parent(s)/legal guardian by telephone.

- Record SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

- Record nonstudy vaccinations as described in Section 6.5.

- Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

- Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator if a medically attended event (eg, doctor’s visit, emergency room visit) or hospitalization occurs.

- Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

- Schedule an appointment for the participant for the next study visit.

- Complete the source documents.

- The investigator or an authorized designee completes the CRFs.

**8.11.1.6. Visit 6 – 12-Month Follow-up Visit (350 to 378 Days After Visit 2)**

- Contact the participant’s parent(s)/legal guardian by telephone.

- Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.
• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19 illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

• Schedule an appointment for the participant for the next study visit.

• Complete the source documents.

• The investigator or an authorized designee completes the CRFs.

**8.11.1.7. Visit 7 – 24-Month Follow-up Visit (714 to 742 Days After Visit 2)**

This visit can be performed as a telephone visit if the study procedure is not required for the participant.

• Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

• Collect the participant’s e-diary or assist the participant or participant’s parent(s)/legal guardian to remove the study application from his or her own personal device.

• Complete the source documents.

• The investigator or an authorized designee completes the CRFs.

• Inform the participant’s parent(s)/legal guardian that the participant’s study participation has ended.

**8.11.2. Phase 2/3**

**8.11.2.1. Visit 1 – Dose 1 (Day 1)**

Before enrollment and before any study-related procedures are performed, voluntary, written, study-specific informed consent and assent if appropriate will be obtained from the participant’s parent(s)/legal guardian. Each signature on the ICD must be personally dated by the signatory. The investigator or his or her designee will also sign the ICD. A copy of the signed and dated ICD must be given to the participant’s parent(s)/legal guardian. The source data must reflect that the informed consent was obtained before participation in the study.

It is anticipated that the procedures below will be conducted in a stepwise manner. The visit may be conducted across 2 consecutive days; if so, all steps from assessing the inclusion and exclusion criteria onwards must be conducted on the day of vaccination. Ensure that procedures listed prior to administration of the vaccine are conducted prior to vaccination.

• If a participant is eligible for the study, assign a single participant number using the IRT system.
• Obtain the participant’s demography (including date of birth, sex, race, and ethnicity). The full date of birth will be collected to critically evaluate the immune response and safety profile by age.

• Obtain the participant’s medical history of clinically significance.

• Measure the participant’s vital signs (including body temperature).

• On the day of and before vaccination, perform physical examination including at a minimum, measurement of height and weight, assessments of general appearance, lungs, cardiovascular system, and lymph node survey.

• For participants who are HIV positive, record HIV viral load and CD4 count results from the most recent test performed in the previous 6 months.

• On the day of and prior to vaccination, perform a urine pregnancy test on all female participants who are biologically capable of having children as described in Section 8.2.7. A negative pregnancy test result is required before the participant may receive the study intervention.

• Discuss contraceptive use as described in Section 5.3.1.

• Record nonstudy vaccinations as described in Section 6.5.

• Ensure and document that all of the inclusion criteria and none of the exclusion criteria are met.

• Ensure that the participant meets none of the temporary delay criteria as described in Section 5.5.

• Obtain the participant’s randomization number and study intervention allocation number using the IRT system. Only an unblinded site staff member may obtain this information.

• Obtain a nasal (anterior nares) swab (collected by site staff) and provide nasal swab, media, and instructions to the participant or participant’s parent(s)/legal guardian on the technique for collecting a nasal swab at home.

• Collect a blood sample (approximately 5 mL) for immunogenicity testing.

• At designated sites participating in collection of blood samples for description of cell-mediated immune responses, the following additional procedures may be completed for participants ≥10 years of age:
  • Obtain written informed consent from parent(s)/legal guardian (and assent from the participant, if appropriate) agreeing to collection of the additional blood sample.
• Collect a whole blood sample of approximately 10 mL for PBMC isolation.

• Unblinded site staff member(s) will dispense/administer 1 dose of study intervention:
  • For participants ≥2 to <12 years of age, into the deltid muscle of the (preferably) nondominant arm.
  • For participants 6 months to <2 years of age, into the anterior thigh muscle of the (preferably) left leg.

• Please refer to the IP manual for further instruction on this process.

• Blinded site staff must observe the participant for at least 30 minutes after study intervention administration for any acute reactions. Record any acute reactions (including time of onset) in the participant’s source documents and on the AE page of the CRF, and on an SAE form as applicable.

• Record AEs and SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

• Issue a caliper device to measure local reactions at the injection site and a thermometer for recording daily temperatures and provide instructions on their use.

• Explain the e-diary technologies available for this study (see Section 8.14), and assist the participant’s parent(s)/legal guardian in downloading the study application onto his or her own device or issue a provisioned device if required.

• Provide instructions on reactogenicity e-diary completion and ask the participant’s parent(s)/legal guardian to complete the reactogenicity e-diary from Day 1 through Day 7, with Day 1 being the day of vaccination.

• Provide instructions on COVID-19/MIS-C illness e-diary completion and ask the participant’s parent(s)/legal guardian to complete the COVID-19/MIS-C illness e-diary if the participant is diagnosed with COVID-19/MIS-C or has possible new or increased symptoms, and when a reminder is received, at least weekly. See Section 8.14 for further details.

• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator immediately if the participant experiences any of the following from Day 1 through Day 7 after vaccination (where Day 1 is the day of vaccination) to determine if an unscheduled reactogenicity visit is required:
  • Fever ≥39.0°C (≥102.1°F).
• Redness or swelling at the injection site measuring greater than 14 caliper units (or >7 cm).

• Grade 3 pain or tenderness at the injection site.

• Any severe systemic event.

• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator if a medically attended event (eg, doctor’s visit, emergency room visit) or hospitalization occurs.

• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

• Schedule an appointment for the participant to return for the next study visit.

• Remind the participant’s parent(s)/legal guardian to bring the e-diary to the next visit.

• Complete the source documents.

• The investigator or an authorized designee completes the CRFs and an unblinded dispenser/administrator updates the study intervention accountability records.

• The investigator or appropriately qualified designee reviews the reactogenicity e-diary data online following vaccination to evaluate participant compliance and as part of the ongoing safety review. Daily review is optimal during the active diary period.

8.11.2.2. Visit 2 – Dose 2 (19 to 23 Days After Visit 1)

It is anticipated that the procedures below will be conducted in a stepwise manner; ensure that procedures listed prior to administration of the vaccine are conducted prior to vaccination.

• Record AEs/SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

• Review the participant’s reactogenicity e-diary data. Collect stop dates of any reactogenicity e-diary events ongoing on the last day that the reactogenicity e-diary was completed and record stop dates in the CRF if required.

• On the day of and prior to vaccination, perform a urine pregnancy test on all female participants who are biologically capable of having children as described in Section 8.2.7.
A negative pregnancy test result is required before the participant may receive the study intervention.

- If appropriate, discuss contraceptive use as described in Section 5.3.1.

- Record nonstudy vaccinations as described in Section 6.5.

- Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

- Ensure and document that all of the inclusion criteria and none of the exclusion criteria are met. If not, the participant may not receive further study intervention but will remain in the study to be evaluated for safety, immunogenicity, and efficacy (see Section 7.1).

- Measure the participant’s vital signs (including body temperature).

- On the day of and before vaccination, perform physical examination including, at a minimum, assessments of general appearance, lungs, cardiovascular system, and lymph node survey.

- Ensure that the participant meets none of the temporary delay criteria as described in Section 5.5.

- Obtain a nasal (anterior nares) swab (collected by site staff). Review with participant’s parent(s)/legal guardian the technique for collecting a nasal swab at home.

- Unblinded site staff member(s) will dispense/administer 1 dose of study intervention:
  - For participants ≥2 to <12 years of age, into the deltoid muscle of the (preferably) nondominant arm.
  - For participants 6 months to <2 years of age, into the anterior thigh muscle of the (preferably) left leg.
  - Please refer to the IP manual for further instruction on this process.

- Blinded site staff must observe the participant for at least 30 minutes after study intervention administration for any acute reactions. Record any acute reactions (including time of onset) in the participant’s source documents and on the AE page of the CRF, and on an SAE form as applicable.

- Ensure the participant’s parent(s)/legal guardian has a caliper device to measure local reactions at the injection site and a thermometer for recording daily temperatures.

- Ensure the participant’s parent(s)/legal guardian remains comfortable with the chosen e-diary platform, confirm instructions on e-diary completion, and ask the participant’s
parent(s)/legal guardian to complete the reactogenicity e-diary from Day 1 through Day 7, with Day 1 being the day of vaccination.

- Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator immediately if the participant experiences any of the following from Day 1 through Day 7 after vaccination (where Day 1 is the day of vaccination) to determine if an unscheduled reactogenicity visit is required:
  - Fever ≥39.0°C (≥102.1°F).
  - Redness or swelling at the injection site measuring greater than 14 caliper units (or >7 cm).
  - Grade 3 pain or tenderness at the injection site.
  - Any severe systemic event.

- Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator if a medically attended event (eg, doctor’s visit, emergency room visit) or hospitalization occurs.

- Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

- Schedule an appointment for the participant to return for the next study visit.

- Remind the participant’s parent(s)/legal guardian, as appropriate, to bring the e-diary to the next visit.

- Complete the source documents.

- The investigator or an authorized designee completes the CRFs and an unblinded dispenser/administrator updates the study intervention accountability records.

- The investigator or appropriately qualified designee reviews the reactogenicity e-diary data online following vaccination to evaluate participant compliance and as part of the ongoing safety review. Daily review is optimal during the active diary period.

8.11.2.3. Visit 3 – 1-Week Follow-up Visit (After Visit 2) (6 to 8 Days After Visit 2): Only for Those Participants Having Blood Drawn for PBMC Isolation

This visit should only be conducted for participants who provided consent for collection of additional blood samples for PBMC isolation.
8.11.2.4. Visit 4 – 1-Month Follow-up Visit (After Visit 2) (28 to 35 Days After Visit 2)

This visit can be performed as a telephone visit if the study procedure is not required for the participant.

- Review the participant’s reactogenicity e-diary data. Collect stop dates of any reactogenicity e-diary events ongoing on the last day that the reactogenicity e-diary was completed and record stop dates in the CRF if required. Collect the caliper device.

- Record AEs/SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

- Record nonstudy vaccinations as described in Section 6.5.
• Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

• For participants who are HIV positive, record HIV viral load and CD4 count results from the most recent test performed since Visit 1 (if any).

• Discuss contraceptive use as described in Section 5.3.1.

• Collect a blood sample (approximately 5 mL) for immunogenicity testing if the participant is in the group where blood collection at this visit is required.

• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator if a medically attended event (eg, doctor’s visit, emergency room visit) or hospitalization occurs.

• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

• Schedule an appointment for the participant for the next study visit.

• Complete the source documents.

• The investigator or an authorized designee completes the CRFs.

• Record any AEs that occur within the 48 hours after the blood draw as described in Section 8.3.

8.11.2.5. Visit 5 – 6-Month Follow-up Visit (175 to 189 Days After Visit 2)

• Record SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

• Record nonstudy vaccinations as described in Section 6.5.

• For participants who are HIV positive, record HIV viral load and CD4 count results from the most recent test performed since Visit 4 (if any).

• Collect a blood sample (approximately 5 mL) for immunogenicity testing.

• Collect a whole blood sample of approximately 10 mL for PBMC isolation if the participant’s parent(s)/legal guardian has provided consent to do so.
- Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

- Unblind the participant for the remainder of the study visits;
  - If the participant previously received BNT162b2, complete this visit for the remainder of visit activities and schedule an appointment for the participant for the next study visit as in Section 8.11.3.
  - If the participant originally received placebo, move the participant to Section 8.11.4 for the remainder of this visit’s activities and future visits.

- Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19 illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

- Complete the source documents.

- The investigator or an authorized designee completes the CRFs.

- If applicable, record any AEs that occur within the 48 hours after the blood draw as described in Section 8.3.

### 8.11.3. Phase 2/3 Participants Who Originally Received BNT162b2 or Placebo Recipients Who Decline BNT162b2

#### 8.11.3.1. Visit X – 12-Month Follow-up Visit (350 to 378 Days After Visit 2)

This visit can be performed as a telephone visit if the study procedure is not required for the participant.

- Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

- For participants who are HIV positive, record HIV viral load and CD4 count results from the most recent test performed since Visit 5 (if any).

- Collect a blood sample (approximately 5 mL) for immunogenicity testing if the participant is in the group where blood collection at this visit is required. Note: If the participant had an unplanned potential COVID-19 convalescent visit within ≤42 days prior to this visit, or if the participant originally received placebo and declines the offer of BNT162b2, blood collection is not required at this visit.

- Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.
• Schedule an appointment for the participant to return for the next study visit.

• Complete the source documents.

• The investigator or an authorized designee completes the CRFs.

• If applicable, record any AEs that occur within the 48 hours after the blood draw as described in Section 8.3.

8.11.3.2. Visit Y – 24-Month Follow-up Visit (714 to 742 Days After Visit 2)
This visit can be performed as a telephone visit if the study procedure is not required for the participant.

• Record details of any of the prohibited medications specified in Section 6.5.1. received by the participant if required for his or her clinical care.

• For participants who are HIV positive, record HIV viral load and CD4 count results from the most recent test performed since Visit X (if any).

• Collect a blood sample (approximately 5 mL) for immunogenicity testing if the participant is in the group where blood collection at this visit is required. Note: If the participant had an unplanned potential COVID-19 convalescent visit within ≤42 days prior to this visit, or if the participant originally received placebo and declines the offer of BNT162b2, blood collection is not required at this visit.

• Collect the participant’s e-diary or assist the participant’s parent(s)/legal guardian to remove the study application from his or her own personal device.

• Complete the source documents.

• The investigator or an authorized designee completes the CRFs.

• If applicable, record any AEs that occur within the 48 hours after the blood draw as described in Section 8.3.

• Inform the participant’s parent(s)/legal guardian that the participant’s study participation has ended.

8.11.4. Phase 2/3 Participants Who Originally Received Placebo
8.11.4.1. Visit A – Dose 3 (175 to 189 Days After Dose 2 and Same Date as Visit 5)
It is anticipated that the procedures below will be conducted in a stepwise manner; ensure that procedures listed prior to administration of the vaccine are conducted prior to vaccination. It is preferable that this visit occur on the same day as Visit 5.
• Confirm that the participant originally received placebo at Visit 1 (Dose 1) and Visit 2 (Dose 2). Secondary confirmation by another site staff member is required. Assess and document the participant’s continued eligibility per the criteria in Section 5.

• Measure the participant’s vital signs (including body temperature).

• On the day of and before vaccination, perform physical examination including, at a minimum, assessments of general appearance, lungs, cardiovascular system, and lymph node survey.

• For participants who are HIV positive, record HIV viral load and CD4 count results from the most recent test performed in the previous 6 months.

• Review and consider inclusion criteria 2 through 7 and exclusion criteria 3 through 15 prior to vaccination. If, in the investigator’s judgment, vaccination is in the best interests of the participant, vaccination may proceed, even if inclusion criteria are not met and exclusion criteria are met. Such exceptions should be recorded in the participant’s source documents.

• On the day of and prior to vaccination, perform a urine pregnancy test on all female participants who are biologically capable of having children as described in Section 8.2.7. A negative pregnancy test result is required before the participant may receive the study intervention.

• If appropriate, discuss contraceptive use as described in Section 5.3.1.

• Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

• Ensure that the participant meets none of the temporary delay criteria as described in Section 5.5.

• Obtain a nasal (anterior nares) swab (collected by site staff). Review with the participant or participant’s parent(s)/legal guardian the technique for collecting a nasal swab at home.

• Obtain the participant’s vaccine vial allocation using the IRT system.

• Site staff member(s) will dispense/administer 1 dose of BNT162b2:
  • For participants ≥2 to <12 years of age, into the deltoid muscle of the (preferably) nondominant arm.
  • For participants 6 months to <2 years of age, into the anterior thigh muscle of the (preferably) left leg.
- Please refer to the IP manual for further instruction on this process.

- Site staff must observe the participant for at least 30 minutes after study intervention administration for any acute reactions. Record any acute reactions (including time of onset) in the participant’s source documents and on the AE page of the CRF, and on an SAE form as applicable.

- Record AEs and SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

- Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator if a medically attended event (eg, doctor’s visit, emergency room visit) or hospitalization occurs.

- Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

- Schedule an appointment for the participant to return for the next study visit.

- Complete the source documents.

- The investigator or an authorized designee completes the CRFs and a dispenser/administrator updates the study intervention accountability records.

8.11.4.2. Visit B – Dose 4 (19 to 23 Days After Visit A)

It is anticipated that the procedures below will be conducted in a stepwise manner; ensure that procedures listed prior to administration of the vaccine are conducted prior to vaccination.

- Record AEs/SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

- On the day of and prior to vaccination, perform a urine pregnancy test on all female participants who are biologically capable of having children as described in Section 8.2.7. A negative pregnancy test result is required before the participant may receive the study intervention.

- If appropriate, discuss contraceptive use as described in Section 5.3.1.
• Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

• Review and consider inclusion criteria 2 through 7 and exclusion criteria 3 through 15 prior to vaccination. If, in the investigator’s judgment, vaccination is in the best interests of the participant, vaccination may proceed, even if inclusion criteria are not met and exclusion criteria are met. Such exceptions should be recorded in the participant’s source documents.

• Measure the participant’s vital signs (including body temperature).

• On the day of and before vaccination, perform physical examination including, at a minimum, assessments of general appearance, lungs, cardiovascular system, and lymph node survey.

• Ensure that the participant meets none of the temporary delay criteria as described in Section 5.5.

• Obtain a nasal (anterior nares) swab (collected by site staff). Review with the participant or participant’s parent(s)/legal guardian the technique for collecting a nasal swab at home.

• Site staff member(s) will dispense/administer 1 dose of BNT162b2:
  • For participants ≥2 to <12 years of age, into the deltoid muscle of the (preferably) non-dominant arm.
  • For participants 6 months to <2 years of age, into the anterior thigh muscle of the (preferably) left leg.
  • Please refer to the IP manual for further instruction on this process.

• Site staff must observe the participant for at least 30 minutes after study intervention administration for any acute reactions. Record any acute reactions (including time of onset) in the participant’s source documents and on the AE page of the CRF, and on an SAE form as applicable.

• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator if a medically attended event (eg, doctor’s visit, emergency room visit) or hospitalization occurs.

• Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

• Schedule an appointment for the participant to return for the next study visit.
- Complete the source documents.

- The investigator or an authorized designee completes the CRFs and an unblinded dispenser/administrator updates the study intervention accountability records.

8.11.4.3. Visit C – 1-Month Follow-up Telephone Contact (After Dose 4) (28 to 35 Days After Visit B)

- Contact the participant’s parent(s)/legal guardian by telephone.

- Record AEs/SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

- Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

- For participants who are HIV positive, record HIV viral load and CD4 count results from the most recent test performed since Visit A (if any).

- Discuss contraceptive use as described in Section 5.3.1.

- Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator if a medically attended event (eg, doctor’s visit, emergency room visit) or hospitalization occurs.

- Ask the participant or participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

- Schedule an appointment for the participant for the next study visit.

- Complete the source documents.

- The investigator or an authorized designee completes the CRFs.

8.11.4.4. Visit D – 6-Month Follow-up Telephone Contact (After Dose 4) (175 to 189 Days After Visit B)

- Contact the participant’s parent(s)/legal guardian by telephone.

- Record SAEs as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs. These data will be captured to describe disease endpoints
for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

- For participants who are HIV positive, record HIV viral load and CD4 count results from the most recent test performed since Visit C (if any).

- Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

- Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19 illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

- Schedule an appointment for the participant for the next study visit.

- Complete the source documents.

- The investigator or an authorized designee completes the CRFs.

**8.11.4.5. Visit E – 12-Month Follow-up Telephone Contact (After Dose 4) (350 to 378 Days After Visit B)**

- Contact the participant’s parent(s)/legal guardian by telephone.

- Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

- For participants who are HIV positive, record HIV viral load and CD4 count results from the most recent test performed since Visit D (if any).

- Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator (this could be via the COVID-19/MIS-C illness e-diary) immediately if the participant experiences any acute symptoms as detailed in Section 8.13.

- Schedule an appointment for the participant to return for the next study visit.

- Complete the source documents.

- The investigator or an authorized designee completes the CRFs.

**8.11.4.6. Visit F – 18-Month Follow-up Telephone Contact (After Dose 4) (532 to 560 Days After Visit B)**

This visit can be performed as a telephone visit.

- Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.
• For participants who are HIV positive, record HIV viral load and CD4 count results from
  the most recent test performed since Visit E (if any).

• Request the return of the participant’s e-diary or assist the participant’s parent(s)/legal
guardian to remove the study application from his or her own personal device.

• Complete the source documents.

• The investigator or an authorized designee completes the CRFs.

• Inform the participant’s parent(s)/legal guardian that the participant’s study participation
  has ended.

8.12. Unscheduled Visit for Fever or a Grade 3 or Suspected Grade 4 Reaction

If a participant’s parent/legal guardian reports redness or swelling >14 caliper units or Grade
3 local reaction (Section 8.2.4.2), any Grade 3 systemic event (Section 8.2.4.3), or fever
≥39.0°C (102.1°F) (Section 8.2.4.4) in the reactogenicity e-diary, a telephone contact should
occur to ascertain further details and determine whether a site visit is clinically indicated. If
suspected Grade 4 local reaction (Section 8.2.4.2), systemic event (Section 8.2.4.3), or fever
(Section 8.2.4.4) is reported in the reactogenicity e-diary, a telephone contact or site visit
should occur to confirm whether the event meets the criteria for Grade 4.

A site visit must be scheduled as soon as possible to assess the participant unless any of the
following is true:

• The participant is unable to attend the unscheduled visit.

• The local reaction/systemic event is no longer present at the time of the telephone
  contact.

• The participant’s parent(s)/legal guardian recorded an incorrect value in the
  reactogenicity e-diary (confirmation of a reactogenicity e-diary data entry error).

• The PI or authorized designee determined it was not needed.

This telephone contact will be recorded in the participant’s source documentation and the
CRF.

If the participant is unable to attend the unscheduled visit, or the PI or authorized designee
determined it was not needed, any ongoing local reactions/systemic events must be assessed
at the next study visit.

During the unscheduled visit, the reactions should be assessed by the investigator or a
medically qualified member of the study staff such as a study physician or a study nurse, as
applicable to the investigator’s local practice, who will:
• Measure body temperature (°F/°C).

• Measure minimum and maximum diameters of redness (if present).

• Measure minimum and maximum diameters of swelling (if present).

• Assess injection site pain/tenderness (if present) in accordance with the grades provided in Section 8.2.4.2.

• Assess systemic events (if present) in accordance with the grades provided in Section 8.2.4.3.

• Assess for other findings associated with the reaction and record on the AE page of the CRF, if appropriate.

The investigator or an authorized designee will complete the unscheduled visit assessment page of the CRF.

8.13. COVID-19 and MIS-C Surveillance (All Participants)

COVID-19 Surveillance: If a participant experiences any of the following (irrespective of perceived etiology or clinical significance), the participant or his/her parent(s)/legal guardian is instructed to contact the site immediately. Optimally within 3 days after symptom onset (and at the latest 4 days after symptom resolution), the site should schedule and conduct either an in-person or telehealth visit as soon as possible, unless the symptom(s) has an identifiable alternative etiology, is clinically insignificant, or is a single symptom lasting 1 calendar day. Note that, if new symptoms are reported within 4 days after resolution of all previous symptoms, they will be considered as part of a single illness, and a second illness visit is not required.

During the 7 days following each dose, potential COVID-19 symptoms that overlap with systemic events (ie, fever, chills, new or increased muscle pain, diarrhea, vomiting) should not trigger a potential COVID-19 illness visit unless, in the investigator’s opinion, the clinical picture is more indicative of a possible COVID-19 illness than vaccine reactogenicity. If, in the investigator’s opinion, the symptoms are considered more likely to be vaccine reactogenicity, but a participant is required to demonstrate that he or she is SARS-CoV-2 negative, a local SARS-CoV-2 test may be performed: unless positive, the symptoms should be recorded not as a potential COVID-19 illness, but rather as AEs.

MIS-C Surveillance: If a participant experiences a hospitalization for a severe illness with no other alternative etiology, the participant’s parent(s)/legal guardian is instructed to contact the site immediately and participate in an in-person or telehealth visit as soon as possible, optimally within 3 days after symptom onset (and at the latest 4 days after symptom resolution). Note that, if new symptoms are reported within 4 days after resolution of all previous symptoms, they will be considered as part of a single illness, and a second illness visit is not required.
COVID-19/MIS-C Surveillance

The participant’s parent(s)/legal guardian may utilize a COVID-19/MIS-C illness e-diary through an application (see Section 8.14) installed on a provisioned device or on a personal device to report any symptoms listed below. Note that this does not substitute for a participant’s routine medical care. Therefore, participants should be encouraged to seek care, if appropriate, from their usual provider.

- A diagnosis of COVID-19;
- Fever;
- New or increased cough;
- Diarrhea;
- Vomiting;
- New or increased shortness of breath;
- Chills;
- New or increased muscle pain;
- New loss of taste/smell;
- Sore throat;
- Inability to eat/poor feeding in participants <5 years of age;
- Abdominal pain;
- Hospitalization for a severe illness with no other alternative etiology;
- Hospitalization due to confirmed COVID-19 infection.


This visit may be conducted as an in-person or telehealth visit; a telehealth visit involves the sharing of healthcare information and services via telecommunication technologies (eg, audio, video, videoconferencing software) remotely, thus allowing the participant’s parent(s)/legal guardian and investigator to communicate on aspects of clinical care.

As a participant’s COVID-19/MIS-C illness may evolve over time, several contacts may be required to obtain the following information:
• Record AE/SAEs as appropriate, as described in Section 8.3. Note: Potential COVID-19/MIS-C illnesses and their sequelae that are consistent with the clinical endpoint definition (Section 8.1) should not be recorded as AEs/SAEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment data only on the relevant pages of the CRF, as these are expected endpoints.

• Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.

• If the visit is conducted in person, obtain a nasal (anterior nares) swab (collected by site staff). Alternatively, if conducted by telehealth, instruct the participant’s parent(s)/legal guardian to self-collect a nasal (anterior nares) swab and ship for assessment at the central laboratory.

• Collect COVID-19/MIS-C–related standard-of-care clinical and laboratory information. This includes symptoms and signs including, but not limited to:
  
  • Clinical signs at rest indicative of severe systemic illness:
    
    • RR (breaths/min) and HR (beats/min) as shown in Table 4;30
    
    • SpO₂ ≤92% on room air or >50% FiO₂ to maintain ≥92%, or PaO₂/FiO₂ <300 mm Hg;
    
    • Respiratory failure (defined as needing high-flow oxygen, including CPaP, BiPaP, noninvasive ventilation, mechanical ventilation, or ECMO);
    
    • Evidence of shock or cardiac failure:
      
      • SBP (mm Hg) <70 + (age in years × 2) for age up to 10 years, <90 + (age in years × 2) for age ≥10 years; or
      
      • requiring vasoactive drugs to maintain BP in the normal range;
      
    • Significant acute renal failure (serum creatinine ≥2 times ULN for age or 2-fold increase in baseline creatinine);
      
    • Significant GI/hepatic failure (total bilirubin ≥4 mg/dL or ALT 2 times ULN for age); or
      
    • Significant neurological dysfunction: Glasgow Coma Scale score ≤11 or acute change in mental status with a decrease in Glasgow Coma Scale score ≥3 points from abnormal baseline;
      
    • Admission to an ICU;
Collect MIS-C data:

- Additional clinical signs and symptoms related to hematologic, dermatologic, and/or other;
- Any potential cardiac, respiratory, neurological, or GI/hepatic complications;
- COVID-19 exposure within the 4 weeks prior to the onset of symptoms;
- Imaging (chest, abdominal, etc), CSF studies, and/or echocardiogram;
- Clinical diagnosis;
- Local laboratory SARS-CoV-2 test result(s), including RT-PCR, serology, or antigen test. Note that, if it is routine practice to perform a repeat local SARS-CoV-2 test for any reason, then a repeat nasal (anterior nares) swab should also be obtained and shipped for assessment at the central laboratory;
- Full blood count, blood chemistry, specifically creatinine, urea, LFTs, and CRP, ESR, fibrinogen, procalcitonin, D-dimer, ferritin, LDH, or IL-6 if available;
- Number and type of any healthcare contact; duration of hospitalization and ICU stay;
- Death.

Schedule an appointment for the participant to return for the potential COVID-19/MIS-C convalescent visit.

Complete the source documents.

The investigator or an authorized designee completes the CRFs.


- Record AE/SAEs as appropriate, as described in Section 8.3. Note: Potential COVID-19 illnesses that are consistent with the clinical endpoint definition should not be recorded as AEs. These data will be captured to describe disease endpoints for lack-of-efficacy assessment only on the relevant pages of the CRF, as these are expected endpoints.
- Record details of any of the prohibited medications specified in Section 6.5.1 received by the participant if required for his or her clinical care.
- Collect a blood sample (approximately 5 mL) for immunogenicity testing.
- Collect/update COVID-19–related clinical and laboratory information (detailed in Section 8.13.1).

- Complete the source documents.

- The investigator or an authorized designee completes the CRFs.

- Record any AEs that occur within the 48 hours after the blood draw as described in Section 8.3.

8.14. Communication and Use of Technology

In a study of this nature that requires illness events to be reported outside of scheduled study visits, it is vital that communication between the study site and the participant’s parent(s)/legal guardian is maintained so that safety events or endpoint events are not missed. This study will employ various methods, tailored to the individual participant, to ensure that communication is maintained and study information can be transmitted securely. Using appropriate technology, such as a study application, a communication pathway between the participant’s parent(s)/legal guardian and the study site staff will be established. The participant’s parent(s)/legal guardian may be able to utilize his or her own device to access this technology, or use a device provided by the sponsor. Traditional methods of telephone communication will also be available. The technology solution may facilitate the following:

- Contact with the investigator, including the ability of the participant’s parent(s)/legal guardian, as appropriate, to report whether or not the participant has experienced symptoms that could represent a potential COVID-19 illness (COVID-19 illness e-diary; see Section 8.13).

- An alert in the event that the participant is hospitalized.

- Visit reminders.

- Messages of thanks and encouragement from the study team.

- A platform for recording local reactions and systemic events (reactogenicity e-diary) – see Section 8.2.4.

If a participant’s parent(s)/legal guardian is not actively completing either the reactogenicity or COVID-19 illness e-diary, the investigator or designee is required to contact the participant’s parent(s)/legal guardian to ascertain the reason and also to obtain details of any missed events.

8.15. SARS-CoV-2 NAAT Nasal (Anterior Nares) Swab Results

Nasal (anterior nares) swabs for SARS-CoV-2 NAAT are obtained at:
• Visits 1, Visit 2, Visit A, and Visit B (Visits A and B per Section 1.3.2.2): to determine whether a participant will be included in analyses of those with no serological or virological evidence (prior to 7 days after receipt of Dose 2) of past SARS-CoV-2 infection.

• Potential COVID-19/MIS-C illness visits: to determine whether symptoms experienced by the participant fulfill the COVID-19/MIS-C case definition.

Central laboratory–generated positive results from the Visit 1, Visit 2, Visit A, and Visit B swabs, and all results from the illness visit swabs, will be provided to the site once available, but this will not be in real time, and cannot be relied upon to direct clinical care. Therefore, the participant or participant’s parent(s)/legal guardian should be directed to seek additional testing through the participant’s healthcare providers at a licensed clinical laboratory when the participant exhibits potential COVID-19 symptoms or otherwise receives a positive result and should be counseled on whether to take any precautionary measures pending confirmatory testing.

**Phase 1** participants who have a positive SARS-CoV-2 NAAT result prior to Visit 2 should be handled as follows:

• Positive SARS-CoV-2 test with no symptoms, either at Visit 1 or any time between Visit 1 and Visit 2: a positive test in an asymptomatic participant does not meet exclusion criterion 1; therefore, administration of Dose 2 should proceed as normal.

• Confirmed COVID-19 (ie, symptoms and positive SARS-CoV-2 test): this meets exclusion criterion 1; therefore, Dose 2 should not be given but the participant should remain in the study.

## 9. STATISTICAL CONSIDERATIONS

Methodology for summary and statistical analyses of the data collected in this study is outlined here and further detailed in a SAP, which will be maintained by the sponsor. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.

### 9.1. Estimands and Statistical Hypotheses

#### 9.1.1. Estimands

The estimands corresponding to the primary, secondary, and exploratory objectives for Phase 1 and Phase 2/3 are described in the table in *Section 3*.

In the primary safety objective evaluations, missing reactogenicity e-diary data will not be imputed. Missing AE start dates will be imputed according to Pfizer safety rules. No other missing information will be imputed in the safety analysis.
The estimands to evaluate the immunogenicity objectives are based on the evaluable immunogenicity population (Section 9.3). These estimands estimate the vaccine effect in the hypothetical settings where participants follow the study schedules and protocol requirements as directed. Missing antibody results will not be imputed. Immunogenicity results that are below the LLOQ will be set to 0.5 \times LLOQ in the analysis; this may be adjusted once additional data on the assay characteristics become available.

The estimands to evaluate the efficacy objectives are based on the evaluable efficacy population (Section 9.3). These estimands estimate the vaccine effect in the hypothetical setting where participants follow the study schedules and protocol requirements as directed. In addition, VE will also be analyzed for the all-available efficacy populations. Missing laboratory results will not be imputed.

9.1.2. Statistical Hypothesis

9.1.2.1. Statistical Hypothesis Evaluation for Immunogenicity

The primary immunogenicity objective in Phase 2/3 is to evaluate immunobridging of the immune response to prophylactic BNT162b2 at the dose level selected in each age group (participants \( \geq 5 \) to <12 years, \( \geq 2 \) to <5 years, and \( \geq 6 \) months to <2 years of age) at 1 month after Dose 2 compared to participants 16 to 25 years of age from Phase 2/3 of the C4591001 study. The evaluable immunogenicity population will be used for the following hypothesis testing:

\[
H_0: \ln(\mu_2) - \ln(\mu_1) \leq \ln (0.67)
\]

where \( \ln (0.67) \) corresponds to a 1.5-fold margin for immunobridging, and \( \ln(\mu_2) \) and \( \ln(\mu_1) \) are the natural log of the geometric mean of SARS-CoV-2 neutralizing titers from BNT162b2 recipients in each younger age group (\( \geq 5 \) to <12 years, \( \geq 2 \) to <5 years, and \( \geq 6 \) months to <2 years of age) and in participants 16 to 25 years of age from Phase 2/3 of the C4591001 study, respectively, measured 1 month after Dose 2.

The hypothesis for each age group will be evaluated separately. Immunobriding success will be declared for an age group if the lower limit of the 95% CI for the GMR (younger age group to the 16- to 25-year age group from C4591001) is >0.67.

9.1.2.2. Statistical Hypothesis Evaluation for Efficacy

The secondary efficacy endpoints are to evaluate VE defined as \( 100 \times (1 - IRR) \) in all age groups where immunobridging success is declared. Age groups in which immunobridging is not shown to be successful will not be included in the VE evaluation. IRR is calculated as the ratio of the first confirmed COVID-19 illness rate in the vaccine group to the corresponding illness rate in the placebo group. VE\(_1\) represents VE for prophylactic BNT162b2 against confirmed COVID-19 in participants without evidence of prior infection, and VE\(_2\) represents VE for prophylactic BNT162b2 against confirmed COVID-19 in all participants after vaccination. The assessment of VE will be based on testing the following hypothesis:
H₀: VE ≤ 20% vs H₁: VE > 20%

for VE₁ and VE₂, respectively.

For participants with multiple confirmed cases, only the first case will contribute to the VE calculation for each hypothesis.

9.1.3. Multiplicity Considerations

For the primary immunogenicity objectives of immunobridging of BNT162b2 in each of 3 younger age groups (≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age) to the group 16 to 25 years of age from Phase 2/3 of the C4591001 study, the hypothesis testing for each group will be carried out separately. Each immunobridging analysis corresponds to a separate analysis of the respective age group, with a separate objective. The age groups are included in the same study to improve operational efficiency. Therefore, there is no increase in the type I error rate, and no type I error adjustments are needed in the immunogenicity assessments for the 3 age groups.

In all age groups where immunobridging success is declared, if the required number of confirmed COVID-19 cases accrued across those age groups, then the secondary VE objectives, VE₁ and VE₂, will be tested sequentially in the order as stated. Thus, this sequential testing strategy controls type I error under the desired level of 2.5%.

9.2. Sample Size Determination

The study sample size for Phase 1 of the study is not based on any statistical hypothesis testing. Phase 1 comprises 16 participants receiving active vaccine per group for each dose level; 9 groups are studied, corresponding to a total of 144 participants.

Phase 2/3 will comprise approximately 2250 participants (randomization ratio of 2:1 so that 1500 receive active vaccine and 750 receive placebo) for the age group of ≥5 to <12 years old, and 1125 (randomization ratio of 2:1 so that 750 receive active vaccine and 375 receive placebo) for each of the age groups of ≥2 to <5 years old and ≥6 months to <2 years old, with a total of approximately 4500 participants. The total sample size in Phase 2/3 is not based on statistical hypothesis testing.

Participants with 1-month post–Dose 2 blood sample collection in Phase 2/3 of the study and a random sample of approximately 300 participants in the 16- to 25-year age group from Phase 2/3 of the C4591001 study who received BNT162b2 will be the immunogenicity subset for the primary immunobridging assessment. With the standard deviation and observed GMT difference assumed in the power analysis below, a sample size of 225 evaluable participants per age group will provide a power of 90.4% to declare immunobridging success of each younger to older age group in terms of neutralizing antibody GMR, 1 month after Dose 2 (see Table 9). Assuming a 25% nonevaluable rate, this will require approximately 450 participants (300 in the active vaccine group and 150 in the placebo group) for each age group with 1-month post–Dose 2 blood sample collection in Phase 2/3 of the study to achieve 225 evaluable participants in the active vaccine group.
Table 9. Power Analysis for Immunobridging Assessment

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Standard Deviation (Log Value)</th>
<th>Assumed Observed GMT Difference (Log Scale)</th>
<th>Number of Evaluable Participants per Age Group</th>
<th>Powerb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lower limit of 95% CI for GMR (younger age group/16- to 25-year age group) &gt;0.67</td>
<td>0.65</td>
<td>-0.2</td>
<td>225</td>
<td>90.4%</td>
</tr>
</tbody>
</table>

Abbreviations: GMR = geometric mean ratio; GMT = geometric mean titer.

a. Reference: 1 month after Dose 2, BNT162b2 (30 µg), 18- to 55-year age group (C4591001 Phase 2).

b. At a 0.05 alpha level (2-sided).

The persistence of immune response will be based on Phase 2/3 participants with baseline and 1-, 6-, 12-, or 24-month post–Dose 2 immunogenicity data. In each age group, blood samples will be tested for approximately 450 participants at 1 month and 6 months (300 in the active vaccine group, and 150 in the placebo group), and for approximately 70 participants in the original BNT162b2 group at 12 or 24 months after Dose 2. Assuming a nonevaluable rate of 25%, there will be ~225 and ~50 evaluable participants at 1 and 6 months, and later time points, respectively.

Table 10 displays the ratio of the upper 2-sided 95% confidence limit of GMT relative to the GMT as a measure of precision for the immunogenicity endpoint SARS-CoV-2 neutralizing titer. With 50 evaluable participants in the vaccine group, the upper 95% confidence limit of the GMT would be 20% higher than the corresponding GMT.

Table 10. Precision of SARS-CoV-2 Neutralizing Titer GMT

<table>
<thead>
<tr>
<th>Standard Deviation (Log Value)a</th>
<th>Upper 2-Sided 95% Confidence Limit of GMT Relative to GMT × 100</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.65</td>
<td>1.20</td>
</tr>
<tr>
<td></td>
<td>1.09</td>
</tr>
</tbody>
</table>

Abbreviation: GMT = geometric mean titer.

a. Reference: 1 month after Dose 2, BNT162b2 (30 µg), 18- to 55-year age group (C4591001 Phase 2).

For VE evaluation, with a total of approximately 2250 participants ≥5 to <12 years of age (1500 participants randomized to the vaccine group and 750 participants randomized to the placebo group), assuming 25% of the participants being nonevaluable and 1.3% annual attack rate, a total of approximately 5 first confirmed COVID-19 illness cases will be observed within 6 months after vaccination. This provides approximately 13.2% power to conclude true VE >20% with assumptions of a true VE of 75%. If immunobridging success can be declared in all 3 age groups, then the VE will be assessed by combining 3 age groups, resulting in a total of approximately 11 confirmed COVID-19 illness cases within 6 months after vaccination. This provides approximately 47.3% power for VE evaluation. Dependent upon the evolution of the pandemic, it is possible that the COVID-19 attack rate may be
higher, in which case accrual would be expected to be more rapid. Since it requires at least 22 cases to achieve 70% power, hypothesis testing will be conducted only if at least 22 cases are accrued within age groups in which immunobridging is shown to be successful (Table 11).

Table 11. Power for Vaccine Efficacy Assessment

<table>
<thead>
<tr>
<th>Power</th>
<th>Total Cases</th>
<th>Case Split(^a) to Claim Success(^b) (VE%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.2%</td>
<td>5</td>
<td>0:5 (100%)</td>
</tr>
<tr>
<td>47.3%</td>
<td>11</td>
<td>3:8 (81.3%)</td>
</tr>
<tr>
<td>70.7%</td>
<td>22</td>
<td>8:14 (71.4%)</td>
</tr>
<tr>
<td>82.2%</td>
<td>25</td>
<td>10:15 (66.7%)</td>
</tr>
<tr>
<td>90.0%</td>
<td>33</td>
<td>14:19 (63.2%)</td>
</tr>
</tbody>
</table>

Abbreviation: VE = vaccine efficacy.

a. Case split numbers represent the number of cases in the active vaccine group vs the number of cases in the placebo group.
b. Success criterion: lower bound of 95% CI for VE >20%.

For safety outcomes, Table 12 shows the probability of observing at least 1 AE for a given true event rate of a particular AE, for various sample sizes. For example, if the true AE rate is 10%, with 16 participants in a vaccine group, there is 81% probability of observing at least 1 AE.

Table 12. Probability of Observing at Least 1 AE by Assumed True Event Rates With Different Sample Sizes

<table>
<thead>
<tr>
<th>Assumed True Event Rate of an AE</th>
<th>N=16</th>
<th>N=48</th>
<th>N=144</th>
<th>N=1500</th>
<th>N=3000</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.01%</td>
<td>0.00</td>
<td>0.00</td>
<td>0.01</td>
<td>0.14</td>
<td>0.26</td>
</tr>
<tr>
<td>0.02%</td>
<td>0.00</td>
<td>0.01</td>
<td>0.03</td>
<td>0.26</td>
<td>0.45</td>
</tr>
<tr>
<td>0.04%</td>
<td>0.01</td>
<td>0.02</td>
<td>0.06</td>
<td>0.45</td>
<td>0.70</td>
</tr>
<tr>
<td>0.06%</td>
<td>0.01</td>
<td>0.03</td>
<td>0.08</td>
<td>0.59</td>
<td>0.83</td>
</tr>
<tr>
<td>0.08%</td>
<td>0.01</td>
<td>0.04</td>
<td>0.11</td>
<td>0.70</td>
<td>0.91</td>
</tr>
<tr>
<td>0.10%</td>
<td>0.02</td>
<td>0.05</td>
<td>0.13</td>
<td>0.78</td>
<td>0.95</td>
</tr>
<tr>
<td>0.15%</td>
<td>0.02</td>
<td>0.07</td>
<td>0.19</td>
<td>0.89</td>
<td>0.99</td>
</tr>
<tr>
<td>0.20%</td>
<td>0.03</td>
<td>0.09</td>
<td>0.25</td>
<td>0.95</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>0.25%</td>
<td>0.04</td>
<td>0.11</td>
<td>0.30</td>
<td>0.98</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>0.30%</td>
<td>0.05</td>
<td>0.13</td>
<td>0.35</td>
<td>0.99</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>0.35%</td>
<td>0.05</td>
<td>0.15</td>
<td>0.40</td>
<td>0.99</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>0.50%</td>
<td>0.08</td>
<td>0.21</td>
<td>0.51</td>
<td>&gt;0.99</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>1.00%</td>
<td>0.15</td>
<td>0.38</td>
<td>0.76</td>
<td>&gt;0.99</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>2.00%</td>
<td>0.28</td>
<td>0.62</td>
<td>0.95</td>
<td>&gt;0.99</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>3.00%</td>
<td>0.39</td>
<td>0.77</td>
<td>0.99</td>
<td>&gt;0.99</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>5.00%</td>
<td>0.56</td>
<td>0.91</td>
<td>&gt;0.99</td>
<td>&gt;0.99</td>
<td>&gt;0.99</td>
</tr>
</tbody>
</table>
Table 12. Probability of Observing at Least 1 AE by Assumed True Event Rates With Different Sample Sizes

<table>
<thead>
<tr>
<th>Assumed True Event Rate of an AE</th>
<th>N=16</th>
<th>N=48</th>
<th>N=144</th>
<th>N=1500</th>
<th>N=3000</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.00%</td>
<td>0.69</td>
<td>0.97</td>
<td>&gt;0.99</td>
<td>&gt;0.99</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>10.00%</td>
<td>0.81</td>
<td>0.99</td>
<td>&gt;0.99</td>
<td>&gt;0.99</td>
<td>&gt;0.99</td>
</tr>
</tbody>
</table>

Note: N = number of participants in a vaccine group. In Phase 1, 16 participants in each dose level and a total of 144 participants are to be vaccinated with any of the 3 dose levels. A total of 3000 participants in Phase 2/3 will receive the active vaccine at the selected dose level.

9.3. Analysis Sets

<table>
<thead>
<tr>
<th>Population</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enrolled</td>
<td>All participants who have a signed ICD.</td>
</tr>
<tr>
<td>Randomized</td>
<td>All participants who are assigned a randomization number in the IWR system.</td>
</tr>
<tr>
<td>Evaluable immunogenicity</td>
<td>All eligible randomized participants who receive 2 doses of the vaccine to which they are randomized within the predefined window, have at least 1 valid and determinate immunogenicity result from the blood sample collected within an appropriate window, and have no other important protocol deviations as determined by the clinician.</td>
</tr>
<tr>
<td>Dose 1 evaluable immunogenicity</td>
<td>Phase 1 only: All eligible randomized participants who receive Dose 1 of the vaccine to which they are randomized, have at least 1 valid and determinate immunogenicity result from the blood sample collected after Dose 1 and before Dose 2, and have no other important protocol deviations before Dose 2 as determined by the clinician.</td>
</tr>
<tr>
<td>All-available immunogenicity</td>
<td>All participants who receive at least 1 dose of the study intervention with at least 1 valid and determinate immunogenicity result after vaccination.</td>
</tr>
<tr>
<td>Evaluable efficacy</td>
<td>All eligible randomized participants who receive all vaccination(s) as randomized within the predefined window and have no other important protocol deviations as determined by the clinician.</td>
</tr>
<tr>
<td>All-available efficacy (mITT)</td>
<td>Dose 1 all-available efficacy: All randomized participants who receive at least 1 vaccination. Dose 2 all-available efficacy: All randomized participants who complete 2 vaccination doses.</td>
</tr>
<tr>
<td>Safety</td>
<td>All randomized participants who receive at least 1 dose of the study intervention.</td>
</tr>
</tbody>
</table>
9.4. Statistical Analyses

The SAP will be developed and finalized before any analyses are performed and will describe the analyses and procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary, secondary, and exploratory endpoints.

9.4.1. General Considerations

All safety and immunogenicity will be analyzed separately for each age group. VE will be evaluated by combining age groups for which immunobridging success is declared.

CIs for all endpoints in the statistical analysis will be presented as 2-sided at the 95% level unless specified otherwise.

The safety analyses are based on the safety population. Participants will be summarized by vaccine group according to the study interventions they actually received. Missing reactogenicity e-diary data will not be imputed; missing AE dates will be handled according to the Pfizer safety rules.

For all the immunogenicity endpoints, the analysis will be based on the evaluable immunogenicity population. An additional analysis may be performed based on the all-available immunogenicity populations if there is a large enough difference in sample size between the all-available immunogenicity population and the evaluable immunogenicity population. Participants will be summarized according to the vaccine group to which they were randomized. Missing serology data will not be imputed.

The evaluable efficacy population will be the primary analysis population for all efficacy analyses. Additional analyses based on the all-available efficacy (mITT) population will be performed. Participants will be summarized according to the vaccine group to which they were randomized. Missing laboratory results will not be imputed.

9.4.1.1. Analyses for Binary Data

Descriptive statistics for categorical variables (eg, proportions) are the percentage (%), the numerator (n) and the denominator (N) used in the percentage calculation, and the 95% CIs where applicable.

The exact 95% CI for binary endpoints for each group will be computed using the F distribution (Clopper-Pearson). The 95% CI for the between-group difference for binary endpoints will be calculated using the Miettinen and Nurminen method.

For Phase 2/3 only, the 3-tier approach will be used to summarize AEs. For both Tier 1 (if any are identified during the study) and Tier 2 events, a 95% CI for the between-group difference in proportions will be calculated based on the Miettinen and Nurminen method. In addition, for Tier 1 events (if any), the asymptotic p-values will also be presented for the difference in proportions, based on the same test statistic and under the assumption that the
test statistic is asymptotically normally distributed. For Tier 3 events, counts and percentages for each vaccine group will be provided.

9.4.1.2. Analyses for Continuous Data

Unless otherwise stated, descriptive statistics for continuous variables are n, mean, median, standard deviation, minimum, and maximum.

9.4.1.2.1. Geometric Means

The geometric means will be calculated as the mean of the assay results after making the logarithm transformation and then exponentiating the mean to express results on the original scale. Two-sided 95% CIs will be obtained by taking log transforms of assay results, calculating the 95% CI with reference to Student’s t-distribution, and then exponentiating the confidence limits.

9.4.1.2.2. Geometric Mean Fold Rises

GMFRs are defined as ratios of the results after vaccination to the results before vaccination. GMFRs are limited to participants with nonmissing values at both time points.

GMFRs will be calculated as the mean of the difference of logarithmically transformed assay results (later time point minus earlier time point) and exponentiating the mean. The associated 2-sided 95% CIs will be obtained by constructing CIs using Student’s t-distribution for the mean difference on the logarithm scale and exponentiating the confidence limits.

9.4.1.2.3. Geometric Mean Ratios

The GMR will be calculated as the mean of the difference of logarithmically transformed assay results (eg, SARS-CoV-2 neutralizing titers in the younger age group minus that in 16- to 25-year age group) and exponentiating the mean. Two-sided CIs will be obtained by calculating CIs using Student’s t-distribution for the mean difference of the logarithmically transformed assay results and exponentiating the confidence limits.

9.4.1.2.4. Reverse Cumulative Distribution Curves

Empirical RCDCs will plot proportions of participants with values equal to or exceeding a specified assay value versus the indicated assay value, for all observed assay values. Data points will be joined by a step function with data points on the left side of the step.

9.4.2. Primary Endpoint(s)

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Statistical Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety</td>
<td>Descriptive statistics will be provided for each reactogenicity endpoint for each dose and vaccine group. Local reactions and systemic events from Day 1 through Day 7 after each vaccination (where Day 1 is the day of vaccination) will be presented by severity and cumulatively across severity levels. Descriptive summary statistics will include</td>
</tr>
</tbody>
</table>
### Endpoint Statistical Analysis Methods

**Counts and percentages of participants with the indicated endpoint and the associated Clopper-Pearson 95% CIs** (see Section 9.4.1.1).

AEs will be categorized according to MedDRA terms. Counts, percentages, and the associated Clopper-Pearson 95% CIs of AEs from Dose 1 to 1 month after Dose 2 will be provided for each vaccine group.

A 3-tier approach will be used to summarize AEs in Phase 2/3. Under this approach AEs are classified into 1 of 3 tiers: (1) Tier 1 events are prespecified events of clinical importance and are identified in a list in the product’s safety review plan; (2) Tier 2 events are those that are not Tier 1 but are considered “relatively common”; a MedDRA preferred term is defined as a Tier 2 event if there are at least 1% of participants in at least 1 vaccine group reporting the event; and (3) Tier 3 events are those that are neither Tier 1 nor Tier 2 events. Analyses methods are described in Section 9.4.1.1.

SAEs will be categorized according to MedDRA terms. Counts, percentages, and the associated Clopper-Pearson 95% CIs of SAEs from Dose 1 to 6 months after Dose 2 will be provided for each vaccine group.

In addition, for the approximately 450 participants included in the immunobridging analysis per age group in Phase 2/3, SAEs from Dose 1 to 1 month after Dose 2 will be summarized using the same method.

<table>
<thead>
<tr>
<th>Immunogenicity (Phase 2/3)</th>
<th><strong>GMR of SARS-CoV-2 neutralizing titers in participants ≥5 to &lt;12 years, ≥2 to &lt;5 years, or ≥6 months to &lt;2 years of age to those 16 to 25 years of age in Study C4591001</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>The GMR, estimated by the ratio of the geometric mean of SARS-CoV-2 neutralizing titers in each younger age group (≥5 to &lt;12 years, ≥2 to &lt;5 years, and ≥6 months to &lt;2 years of age) to the 16- to 25-year age group 1 month after Dose 2, will be provided along with associated 2-sided 95% CIs (see Section 9.4.1.2.3). Only participants with no serological or virological evidence (up to 1 month after receipt of Dose 2) of past SARS-CoV-2 infection will be included in the analysis.</td>
</tr>
<tr>
<td></td>
<td>Immunobridging success will be declared for an age group if the lower bound of the 2-sided 95% for the GMR is greater than 0.67.</td>
</tr>
</tbody>
</table>
### 9.4.3. Secondary Endpoint(s)

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Statistical Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunogenicity (Phase 1)</td>
<td><strong>GMTs of SARS-CoV-2 neutralizing titers</strong></td>
</tr>
<tr>
<td></td>
<td>For SARS-CoV-2 neutralizing titers, GMTs and 2-sided 95% CIs will be provided for each vaccine group at baseline (before Dose 1), before Dose 2, and at 7 days after Dose 2.</td>
</tr>
<tr>
<td></td>
<td>Statistical methods are described in Section 9.4.1.2.1.</td>
</tr>
<tr>
<td><strong>GMFRs of SARS-CoV-2 neutralizing titers</strong></td>
<td>For SARS-CoV-2 neutralizing titers, the GMFRs and 2-sided 95% CIs will be provided for each vaccine group from before Dose 1 to subsequent time points after vaccination (before Dose 2 and 7 days after Dose 2).</td>
</tr>
<tr>
<td></td>
<td>GMFRs will be limited to participants with nonmissing values prior to the first dose and at the postvaccination time point.</td>
</tr>
<tr>
<td></td>
<td>The statistical methods are described in Section 9.4.1.2.2.</td>
</tr>
<tr>
<td>Immunogenicity (Phase 2/3)</td>
<td><strong>GMTs at each time point and GMFRs of SARS-CoV-2 neutralizing titers from before vaccination to each subsequent time point after vaccination will be provided in participants with no serological or virological evidence of past SARS-CoV-2 infection using the same statistical analysis method described above. Participants’ data will be excluded from the time point that the participant is determined as a COVID-19 case or has a positive N-binding result.</strong></td>
</tr>
<tr>
<td>VE (Phase 2/3)</td>
<td><strong>Ratio of confirmed COVID-19 illness from 7 days after Dose 2 per 1000 person-years of follow-up in participants without evidence of infection (prior to 7 days after receipt of Dose 2) for the active vaccine group to the placebo group</strong></td>
</tr>
<tr>
<td></td>
<td>VE will be estimated by 100 × (1 - IRR), where IRR is the calculated ratio of confirmed COVID-19 illness per 1000 person-years of follow-up in the active vaccine group to the corresponding illness rate in the placebo group from 7 days after Dose 2. The 2-sided 95% CI for VE will be provided using the Clopper-Pearson method adjusting for surveillance time.</td>
</tr>
<tr>
<td></td>
<td>The analysis will be based on the evaluable efficacy population and the all-available efficacy population. Missing efficacy data will not be imputed.</td>
</tr>
<tr>
<td></td>
<td><strong>Ratio of confirmed COVID-19 illness from 7 days after Dose 2 per 1000 person-years of follow-up in participants with and without</strong></td>
</tr>
</tbody>
</table>
### Endpoint Statistical Analysis Methods

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Statistical Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>evidence of infection (prior to 7 days after receipt of Dose 2) for the active vaccine group to the placebo group</td>
<td>The same analysis method used for the first VE endpoint will be applied.</td>
</tr>
<tr>
<td>Ratio of incidence of asymptomatic infection of SARS-CoV-2 based on N-binding antibody seroconversion in participants for the active vaccine group to the placebo group in evaluable participants without evidence of past SARS-CoV-2 infection</td>
<td>VE will be estimated by $100 \times (1 - IRR)$, where IRR is the calculated ratio of asymptomatic infection rate in the active vaccine group to the corresponding infection rate in the placebo group. The 2-sided 95% CI for VE will be provided using the Clopper-Pearson method. The analysis will be based on the evaluable efficacy population and the all-available efficacy population without serological or virological evidence of past SARS-CoV-2 infection. Missing efficacy data will not be imputed.</td>
</tr>
</tbody>
</table>

#### 9.4.4. Exploratory Endpoint(s)

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Statistical Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety</td>
<td>Descriptive summary of all safety endpoints will be provided for children with stable HIV disease.</td>
</tr>
<tr>
<td>Immunogenicity (Phase 2/3)</td>
<td>GMTs and GMFRs of SARS-CoV-2 neutralizing titers will be provided in participants with and without serological or virological evidence of past SARS-CoV-2 infection using the same statistical analysis method described for the secondary immunogenicity endpoints. In each subset of participants with confirmed COVID-19, confirmed severe COVID-19, and SARS-CoV-2 infection without confirmed COVID-19, GMTs/GMCs and GMFRs of SARS-CoV-2 neutralizing titers will be summarized using the same statistical analysis method described for the secondary immunogenicity endpoints. Empirical RCDCs will be provided for SARS-CoV-2 neutralizing titers (Section 9.4.1.2.4). Descriptive summary of all immunogenicity endpoints will be performed for children with stable HIV disease. Counts, percentages, and the associated Clopper-Pearson 95% CIs of N-binding antibody seroconversion, and other immune response–related parameters, will be provided.</td>
</tr>
</tbody>
</table>
9.5. Interim Analyses

No formal interim analysis will be conducted for this study. Statistical analyses will be carried out when the final data for specified objectives are available while the study is ongoing. The timing of these planned analysis and reporting events is described in the section below.

9.5.1. Analysis Timing

Statistical analyses will be carried out when the following data are available for a given age group:

- Complete safety and immunogenicity analysis approximately 7 days after Dose 2 for Phase 1 in each age group.

- Safety data through 1 month after Dose 2 from the approximately 450 participants in Phase 2/3 included in the immunobridging analysis in each age group.

- Immunogenicity data through 1 month after Dose 2 from the approximately 450 participants in Phase 2/3 included in the immunobridging analysis in each age group (immunobridging analysis of SARS-CoV-2 neutralizing titers in each age group compared to those in participants 16 to 25 years of age from Phase 2/3 of the C4591001 study).

- Safety data through 1 month after Dose 2 from participants in each age group in Phase 2/3.

- Complete safety and immunogenicity analysis approximately 6 months after Dose 2 for participants in each age group in Phase 2/3.

- Complete safety and persistence-of-immunogenicity analysis after complete data are available in each age group or at the end of the study.

- Efficacy analysis across age groups for which immunobridging success is declared when at least 22 cases are accrued in these age groups.

Certain analyses may be combined as 1 regulatory submission report if the data become available around the same time. Additional analyses may be conducted if required for
regulatory purposes. All analyses conducted on Phase 2/3 data while the study is ongoing will be performed by an unblinded team.

9.6. Data Monitoring Committee or Other Independent Oversight Committee

This study will use an IRC, an external DMC, and a group of internal case reviewers. The IRC is independent of the study team and includes only internal members. The IRC and DMC charters describe the role of the IRC and DMC in more detail.

The responsibilities of the IRC are only in Phase 1 and will include:

- Review of safety data to permit dose finding in each age group
- Review of safety data in the case of a stopping rule being met
- Review of safety and/or immunogenicity data to:
  - Allow groups of participants in each age group to proceed
  - Select dose level(s) to proceed into Phase 2/3. Data supporting these selections, including results for both binding antibody levels and neutralizing titers, and the ratio between them, will also be submitted to the FDA for review.
  - Review of any available safety and/or immunogenicity data generated during the course of this study, to determine:
    - Whether any dose level may not be started
    - Whether any dose level may be terminated early
    - Whether any dose level may be added with dose levels below the lowest stated dose or intermediate between the lowest and highest stated doses

The DMC will be responsible for ongoing monitoring of the safety of participants in the study according to the charter. This may include, but is not limited to:

- Contemporaneous review of related AEs up to 1 month after completion of the vaccination schedule
- Contemporaneous review of all SAEs up to 6 months after completion of the vaccination schedule

The recommendations made by the DMC to alter the conduct of the study will be forwarded to the appropriate Pfizer personnel for final decision. Pfizer will forward such decisions, which may include summaries of aggregate analyses of safety data to regulatory authorities, as appropriate.
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS

10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations

10.1.1. Regulatory and Ethical Considerations

This study will be conducted in accordance with the protocol and with the following:

- Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and CIOMS International Ethical Guidelines;
- Applicable ICH GCP guidelines;
- Applicable laws and regulations, including applicable privacy laws.

The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents (eg, advertisements) must be reviewed and approved by the sponsor and submitted to an IRB/EC by the investigator and reviewed and approved by the IRB/EC before the study is initiated.

Any amendments to the protocol will require IRB/EC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.

The investigator will be responsible for the following:

- Providing written summaries of the status of the study to the IRB/EC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/EC;
- Notifying the IRB/EC of SAEs or other significant safety findings as required by IRB/EC procedures;
- Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations.

10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP

In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable regulatory authority in any area of the world, or if the investigator is aware of any new information that might influence the evaluation of the benefits and risks of the study intervention, Pfizer should be informed immediately.

In addition, the investigator will inform Pfizer immediately of any urgent safety measures taken by the investigator to protect the study participants against any immediate hazard, and of any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
10.1.2. Financial Disclosure

Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial information as requested to allow the sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.

10.1.3. Informed Consent Process

The investigator or his/her representative will explain the nature of the study to the participant and his/her parent(s)/legal guardian and answer all questions regarding the study. The participant and his/her parent(s)/legal guardian should be given sufficient time and opportunity to ask questions and to decide whether or not to participate in the trial.

When consent is obtained from a participant’s parent(s)/legal guardian, the participant’s assent (affirmative agreement) must be subsequently obtained when the participant has the capacity to provide assent, as determined by the IRB/EC. If the investigator determines that a participant’s decisional capacity is so limited he/she cannot reasonably be consulted, then, as permitted by the IRB/EC and consistent with local regulatory and legal requirements, the participant’s assent may be waived with source documentation of the reason assent was not obtained. If the study participant does not provide his or her own assent, the source documents must record why the participant did not provide assent (for example, minor child), how the investigator determined that the person signing the consent was the participant’s parent(s)/legal guardian, the consent signer’s relationship to the study participant, and that the participant’s assent was obtained or waived. If assent is obtained verbally, it must be documented in the source documents.

If study participants are minors who reach the age of majority during the study, as recognized under local law, they must be reconsented as adults to remain in the study. If the enrollment of emancipated minors is permitted by the IRB/EC and local law, they must provide documentation of legal status to give consent without the permission of a legally authorized representative.

Participants and their parent(s)/legal guardian must be informed that their participation is voluntary. The participant’s parent(s)/legal guardian will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, HIPAA requirements, where applicable, and the IRB/EC or study center.

The investigator must ensure that each study participant’s parent(s)/legal guardian and the study participant as applicable is fully informed about the nature and objectives of the study, the sharing of data related to the study, and possible risks associated with participation, including the risks associated with the processing of the participant’s personal data.

The participant’s parent(s)/legal guardian must be informed that the participant’s personal study-related data will be used by the sponsor in accordance with local data protection
law. The level of disclosure must also be explained to the participant’s parent(s)/legal guardian.

The participant’s parent(s)/legal guardian must be informed that the participant’s medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the sponsor, by appropriate IRB/EC members, and by inspectors from regulatory authorities.

The investigator further must ensure that each study participant’s parent(s)/legal guardian is fully informed about his or her right to access and correct his or her child’s personal data and to withdraw consent for the processing of his or her child’s personal data, keeping in mind the privacy rights that may restrict access of older adolescents’ medical records by their parent(s)/legal guardian in certain regions.

The source documentation must include a statement that written informed consent and, as applicable, assent, was obtained before the participant was enrolled in the study and the date the written consent/assent was obtained. The authorized person obtaining the informed consent must also sign the ICD.

Parent(s)/legal guardian and the participant must be reconsented to the most current version of the ICD(s)/assent during their participation in the study.

A copy of the ICD(s) and assent, if written, must be provided to the parent(s)/legal guardian and the participant.

10.1.4. Data Protection

All parties will comply with all applicable laws, including laws regarding the implementation of organizational and technical measures to ensure protection of participant data.

Participants’ personal data will be stored at the study site in encrypted electronic and/or paper form and will be password protected or secured in a locked room to ensure that only authorized study staff have access. The study site will implement appropriate technical and organizational measures to ensure that the personal data can be recovered in the event of disaster. In the event of a potential personal data breach, the study site will be responsible for determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by law.

To protect the rights and freedoms of participants with regard to the processing of personal data, participants will be assigned a single, participant-specific numerical code. Any participant records or data sets that are transferred to the sponsor will contain the numerical code; participant names will not be transferred. All other identifiable data transferred to the sponsor will be identified by this single, participant-specific code. The study site will maintain a confidential list of participants who participated in the study, linking each participant’s numerical code to his or her actual identity and medical record identification. In case of data transfer, the sponsor will protect the confidentiality of participants’ personal data consistent with the clinical study agreement and applicable privacy laws.
10.1.5. Dissemination of Clinical Study Data

Pfizer fulfills its commitment to publicly disclose clinical study results through posting the results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or www.pfizer.com, and other public registries in accordance with applicable local laws/regulations. In addition, Pfizer reports study results outside of the requirements of local laws/regulations pursuant to its SOPs.

In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and complete manner and are reported regardless of the outcome of the study or the country in which the study was conducted.

www.clinicaltrials.gov

Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer-sponsored interventional studies (conducted in patients) that evaluate the safety and/or efficacy of a product, regardless of the geographical location in which the study is conducted. These results are submitted for posting in accordance with the format and timelines set forth by US law.

EudraCT

Pfizer posts clinical trial results on EudraCT for Pfizer-sponsored interventional studies in accordance with the format and timelines set forth by EU requirements.

www.pfizer.com

Pfizer posts public disclosure synopses (CSR synopses in which any data that could be used to identify individual participants have been removed) on www.pfizer.com for Pfizer-sponsored interventional studies at the same time the corresponding study results are posted to www.clinicaltrials.gov.

Documents within marketing authorization packages/submissions

Pfizer complies with the European Union Policy 0070, the proactive publication of clinical data to the EMA website. Clinical data, under Phase 1 of this policy, includes clinical overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this policy, includes the publishing of individual participant data. Policy 0070 applies to new marketing authorization applications submitted via the centralized procedure since 01 January 2015 and applications for line extensions and for new indications submitted via the centralized procedure since 01 July 2015.

Data Sharing

Pfizer provides researchers secure access to patient-level data or full CSRs for the purposes of “bona-fide scientific research” that contributes to the scientific understanding of the disease, target, or compound class. Pfizer will make available data from these trials
24 months after study completion. Patient-level data will be anonymized in accordance with applicable privacy laws and regulations. CSRs will have personally identifiable information redacted.

Data requests are considered from qualified researchers with the appropriate competencies to perform the proposed analyses. Research teams must include a biostatistician. Data will not be provided to applicants with significant conflicts of interest, including individuals requesting access for commercial/competitive or legal purposes.

10.1.6. Data Quality Assurance

All participant data relating to the study will be recorded on printed or electronic CRF unless transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the CRF.

The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.

The investigator must ensure that the CRFs are securely stored at the study site in encrypted electronic and/or paper form and are password protected or secured in a locked room to prevent access by unauthorized third parties.

The investigator must permit study-related monitoring, audits, IRB/EC review, and regulatory agency inspections and provide direct access to source data documents. This verification may also occur after study completion. It is important that the investigator(s) and their relevant personnel are available during the monitoring visits and possible audits or inspections and that sufficient time is devoted to the process.

Monitoring details describing strategy, including definition of study critical data items and processes (eg, risk-based initiatives in operations and quality such as risk management and mitigation strategies and analytical risk-based monitoring), methods, responsibilities, and requirements, including handling of noncompliance issues and monitoring techniques (central, virtual, or on-site monitoring), are provided in the data management plan and monitoring plan maintained and utilized by the sponsor or designee.

The sponsor or designee is responsible for the data management of this study, including quality checking of the data.

Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.

Records and documents, including signed ICDs, pertaining to the conduct of this study must be retained by the investigator for 15 years after study completion unless local regulations or
institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the sponsor. No records may be transferred to another location or party without written notification to the sponsor. The investigator must ensure that the records continue to be stored securely for as long as they are maintained.

When participant data are to be deleted, the investigator will ensure that all copies of such data are promptly and irrevocably deleted from all systems.

The investigator(s) will notify the sponsor or its agents immediately of any regulatory inspection notification in relation to the study. Furthermore, the investigator will cooperate with the sponsor or its agents to prepare the investigator site for the inspection and will allow the sponsor or its agent, whenever feasible, to be present during the inspection. The investigator site and investigator will promptly resolve any discrepancies that are identified between the study data and the participant's medical records. The investigator will promptly provide copies of the inspection findings to the sponsor or its agent. Before response submission to the regulatory authorities, the investigator will provide the sponsor or its agents with an opportunity to review and comment on responses to any such findings.

10.1.7. Source Documents

Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. Source documents are filed at the investigator site.

Data reported on the CRF or entered in the eCRF that are from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

Definition of what constitutes source data can be found in the study monitoring plan.

Description of the use of computerized system is documented in the data management plan.

10.1.8. Study and Site Start and Closure

The study start date is the date on which the clinical study will be open for recruitment of participants.

The first act of recruitment is the date of the first participant’s first visit and will be the study start date.

The sponsor designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time upon notification to the sponsor or designee if requested to do so by the responsible IRB/EC or if such termination is required to protect the health of study participants.

Reasons for the early closure of a study site by the sponsor may include but are not limited to:

- Failure of the investigator to comply with the protocol, the requirements of the IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
- Inadequate recruitment of participants by the investigator;
- Discontinuation of further study intervention development.

If the study is prematurely terminated or suspended, the sponsor shall promptly inform the investigators, the ECs/IRBs, the regulatory authorities, and any CRO(s) used in the study of the reason for termination or suspension, as specified by the applicable regulatory requirements. The investigator shall promptly inform the participant and should assure appropriate participant therapy and/or follow-up.

Study termination is also provided for in the clinical study agreement. If there is any conflict between the contract and this protocol, the contract will control as to termination rights.

10.1.9. Publication Policy

The results of this study may be published or presented at scientific meetings by the investigator after publication of the overall study results or 1 year after the end of the study (or study termination), whichever comes first.

The investigator agrees to refer to the primary publication in any subsequent publications such as secondary manuscripts, and submits all manuscripts or abstracts to the sponsor 30 days before submission. This allows the sponsor to protect proprietary information and to provide comments and the investigator will, on request, remove any previously undisclosed confidential information before disclosure, except for any study- or Pfizer intervention-related information necessary for the appropriate scientific presentation or understanding of the study results.

For all publications relating to the study, the investigator will comply with recognized ethical standards concerning publications and authorship, including those established by the International Committee of Medical Journal Editors.

The sponsor will comply with the requirements for publication of the overall study results covering all investigator sites. In accordance with standard editorial and ethical practice, the sponsor will support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement.
Authorship of publications for the overall study results will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.

If publication is addressed in the clinical study agreement, the publication policy set out in this section will not apply.

**10.1.10. Sponsor’s Qualified Medical Personnel**

The contact information for the sponsor's appropriately qualified medical personnel for the study is documented in the study contact list located in the supporting study documentation.

To facilitate access to appropriately qualified medical personnel on study-related medical questions or problems, participants are provided with a contact card at the time of informed consent. The contact card contains, at a minimum, protocol and study intervention identifiers, participant numbers, contact information for the investigator site, and contact details for a contact center in the event that the investigator site staff cannot be reached to provide advice on a medical question or problem originating from another healthcare professional not involved in the participant’s participation in the study. The contact number can also be used by investigator staff if they are seeking advice on medical questions or problems; however, it should be used only in the event that the established communication pathways between the investigator site and the study team are not available. It is therefore intended to augment, but not replace, the established communication pathways between the investigator site and the study team for advice on medical questions or problems that may arise during the study. The contact number is not intended for use by the participant directly, and if a participant calls that number, he or she will be directed back to the investigator site.

**10.2. Appendix 2: Clinical Laboratory Tests**

Not applicable.
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting

10.3.1. Definition of AE

### AE Definition

- An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

- NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.

### Events Meeting the AE Definition

- Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, ECG, radiological scans, vital sign measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator. Any abnormal laboratory test results that meet any of the conditions below must be recorded as an AE:
  - Is associated with accompanying symptoms.
  - Requires additional diagnostic testing or medical/surgical intervention.
  - Leads to a change in study dosing (outside of any protocol-specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy.
  - Exacerbation of a chronic or intermittent preexisting condition including either an increase in frequency and/or intensity of the condition.
  - New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study.
  - Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
  - Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible
suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.

- The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as an AE or SAE if they fulfill the definition of an AE or SAE and meet the requirements as per Section 8.3.8.1. Also, “lack of efficacy” or “failure of expected pharmacological action” does constitute an AE or SAE.

**Events NOT Meeting the AE Definition**

- Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant’s condition.

- The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant’s condition.

- Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure is the AE.

- Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).

- Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present or detected at the start of the study that do not worsen.

### 10.3.2. Definition of SAE

If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met (e.g., hospitalization for signs/symptoms of the disease under study, death due to progression of disease).

**An SAE is defined as any untoward medical occurrence that, at any dose:**

a. **Results in death**

b. **Is life-threatening**

The term “life-threatening” in the definition of “serious” refers to an event in which the participant was at risk of death at the time of the event. It does not refer to an event that hypothetically might have caused death if it were more severe.
c. Requires inpatient hospitalization or prolongation of existing hospitalization

In general, hospitalization signifies that the participant has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE should be considered serious.

Hospitalization for elective treatment of a preexisting condition that did not worsen from baseline is not considered an AE.

d. Results in persistent disability/incapacity

- The term disability means a substantial disruption of a person’s ability to conduct normal life functions.

- This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.

e. Is a congenital anomaly/birth defect

f. Other situations:

- Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious.

- Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

- Suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, is considered serious. The event may be suspected from clinical symptoms or laboratory findings indicating an infection in a patient exposed to a Pfizer product. The terms “suspected transmission” and “transmission” are considered synonymous. These cases are considered unexpected and handled as serious expedited cases by pharmacovigilance personnel. Such cases are also considered for reporting as product defects, if appropriate.
10.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs

<table>
<thead>
<tr>
<th>Safety Event</th>
<th>Recorded on the CRF</th>
<th>Reported on the Vaccine SAE Reporting Form to Pfizer Safety Within 24 Hours of Awareness</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAE</td>
<td>All</td>
<td>All</td>
</tr>
<tr>
<td>Nonserious AE</td>
<td>All</td>
<td>None</td>
</tr>
<tr>
<td>Exposure to the study intervention under study during pregnancy or breastfeeding, and occupational exposure</td>
<td>All AEs/SAEs associated with exposure during pregnancy or breastfeeding Occupational exposure is not recorded.</td>
<td>All (and EDP supplemental form for EDP) Note: Include all SAEs associated with exposure during pregnancy or breastfeeding. Include all AEs/SAEs associated with occupational exposure.</td>
</tr>
</tbody>
</table>

- When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g., hospital progress notes, laboratory reports, and diagnostic reports) related to the event.
- The investigator will then record all relevant AE/SAE information in the CRF.
- It is not acceptable for the investigator to send photocopies of the participant’s medical records to Pfizer Safety in lieu of completion of the Vaccine SAE Reporting Form/AE/SAE CRF page.
- There may be instances when copies of medical records for certain cases are requested by Pfizer Safety. In this case, all participant identifiers, with the exception of the participant number, will be redacted on the copies of the medical records before submission to Pfizer Safety.
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.

### Assessment of Intensity

The investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to 1 of the following categories:

- **Mild**: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities.
- **Moderate**: An event that causes sufficient discomfort and interferes with normal everyday activities.
- **Severe**: An event that prevents normal everyday activities. An AE that is assessed as severe should not be confused with an SAE. Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.
- **An event is defined as “serious” when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, NOT when it is rated as severe.**

<table>
<thead>
<tr>
<th>GRADE</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><strong>MILD</strong> Does not interfere with participant's usual function.</td>
</tr>
<tr>
<td>2</td>
<td><strong>MODERATE</strong> Interferes to some extent with participant's usual function.</td>
</tr>
<tr>
<td>3</td>
<td><strong>SEVERE</strong> Interferes significantly with participant's usual function.</td>
</tr>
<tr>
<td>4</td>
<td><strong>LIFE-THREATENING</strong> Life-threatening consequences; urgent intervention indicated.</td>
</tr>
</tbody>
</table>
Assessment of Causality

- The investigator is obligated to assess the relationship between study intervention and each occurrence of each AE/SAE.

- A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.

- The investigator will use clinical judgment to determine the relationship.

- Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration, will be considered and investigated.

- The investigator will also consult the IB and/or product information, for marketed products, in his/her assessment.

- For each AE/SAE, the investigator must document in the medical notes that he/she has reviewed the AE/SAE and has provided an assessment of causality.

- There may be situations in which an SAE has occurred and the investigator has minimal information to include in the initial report to the sponsor. However, it is very important that the investigator always make an assessment of causality for every event before the initial transmission of the SAE data to the sponsor.

- The investigator may change his/her opinion of causality in light of follow-up information and send an SAE follow-up report with the updated causality assessment.

- The causality assessment is one of the criteria used when determining regulatory reporting requirements.

- If the investigator does not know whether or not the study intervention caused the event, then the event will be handled as “related to study intervention” for reporting purposes, as defined by the sponsor. In addition, if the investigator determines that an SAE is associated with study procedures, the investigator must record this causal relationship in the source documents and CRF, and report such an assessment in the dedicated section of the Vaccine SAE Reporting Form and in accordance with the SAE reporting requirements.
Follow-up of AEs and SAEs

- The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by the sponsor to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other healthcare providers.
- New or updated information will be recorded in the originally completed CRF.
- The investigator will submit any updated SAE data to the sponsor within 24 hours of receipt of the information.

10.3.4. Reporting of SAEs

SAE Reporting to Pfizer Safety via Vaccine SAE Report Form

- Facsimile transmission of the Vaccine SAE Report Form is the preferred method to transmit this information to Pfizer Safety.
- In circumstances when the facsimile is not working, notification by telephone is acceptable with a copy of the Vaccine SAE Report Form sent by overnight mail or courier service.
- Initial notification via telephone does not replace the need for the investigator to complete and sign the Vaccine SAE Report Form pages within the designated reporting time frames.
10.4. Appendix 4: Contraceptive Guidance

10.4.1. Male Participant Reproductive Inclusion Criteria

Male participants are eligible to participate if they agree to the following requirements during the intervention period and for at least 28 days after the last dose of study intervention, which corresponds to the time needed to eliminate reproductive safety risk of the study intervention(s):

- Refrain from donating sperm.

PLUS either:

- Be abstinent from heterosexual intercourse with female of childbearing potential as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.

OR

- Must agree to use contraception/barrier as detailed below.
  - Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person.

10.4.2. Female Participant Reproductive Inclusion Criteria

A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:

- Is not a WOCBP (see definitions below in Section 10.4.3).

OR

- Is a WOCBP and using an acceptable contraceptive method as described below during the intervention period (for a minimum of 28 days after the last dose of study intervention). The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.

The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
10.4.3. Woman of Childbearing Potential

A woman is considered fertile following menarche and until becoming postmenopausal unless permanently sterile (see below).

If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before the first dose of study intervention, additional evaluation should be considered.

Women in the following categories are not considered WOCBP:

1. Premenarchal.

2. Premenopausal female with 1 of the following:
   - Documented hysterectomy;
   - Documented bilateral salpingectomy;
   - Documented bilateral oophorectomy.

For individuals with permanent infertility due to an alternate medical cause other than the above, (e.g., mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.

Note: Documentation for any of the above categories can come from the site personnel’s review of the participant’s medical records, medical examination, or medical history interview. The method of documentation should be recorded in the participant’s medical record for the study.

3. Postmenopausal female:
   - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. In addition, a
     - high FSH level in the postmenopausal range must be used to confirm a postmenopausal state in women under 60 years of age and not using hormonal contraception or HRT.
     - Female on HRT and whose menopausal status is in doubt will be required to use one of the nonestrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
10.4.4. Contraception Methods

Contraceptive use by men or women should be consistent with local availability/regulations regarding the use of contraceptive methods for those participating in clinical trials.

1. Implantable progestogen-only hormone contraception associated with inhibition of ovulation.

2. Intrauterine device.

3. Intrauterine hormone-releasing system.


5. Vasectomized partner:
   
   • Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days.

6. Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation:
   
   • Oral;
   
   • Intravaginal;
   
   • Transdermal;
   
   • Injectable.

7. Progestogen-only hormone contraception associated with inhibition of ovulation:
   
   • Oral;
   
   • Injectable.

8. Sexual abstinence:
   
   • Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
9. Progestogen-only oral hormonal contraception where inhibition of ovulation is not the primary mode of action.

10. Male or female condom with or without spermicide.

11. Cervical cap, diaphragm, or sponge with spermicide.

12. A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods).

10.5. Appendix 5: Liver Safety: Suggested Actions and Follow-up Assessments

Potential Cases of Drug-Induced Liver Injury

Humans exposed to a drug who show no sign of liver injury (as determined by elevations in transaminases) are termed “tolerators,” while those who show transient liver injury, but adapt are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a more serious potential outcome. These participants fail to adapt and therefore are "susceptible" to progressive and serious liver injury, commonly referred to as DILI. Participants who experience a transaminase elevation above $3 \times ULN$ should be monitored more frequently to determine if they are an “adaptor” or are “susceptible.”

LFTs are not required as a routine safety monitoring procedure in this study. However, should an investigator deem it necessary to assess LFTs because a participant presents with clinical signs/symptoms, such LFT results should be managed and followed as described below.

In the majority of DILI cases, elevations in AST and/or ALT precede TBili elevations ($>2 \times ULN$) by several days or weeks. The increase in TBili typically occurs while AST/ALT is/are still elevated above $3 \times ULN$ (ie, AST/ALT and TBili values will be elevated within the same laboratory sample). In rare instances, by the time TBili elevations are detected, AST/ALT values might have decreased. This occurrence is still regarded as a potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to TBili that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law criteria) cases and should always be considered important medical events, even before all other possible causes of liver injury have been excluded.

The threshold of laboratory abnormalities for a potential DILI case depends on the participant’s individual baseline values and underlying conditions. Participants who present with the following laboratory abnormalities should be evaluated further as potential DILI (Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:

- Participants with AST/ALT and TBili baseline values within the normal range who subsequently present with AST OR ALT values $>3 \times ULN$ AND a TBili value $>2 \times ULN$ with no evidence of hemolysis and an alkaline phosphatase value $<2 \times ULN$ or not available.
• For participants with baseline AST OR ALT OR TBili values above the ULN, the following threshold values are used in the definition mentioned above, as needed, depending on which values are above the ULN at baseline:

• Preexisting AST or ALT baseline values above the normal range: AST or ALT values >2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is smaller).

• Preexisting values of TBili above the normal range: TBili level increased from baseline value by an amount of at least 1 × ULN or if the value reaches >3 × ULN (whichever is smaller).

Rises in AST/ALT and TBili separated by more than a few weeks should be assessed individually based on clinical judgment; any case where uncertainty remains as to whether it represents a potential Hy’s law case should be reviewed with the sponsor.

The participant should return to the investigator site and be evaluated as soon as possible, preferably within 48 hours from awareness of the abnormal results. This evaluation should include laboratory tests, detailed history, and physical assessment.

In addition to repeating measurements of AST and ALT and TBili for suspected cases of Hy’s law, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further testing, as needed, for further contemporaneous analyses at the time of the recognized initial abnormalities to determine etiology. A detailed history, including relevant information, such as review of ethanol, acetaminophen/paracetamol (either by itself or as a coformulated product in prescription or over-the-counter medications), recreational drug, supplement (herbal) use and consumption, family history, sexual history, travel history, history of contact with a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and potential occupational exposure to chemicals, should be collected. Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary tract) and collection of serum samples for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted.

All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and TBili elevation defined above should be considered potential DILI (Hy’s law) cases if no other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability of all the results of the investigations performed to determine etiology of the LFT abnormalities.

A potential DILI (Hy’s law) case becomes a confirmed case only after all results of reasonable investigations have been received and have excluded an alternative etiology.
10.6. Appendix 6: Abbreviations

The following is a list of abbreviations that may be used in the protocol.

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019-nCoV</td>
<td>novel coronavirus 2019</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>app</td>
<td>application</td>
</tr>
<tr>
<td>ARDS</td>
<td>adult respiratory distress syndrome</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>BiPaP</td>
<td>bilevel positive airway pressure</td>
</tr>
<tr>
<td>BNP</td>
<td>brain natriuretic peptide</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>CBER</td>
<td>Center for Biologics Evaluation and Research</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention (United States)</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CIOMS</td>
<td>Council for International Organizations of Medical Sciences</td>
</tr>
<tr>
<td>CK</td>
<td>creatine kinase</td>
</tr>
<tr>
<td>CONSORT</td>
<td>Consolidated Standards of Reporting Trials</td>
</tr>
<tr>
<td>COVID-19</td>
<td>coronavirus disease 2019</td>
</tr>
<tr>
<td>CPaP</td>
<td>continuous positive airway pressure</td>
</tr>
<tr>
<td>CRF</td>
<td>case report form</td>
</tr>
<tr>
<td>CRO</td>
<td>contract research organization</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>CSF</td>
<td>cerebrospinal fluid</td>
</tr>
<tr>
<td>CSR</td>
<td>clinical study report</td>
</tr>
<tr>
<td>CVA</td>
<td>cerebrovascular accident</td>
</tr>
<tr>
<td>DILI</td>
<td>drug-induced liver injury</td>
</tr>
<tr>
<td>DMC</td>
<td>data monitoring committee</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>EC</td>
<td>ethics committee</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>ECMO</td>
<td>extracorporeal membrane oxygenation</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic case report form</td>
</tr>
<tr>
<td>e-diary</td>
<td>electronic diary</td>
</tr>
<tr>
<td>EDP</td>
<td>exposure during pregnancy</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>ESR</td>
<td>erythrocyte sedimentation rate</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>EUA</td>
<td>emergency use authorization</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Term</td>
</tr>
<tr>
<td>--------------</td>
<td>------</td>
</tr>
<tr>
<td>EudraCT</td>
<td>European Clinical Trials Database</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FiO₂</td>
<td>fraction of inspired oxygen</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma-glutamyl transferase</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>GMFR</td>
<td>geometric mean fold rise</td>
</tr>
<tr>
<td>GMR</td>
<td>geometric mean ratio</td>
</tr>
<tr>
<td>GMT</td>
<td>geometric mean titer</td>
</tr>
<tr>
<td>HBe</td>
<td>hepatitis B e</td>
</tr>
<tr>
<td>HBeAg</td>
<td>hepatitis B e antigen</td>
</tr>
<tr>
<td>HBsAg</td>
<td>hepatitis B surface antigen</td>
</tr>
<tr>
<td>HBV</td>
<td>hepatitis B virus</td>
</tr>
<tr>
<td>HCV</td>
<td>hepatitis C virus</td>
</tr>
<tr>
<td>HIPAA</td>
<td>Health Insurance Portability and Accountability Act</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>HR</td>
<td>heart rate</td>
</tr>
<tr>
<td>HRT</td>
<td>hormone replacement therapy</td>
</tr>
<tr>
<td>IB</td>
<td>investigator’s brochure</td>
</tr>
<tr>
<td>ICD</td>
<td>informed consent document</td>
</tr>
<tr>
<td>ICH</td>
<td>International Council for Harmonisation</td>
</tr>
<tr>
<td>ICU</td>
<td>intensive care unit</td>
</tr>
<tr>
<td>ID</td>
<td>identification</td>
</tr>
<tr>
<td>IL-6</td>
<td>interleukin 6</td>
</tr>
<tr>
<td>IMP</td>
<td>investigational medicinal product</td>
</tr>
<tr>
<td>IND</td>
<td>investigational new drug</td>
</tr>
<tr>
<td>INR</td>
<td>international normalized ratio</td>
</tr>
<tr>
<td>IP manual</td>
<td>investigational product manual</td>
</tr>
<tr>
<td>IPAL</td>
<td>Investigational Product Accountability Log</td>
</tr>
<tr>
<td>IRB</td>
<td>institutional review board</td>
</tr>
<tr>
<td>IRC</td>
<td>internal review committee</td>
</tr>
<tr>
<td>IRR</td>
<td>illness rate ratio</td>
</tr>
<tr>
<td>IRT</td>
<td>interactive response technology</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous(ly)</td>
</tr>
<tr>
<td>IVIG</td>
<td>intravenous immunoglobulin</td>
</tr>
<tr>
<td>IWR</td>
<td>interactive Web-based response</td>
</tr>
<tr>
<td>LDH</td>
<td>lactate dehydrogenase</td>
</tr>
<tr>
<td>LFT</td>
<td>liver function test</td>
</tr>
<tr>
<td>LLOQ</td>
<td>lower limit of quantitation</td>
</tr>
<tr>
<td>LNP</td>
<td>lipid nanoparticle</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Term</td>
</tr>
<tr>
<td>--------------</td>
<td>------</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>MERS</td>
<td>Middle East respiratory syndrome</td>
</tr>
<tr>
<td>MIS-C</td>
<td>multisystem inflammatory syndrome in children</td>
</tr>
<tr>
<td>mITT</td>
<td>modified-intent-to-treat</td>
</tr>
<tr>
<td>modRNA</td>
<td>nucleoside-modified messenger ribonucleic acid</td>
</tr>
<tr>
<td>mRNA</td>
<td>messenger ribonucleic acid</td>
</tr>
<tr>
<td>N</td>
<td>SARS-CoV-2 nucleoprotein</td>
</tr>
<tr>
<td>N/A</td>
<td>not applicable</td>
</tr>
<tr>
<td>NAAT</td>
<td>nucleic acid amplification test</td>
</tr>
<tr>
<td>NIMP</td>
<td>noninvestigational medicinal product</td>
</tr>
<tr>
<td>non-S</td>
<td>nonspike protein</td>
</tr>
<tr>
<td>P2 S</td>
<td>SARS-CoV-2 full-length, P2 mutant, prefusion spike glycoprotein</td>
</tr>
<tr>
<td>PaO(_2)</td>
<td>partial pressure of oxygen, arterial</td>
</tr>
<tr>
<td>PBMC</td>
<td>peripheral blood mononuclear cell</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PI</td>
<td>principal investigator</td>
</tr>
<tr>
<td>PPE</td>
<td>personal protective equipment</td>
</tr>
<tr>
<td>PT</td>
<td>prothrombin time</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>RR</td>
<td>respiratory rate</td>
</tr>
<tr>
<td>RSV</td>
<td>respiratory syncytial virus</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>reverse transcription–polymerase chain reaction</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SAP</td>
<td>statistical analysis plan</td>
</tr>
<tr>
<td>SARS</td>
<td>severe acute respiratory syndrome</td>
</tr>
<tr>
<td>SARS-CoV-1</td>
<td>severe acute respiratory syndrome coronavirus</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>severe acute respiratory syndrome coronavirus 2</td>
</tr>
<tr>
<td>SBP</td>
<td>systolic blood pressure</td>
</tr>
<tr>
<td>SoA</td>
<td>schedule of activities</td>
</tr>
<tr>
<td>SOP</td>
<td>standard operating procedure</td>
</tr>
<tr>
<td>SpO(_2)</td>
<td>oxygen saturation as measured by pulse oximetry</td>
</tr>
<tr>
<td>SRSD</td>
<td>single reference safety document</td>
</tr>
<tr>
<td>SUSAR</td>
<td>suspected unexpected serious adverse reaction</td>
</tr>
<tr>
<td>TBili</td>
<td>total bilirubin</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
<tr>
<td>US</td>
<td>United States</td>
</tr>
<tr>
<td>VE</td>
<td>vaccine efficacy</td>
</tr>
<tr>
<td>VAED</td>
<td>vaccine-associated enhanced disease</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WOCBP</td>
<td>woman/women of childbearing potential</td>
</tr>
</tbody>
</table>
10.7. Appendix 7: Criteria for Allowing Inclusion of Participants With Chronic Stable HIV, HCV, or HBV Infection

Potential participants with chronic stable HIV, HCV, or HBV infection may be considered for inclusion if they fulfill the following respective criteria.

**Known HIV infection**

- Confirmed stable HIV disease defined as documented viral load <50 copies/mL and CD4 count >200 cells/mm³ within 6 months before enrollment, and receiving stable antiretroviral therapy for at least 6 months.

**Known HCV infection**

- History of chronic HCV with evidence of sustained virological response (defined as undetectable HCV RNA) for ≥12 weeks following HCV treatment or without evidence of HCV RNA viremia (undetectable HCV viral load).

**Known HBV infection**

Confirmed inactive chronic HBV infection, defined as HBsAg present for ≥6 months and the following:

- HBeAg negative, anti-HBe positive
- Serum HBV DNA <2000 IU/mL
- Persistently normal ALT and/or AST levels

In those who have had a liver biopsy performed,

- Findings that confirm the absence of significant necroinflammation
11. REFERENCES


Document Approval Record

Document Name: C4591007 Clinical Protocol, Amendment 1 Clean Copy, 05March2021

Document Title: A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN < 12 YEARS OF AGE

Signed By: Date(GMT) Signing Capacity

<table>
<thead>
<tr>
<th>Signed By</th>
<th>Date(GMT)</th>
<th>Signing Capacity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koury, Kenneth</td>
<td>05-Mar-2021 16:04:44</td>
<td>Final Approval</td>
</tr>
<tr>
<td>Lockhart, Stephen Paul</td>
<td>05-Mar-2021 17:33:20</td>
<td>Business Line Approver</td>
</tr>
</tbody>
</table>